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Abstract 
Hearing Loss (HL) is the most common sensory disorder in humans, and more than half of 
cases are due to genetic factors. In 30% of cases, hereditary HL is associated with 
additional clinical features, and it is defined syndromic (SHL), whereas in 70% of cases HL 
is the only symptom, and it is considered nonsyndromic (NSHL). HL is characterised by an 
extreme genetic heterogeneity, with more than 150 loci currently associated and at least 100 
genes identified, making extremely challenging to obtain a molecular diagnosis with 
traditional screening methods. For these reasons, whole-exome sequencing (WES) has 
been introduced to search for mutations and novel genes underlying the disease. 
In this frame, this thesis describes the study of the genetic bases of deafness in 11 HL (3 
SHL and 8 NSHL) families applying WES and an accurate functional validation of the 
candidate mutations.  
This approach allowed the identification of the causative mutations in 7 out of the 11 
families analysed, while for 3 NSHL families no strong candidate pathogenic variants 
emerged from our WES data analyses. 
In addition, in one NSHL family we identified a missense variant in the candidate deafness-
causing gene DIAPH2, coding for a protein involved in actin filament elongation. My in-
vitro studies indicate a possible functional impairment of the mutant DIAPH2 protein, 
which might be very relevant in hearing function. In fact, immunohistochemical studies 
indicate that the mouse ortholog protein Diap2 is expressed in the cochlea in the actin-rich 
stereocilia of the sensory outer hair cells during development. Auditory brainstem response 
measurements to evaluate the hearing phenotype of Diaph2 knock-out and knock-in mice 
were also undertaken. However, at least at the time points analysed, no hearing impairment 
was detected in the mouse models. Consequently, the role of DIAPH2 in HL in humans 
still needs to be further clarified. 
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1.1. The ear anatomy and the hearing process 
The ear is responsible for the sense of hearing and equilibrium and it can be divided in 
three anatomical components: the outer, the middle and the inner ear (Fig. 1.1A). 
The outer ear includes the auricle (or pinna), which collects the sound waves, and the ear 
canal, which channels the sound to the tympanic membrane (or eardrum). The middle ear 
is an air-filled compartment, whose principal role is to amplify the air sound waves coming 
from the outer ear and transfer them into the motion of the fluid in the inner ear. This task 
is accomplished through the three ossicles of the middle ear (malleus, incus and stapes) that 
form an ossicular chain which connects the eardrum to the oval window of the cochlea. 
The inner ear comprises the vestibular system, responsible for balance, and the cochlea, 
which contains the organ of Corti (OC), the receptor organ for hearing [Dror and 
Avraham, 2010]. 
The cochlea is a snail-shaped duct filled with fluid which consist of three parallel 
membranous compartments called scalae: the scala media, containing the OC, lies between 
an upper chamber, the scala vestibuli and a lower chamber, the scala tympani (Fig. 1.1B). 
The scalae vestibuli and tympani are connected to the middle ear by the oval and round 
window respectively. Both chambers are filled with a high Na+ and low K+ and Ca2+ fluid 
called perilymph and communicate at the apex of the cochlea through an opening called 
helicotrema. The scala media is isolated from the scalae vestibuli and tympani respectively 
by Reissner and basilar membranes (RM and BM) and contains endolymph, a fluid rich in 
K+ and low in Na+. The stria vascularis (SV), located in the lateral wall of the scala media, is 
responsible for the maintenance of the composition of the endolymph and for the 
generation of the endocochlear potential (EP), which is essential for the sensory 
transduction in the cochlea [Fuchs, 2010]. 
The OC, which resides on the basilar membrane, includes the sensory hair cells (HC) and 
the supporting cells (SC). The apical surfaces of these cells are joined together by 
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intercellular junction complexes and form a reticular lamina which restricts the ion flow 
between the endolymph and the perilymph-like fluid beneath these cells. The hair cells are 
not in direct contact with the BM and are surrounded by several diverse SCs, including 
inner border and inner phalangeal cells, pillar cells, Deiters’ cells, Hensen’s cells and 
Claudius’ cells (Fig. 1.1C). The SCs not only provide a structural support to HCs, but also 
play an important role during development, in cochlear homeostasis and in the response to 
trauma [Gale and Jagger, 2010].  
Figure 1.1. Diagram of the human ear. A. Schematic illustration of the three anatomical 
components of the ear. B. Cross section of the cochlear duct showing the three scalae and 
the organ of Corti, which is further detailed in C. C. The organ of Corti with the overlying 
tectorial membrane is illustrated. Inner hair cells (IHC), outer hair cells (OHC) and the 
main supporting cells (C) subtypes are shown. Inner border and inner phalangeal cells 
surround IHCs, while OHC are supported by Deiters’ cells. Pillar cells form the tunnel of 
Corti. The interdental cells, connecting the tectorial membrane to the spiral limbus, are also 
illustrated. Adapted from Dror and Avraham, 2010. 
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The hair cells are arranged in a highly organised conformation of one inner row (inner hair 
cells, IHC) and three outer rows of hair cells (outer hair cells, OHC) along the duct (Fig. 
1.1C). The apical side of the hair cells contains actin-rich projections organised in rows 
called stereocilia (or hair bundle) that bath in the endolymph. The apical ends of stereocilia 
are linked to the side of the neighboring taller stereocilia through tip links, composed of 
the transmembrane proteins protocadherin 15 and cadherin 23 [McGrath et al., 2017] (Fig. 
1.2). The tallest row of OHC stereocilia is in physical contact with the overlying tectorial 
membrane (TM). The TM, an acellular gelatinous matrix composed of collagen and 
glycoproteins, is attached to the spiral limbus through the interdental cells. It is secreted by 
the cells of the Kölliker’s organ, a transient structure which is present during the 
development and progressively regresses to form the inner sulcus in the mature organ of 
Corti (Fig. 1.1C) [Kelley, 2007]. When the sound wave is transmitted to the oval window by 
the stapes, it travels along the scalae vestibuli and tympani causing the perilymph 
movement which, in turn, induces the vibration of the BM. The displacement of the BM 
results in the movement of the HC towards the TM and in the deflection of the hair 
bundle in the direction of the taller stereocilia. The motion of the hair bundle is coupled to 
the opening of mechanoelectrical transduction (MET) channels - which are localised in the 
tips of stereocilia - by the tip links (Fig. 1.2). The EP, generated by the SV, provides the 
main driving force for sensory transduction. In fact, it helps to drive K+ ions through the 
MET channel rapidly. This results in the depolarisation of the HCs that triggers the 
opening of voltage-sensitive calcium channels and the release of neurotransmitter at the 
base of the HCs, leading to the mechanoelectrical transduction of the sound. Deflection of 
the hair bundle in the opposite direction closes the MET channels, stopping the 
neurotransmitter release [Wangemann, 2002; Richardson et al., 2011]. While the IHCs are 
the true sensory cells, making synaptic connections with afferent spiral ganglion neuron 
(SGN) terminals, the OHCs amplify the signal enhancing the sensitivity and selectivity of 
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the cochlea. In fact, the depolarisation of the OHC results in the change of the cell length 
that amplifies the motion of the OC in that specific region. The length change is made 
possible by the concerted voltage-induced conformational change of prestin protein, 
localised at the basolateral membrane of the OHCs [Zheng et al., 2000].  
Figure 1.2. Schematic representation of hair cell stereocilia during deflection. The 
tip-link proteins protocadherin 15 (in pink) and cadherin 23 (in green) and the MET 
channels are indicated. The blue arrows indicate the entrance of cations through the MET 
channels. The red lines represent actin filaments. Adapted from Richardson et al., 2011. 
The sensory information transduced by the IHCs is conveyed by the SGNs, whose central 
axons form the vestibulocochlear nerve (cranial nerve VIII) and project to the cochlear 
nuclei in the brainstem. Subsequently, the auditory information is transmitted to the 
brainstem superior olivary complex and then travels through the inferior colliculus in the 
midbrain and to the medial geniculate nucleus of the thalamus, and finally to the auditory 
cortex [Butler and Lomber, 2013].  
The cochlea is characterised by a tonotopic organisation, transducing high frequencies at 
the base and low frequencies at the apex. This organization results from several 
morphological gradients existing along the cochlea. For example, the OHCs and their 
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stereocilia become longer from the base to the apex and both the BM and the TM 
membrane become wider and thicker towards the apex, so that the HCs are activated by 
different frequencies depending on their localisation along the sensory epithelium [Son et 
al., 2012]. This tonotopic organisation is also maintained in all relays of the ascending 
auditory pathway [Butler and Lomber, 2013]. 
1.2. The development of the inner ear in mammals 
Although the mouse is most often the preferred animal model, the principal cochlear 
developmental events are similar in all mammals [Bianchi and Fuchs, 2010]. The 
mammalian inner ear forms from a thickening of the ectoderm on either side of the 
rhombencephalon (hindbrain), called the otic placode (Fig. 1.3A). The otic placode, evident 
in the mouse embryo at 8-8.5 days post coitum (dpc) [Kaufman, 1999] and in the human 
embryo at ~20 days post fertilization (dpf) [O'Rahilly, 1983], starts to invaginate to form the 
otic pit (Fig. 1.3B) and, by 10 dpc in the mouse [Kaufman, 1999] and ~28 dpf in the 
human [O'Rahilly, 1983], it completely closes, forming the otic vescicle or otocyst (Fig. 
1.3C). During the otocyst formation, the cochlear and vestibular neurons originate by 
delamination of the anteroventral region of the otic vescicle and form a single structure, 
called statoacustic ganglion (SAG) (Fig. 1.3B-D), from which the cochlear and vestibular 
ganglia will arise later in the development [Torres and Giráldez, 1998]. 
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Figure 1.3. Schematic illustration of mammalian inner ear early development. A. 
Transverse section of the head region of a developing mammalian embryo at the level of 
the hindbrain (HB, dorsal to the top). The otic placodes are shown in purple. NC: 
notochord. B. Invagination of the otic placode into the otic pit. The neuroblasts (NB) 
delaminating from the otic epithelium are shown in lilac. C. The otic vescicle or otocyst 
and the statoacustic ganglion (SAG) are shown. D. Otocyst differentiation: the dorsal 
region will give rise to the vestibular structures, whereas the ventral region will elongate and 
coil to form the cochlea. Adapted from Torres and Giráldez, 1998. 
Numerous signal molecules originating from the hindbrain and the periotic mesenchyme 
contribute to the complex morphogenic changes that establish the dorsoventral and 
anteroposterior axes. As a result, at 10.75 dpc (~32 dpf in human) the cochlear portion 
starts to protrude from the ventral region of the otocyst (Fig. 1.3D) and as it elongates it 
starts to coil, achieving the 1.75 turns of the mature mouse cochlea by 17 dpc and the final 
2.5 turns at 57 dpf in the human [Cantos et al., 2000; O'Rahilly, 1983]. At this stage, the 
scala vestibuli and scala tympani begin to open starting from the base towards the apex. As 
a result, at the apex only one chamber – the developing scala media – can be seen in a cross 
section of a 16.5 dpc mouse cochlea (Fig. 1.4). 
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While these gross morphological changes are occurring, the epithelial cells of the emerging 
cochlear duct, which have proliferated from the apex to the base of the cochlea (12-16 dpc 
in the mouse), begin to differentiate in a base-to-apex direction. In addition, there is a 
modiolar to strial gradient of differentiation, so that IHCs differentiate before OHCs. For 
this reason, at 15 dpc IHCs can be identified in the mid-basal turn of the mouse cochlea, 
while cell differentiation only starts at 18 dpc in the apical turn [Bianchi and Fuchs, 2010]. 
Differences in the dorsal and ventral wall of the cochlear duct can already be observed at 
12.5 dpc, as the dorsal wall epithelium appears thicker than the ventral wall (6 versus 2-3 cell 
layers). By 16 dpc the dorsal epithelium differentiates in two cellular ridges, called the 
greater epithelium ridge (GER), which comprises the Kölliker’s organ and will develop into 
the inner sulcus, spiral limbus and IHCs, and the lesser epithelium ridge (LER), from which 
OHCs, Deiters’ cells and the cells of the outer sulcus will emerge. The pillar cells develop 
at the boundary of the two epithelial ridges and will form the “walls” of the tunnel of Corti 
only after birth in the mouse. In fact, besides being distinguishable at 16 dpc based on their 
position, supporting cells start their morphological differentiation only postnatally [Bianchi 
and Fuchs, 2010], so that the cochlea reaches its mature configuration approximately at 2 
postnatal weeks in the mouse. Therefore, mice start to hear around postnatal day 12 (P12) 
[Mikaelian and Ruben, 1965]. In humans, instead, by 25 weeks post conception the 
structures of the cochlea have a near-adult maturation, so that neonates are able to respond 
to sound stimuli at birth [Bianchi and Fuchs, 2010]. 
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Figure 1.4. Mid-modiolar section of a 16.5 dpc mouse foetus. The scalae tympani (ST) 
and vestibuli (SVe) start to open in a base-to-apex direction. Only the scala media (SM) can 
be observed in the apical turn. Asterisks indicate the spiral ganglia. M: modiolus. Dorsal to 
the bottom. The image was acquired with a Zeiss Axioskop microscope. Scale bar: 100 µm. 
1.3. Hearing Loss 
Hearing loss (HL), affecting at least 1 in 500 newborns, is the most common sensory 
disorder in humans. Over the 5% of the world’s population has disabling hearing loss and 
it is estimated that by 2050 1 in 10 people will be affected by disabling hearing loss (World 
Health Organization, 2018, http://www.who.int/news-room/fact-sheets/detail/deafness-
and-hearing-loss). Hearing loss may have a dramatic impact on the quality of life at any age. 
If not promptly diagnosed in newborns, it could have major effects in speech acquisition 
and social development. When occurring later in adult life, HL could impact the social and 
working life. Also, in elderly people, deafness could lead to isolation and depression 
[Bitner-Glindzicz, 2002; Morton and Giersch, 2010]. 
Hearing loss is a heterogeneous disease that can have environmental or genetic causes. 
Noise exposure, ototoxicity (e.g. aminoglycosides, platinum derivatives), congenital 
(cytomegalovirus, rubella, toxoplasmosis) or acquired (meningitis, measles) infections, 
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prematurity, head trauma are all environmental causes of deafness. However, it is estimated 
that at least half of HL cases has a genetic basis [Schrijver, 2004]. To complicate matters, 
some genetic variants can predispose to environmental and age-related hearing loss [Tu and 
Friedman, 2018]. 
Given its clinical heterogeneity, HL can be further classified considering several criteria, 
such as the severity, being divided in mild (when the hearing loss is between 20 and 39 dB), 
moderate (40-69 dB), severe (70-89 dB), profound (over 90 dB) HL (Fig. 1.5) [Schrijver, 
2004]. HL is defined “disabling” when the hearing loss is greater than 40 dB in adults (from 
15 years old) or greater than 30 dB in children (0-14 years old) in the better hearing ear 
(World Health Organization, 2018, http://www.who.int/news-room/fact-
sheets/detail/deafness-and-hearing-loss). HL can also be classified based on the age of 
onset as prelingual or post-lingual, with reference to the commencement of speech. Based 
on the site of damage, HL can be defined conductive (when the HL is caused by outer 
and/or middle ear abnormalities, such as in otosclerosis) or sensorineural (caused by 
malfunction of the inner ear, the VIII nerve, brainstem, or auditory cortex). When HL is 
characterised both by conductive and sensorineural defects, it is defined mixed. Finally, 
genetic cases of HL can be divided into nonsyndromic (NSHL), when HL is the only 
symptom, or syndromic (SHL), when additional clinical features are present [Korver et al., 
2017].  
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Figure 1.5. Severity of HL. The audiogram is a graph showing the audible thresholds for 
each frequency tested. On the left, audiogram showing the different degrees of hearing 
loss. On the right, example of audiogram from a hearing-impaired individual, showing that 
the severity of HL can vary at different frequencies. The threshold average for the right and 
left ear is represented. 
1.4. Genetics of hearing loss 
The clinical heterogeneity of HL is paralleled by its extreme genetic and allelic 
heterogeneity, reflecting the anatomical and functional complexity of the ear. Not 
surprisingly, it is estimated that up to 1% of all human genes are involved in hearing 
function [Nance 2003]. Approximately 70% of genetic cases are nonsyndromic, while in 
the remaining 30% of cases the presence of additional clinical features associated with HL 
can contribute to the diagnosis of one of the over 400 syndromes that have hearing loss as 
a component [Schrijver, 2004; Korver et al., 2017]. 
1.4.1. Nonsyndromic hearing loss 
To date, more than 150 loci have been associated with NSHL and over 100 responsible 
genes have been identified (Hereditary Hearing Loss Homepage, 
https://hereditaryhearingloss.org/, last accessed: October 2018) (Fig. 1.6). NSHL is most 
often sensorineural and the inheritance pattern can be autosomal recessive (ARNSHL, 80% 
of cases), autosomal dominant (ADNSHL, 15-20%), X-linked (1.5%) or mitochondrial 
(1%) [Schrijver, 2004]. In most cases, recessive NSHL is prelingual and severe, whereas 
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dominant NSHL is post-lingual and progressive [Petit, 1996]. NSHL loci are named based 
on the mode of inheritance as DFNA (AD), DFNB (AR), DFNX (X-linked). One locus 
(DFNY1) for Y-linked NSHL was also mapped [Wang et al., 2004], but no responsible 
gene has been identified yet. In addition, DFNM denotes loci associated with modifier 
genes, whose mutation can affect the phenotype resulting from a mutation in another gene 
[Riazuddin et al., 2000; Bykhovskaya et al., 2000; Yousaf et al., 2018a]. Finally, specific 
symbols are used for mitochondrial NSHL (MTRNR, MTTS), auditory neuropathy 
(AUNA) and otosclerosis (OTSC). A number is assigned to each locus, reflecting the 
chronological order in which they were mapped [Dror and Avraham, 2010]. However, the 
same gene can be associated with multiple loci, as different mutations in the same gene 
might be responsible for both ARNSHL and ADNSHL or even cause SHL (Fig. 1.6, Table 
1.1, Appendix 6.1). The extreme genetic and clinical heterogeneity of the disease has 
hindered a full comprehension of genotype-phenotype correlations in NSHL patients. In 
fact, the onset, severity and progression of NSHL associated with different underlying 
genetic causes are often indiscernible [Vona et al., 2015] (Table 1.1). For instance, mutations 
in many ADNSHL genes with diverse functions cause post-lingual progressive NSHL 
beginning with loss of high frequencies and are characterised by a downsloping audiogram 
(Table 1.1). On the other hand, other ADNSHL genes have more distinctive audiogram 
profiles and thus the phenotype observed might be predictive of the underlying gene. 
Indeed, the AudioGene tool has been developed in order to prioritise candidate genes for 
mutation screening on the basis of the audioprofile [Hildebrand et al., 2009]. In addition, a 
relatively small subset of ARNSHL genes is frequently associated with vestibular symptoms 
or cochlear abnormalities. Therefore, the observation of such clinical features might be 
suggestive of mutations in specific genes (Table 1.1, Appendix 6.1) and thus provide a 
guidance for genetic testing. 
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Figure 1.6. Schematic representation of the localisation of the genes associated with 
HL. The genes associated with autosomal recessive (in red), autosomal dominant (in blue), 
X-linked (in black) NSHL and with some syndromic forms of HL (in green) are indicated. 
The genes both associated with NSHL and SHL are shown in light blue. Updated (based 
on Hereditary Hearing Loss Homepage, https://hereditaryhearingloss.org/, last accessed: 
October 2018) from Raviv et al., 2010. 
In the last 25 years, the identification of NSHL genes through linkage studies in large 
families, characterisation of mouse models (see Paragraph 1.6) and, more recently, next-
generation sequencing (see Paragraph 1.5) allowed the discovery of numerous molecular 
processes fundamental for hearing. Therefore, the genes responsible for NSHL can be 
grouped in broad functional categories, including: gene regulation, mechanotransduction, 
31 
 
ion homeostasis. 
Gene regulation – The exact otocyst patterning and cochlear morphogenesis involve the 
spatiotemporally controlled interaction of many transcription factors (TFs) [Cantos et al., 
2000], therefore several genes encoding TFs are associated with NSHL in humans. 
Examples include two TFs of the POU domain superfamily, POU4F3 and POU3F4, which 
are associated with progressive HL. POU4F3 was shown to be fundamental for OHCs 
survival and maturation as the corresponding Pou4f3 knock-out mouse show OHC 
degeneration [Hertzano et al., 2004]. Mutations in this gene cause ADNSHL DFNA15 
(MIM#602459) [Vahava et al., 1998] in humans. The mouse orthologue of POU3F4, 
instead, is expressed in the periotic mesenchyme and mutant mice show impaired 
endocochlear potential due to defects in spiral ligament fibrocytes [Braunstein et al., 2008]. 
POU3F4 is associated with X-linked HL DFNX2 (MIM#304400), which can be 
sensorineural or mixed, and might be also associated with bony labyrinth defects [de Kok et 
al., 1995]. Besides TFs, other important regulatory molecules are microRNAs (miRNAs), 
which act at the post-transcriptional level by controlling the expression of target genes. In 
particular, the miR-183 family of miRNAs (comprising miR-183, miR-182 and miR-96) 
plays an important role in vertebrate hair cell development: indeed, mutations affecting 
MIR96 gene lead to deafness in both mice (Diminuendo mutant) and humans (autosomal 
dominant deafness DFNA50) [Lewis et al., 2009; Mencía et al., 2009]. 
Mechanotransduction – The process by which hair cells convert the mechanical stimulus of 
sound waves into an electrical signal rely on the integrity of all the cochlear structures 
contributing to this process. Therefore, it should come as no surprise that mutations in 
genes encoding hair bundle proteins, channels and extracellular matrix proteins cause HL. 
The core of stereocilia is composed of packed bundles of crosslinked actin filaments, which 
are regulated by several proteins, such as diaphanous 1 (involved in actin polymerization), 
espin (required for stereocilia integrity and length regulation), unconventional myosins 
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(essential for stereocilia organisation and for the transport of other structural proteins 
along the stereocilia). Mutations in ACTG1 (encoding γ-actin, the predominant actin 
isoform in hair cells), DIAPH1, ESPN genes as well as mutations in the genes encoding 
motor proteins (MYO3A, MYO6, MYO7A, MYO15A, MYH9) have all been linked to 
different types of inherited NSHL [respectively Zhu et al., 2003, van Wijk et al. 2003; Lynch 
et al., 1997; Naz et al., 2004; Walsh et al., 2002, Grati et al., 2016;  Melchionda et al., 
2001, Ahmed et al., 2003a; Liu et al., 1997a, Liu et al., 1997b; Wang et al., 1998; Lalwani et al., 
2000] and, in the case of MYO7A, also to SHL [Weil et al., 1995]. The tip of each 
stereocilium is connected to the side of the adjacent taller stereocilium with a tip link, 
which is composed by cadherin 23 and protocadherin 15 proteins and is fundamental to 
couple the displacement of the hair bundle to the opening of MET channels (Fig. 1.2). 
Although the exact composition of the MET channels is still unclear, TMC1 has been 
recently demonstrated to form their pore, likely with the contribution of other proteins, 
such as TMIE and LHFPL5 [Pan et al., 2018]. The genes encoding these proteins (CDH23, 
PCDH15, TMC1, TMIE, LHFPL5) have also been associated with NSHL [respectively 
Bork et al., 2001; Ahmed et al., 2003b; Kurima et al., 2002; Naz et al., 2002; Kalay et al., 
2006]. 
Finally, another essential structural component for mechanotransduction is the tectorial 
membrane: genes encoding for some of the extracellular matrix protein composing it, 
namely TECTA [Mustapha et al., 1999], COL11A2 [Chen et al., 2005], OTOA [Zwaenepoel 
et al., 2002], OTOG [Schraders et al., 2012] and OTOGL [Yaritz et al., 2012] have also been 
linked to NSHL. 
Ion homeostasis – The mechanotransduction would not take place without the endocochlear 
potential and the precise ion composition existing in the endolymphatic fluid. Not 
surprisingly, several genes coding for proteins involved in the maintenance of ion gradients 
(SLC26A4), in the recycling of potassium (KCNQ4, GJB2, GJB3, GJB6) or contributing to 
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the physical separation of endolympatic and perylimphatic spaces (CLDN14) are associated 
with HL. For instance, the Cl-/HCO3- exchanger pendrin, encoded by SLC26A4 gene and 
expressed in the spiral prominence (the projecting structure at the lower margin of the stria 
vascularis) and in the outer sulcus (between the spiral prominence and the supporting cells 
of Claudius), was found to be important for the maintenance of EP, as demonstrated by 
loss of EP in Slc26a4−/− mice. In fact, lack of pendrin leads to the acidification of 
endolymph which, in turn, inhibits the acid-sensitive calcium channels of the stria 
vascularis, causing an increase of endolymphatic calcium concentration [Wangemann et al., 
2007]. Concerning K+ recycling, the potassium entered in the HCs upon the opening of 
MET channels, is then released into the perilymph from basolateral K+ channels, including 
KCNQ4. The potassium is then recycled through the outer sulcus root cells and the spiral 
ligament fibrocytes, and it is transported from cell to cell via gap junctions to the stria 
vascularis [Wangemann, 2002; Jagger et al., 2010]. Each gap junction between two cells is 
composed of two hexameric hemichannels or connexons, made up of the transmembrane 
protein connexins. Connexin 26 (encoded by GJB2 gene), 30 (GJB6) and 31 (GJB3) form 
the gap junctions in the inner ear. Importantly, recessive mutations in GJB2 account for 
half of the cases of prelingual ARNSHL (DFNB1A, MIM#220290) and GJB2/GJB3 or 
GJB2/GJB6 digenic inheritance has also been described [Del Castillo et al., 2003; Liu et al., 
2009]. Finally, ion homeostasis is preserved thanks to the separation of compartments 
containing fluids with different ion composition. This is made possible by the tight 
junctions that form a semipermeable seal at the apical side of sensorial and supporting cells. 
Tight junctions are composed of several molecules including claudins, occludins and 
tricellulin. Both CLDN14 (encoding claudin 14) and MARVELD2 (coding for tricellulin) 
mutations have been associated with ARNSHL [Wilcox et al., 2001; Riazuddin et al., 2006]. 
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Table 1.1. Example of NSHL genes and their clinical manifestations. 
Gene Locus Onset NSHL phenotype Additional features (SHL) 
ACTG1 DFNA20/26 Post-lingual 
(1st/2nd decade) 
Downsloping audiogram; moderate-to-
profound; progressive 
  
CDH23 DFNB12 Prelingual 
Downsloping; moderate-to-profound; 
progressive 
Usher syndrome (profound congenital 
HL, retinitis pigmentosa, constant 
vestibular dysfunction) 
CLDN14 DFNB29 Prelingual Severe-to-profound; stable   
COL11A2 
DFNA13 
Post-lingual 
(2nd/4th) 
Moderate-to-severe; progressive 
Otospondylomegaepiphyseal dysplasia 
(sensorineural HL and short 
extremities with large epiphyses) 
DFNB53 Prelingual Severe-to-profound; stable   
DIAPH1 DFNA1 Post-lingual (1st) Low-frequency; progresses to profound 
HL involving all frequencies 
High-frequency progressive HL with 
thrombocytopenia 
ESPN DFNB36 Prelingual Profound with or without vestibular areflexia 
GJB2 
DFNA3A Prelingual/post-
lingual (1st/2nd) 
Downsloping; mild-to-profound 
(variable); progressive 
Different syndromic forms causing HL 
and skin problems 
DFNB1A Prelingual Mild-to-profound (variable); progressive 
(~50%). Vestibular symptoms (~50%). 
  
GJB3 DFNA2B Post-lingual (4th) Downsloping; progressive   
GJB6 DFNA3B 
 
Prelingual Downsloping; mild-to-profound; progressive 
  
DFNB1B Prelingual Severe; stable. Possible vestibular symptoms. 
  
KCNQ4 DFNA2A Post-lingual 
(1st/2nd) 
Downsloping; progresses, involving all 
frequencies 
  
LHFPL5 DFNB66/67 Prelingual Severe-to-profound; stable   
MARVELD2 DFNB49 Prelingual Moderate-to-profound; stable   
MIR96 DFNA50 Post-lingual (1st) Flat; mild-to-profound; progressive   
MYH9 DFNA17 
Post-lingual 
(1st/3rd) 
Downsloping; progressive 
Macrothrombocytopenia and 
granulocyte inclusions with or without 
nephritis or sensorineural HL 
MYO15A DFNB3 Prelingual Severe-to-profound; stable   
MYO3A - Post-lingual (1
st) Moderate-to-profound; progressive   
DFNB30 Prelingual Downsloping; moderate-to-profound; progressive 
  MYO6 
DFNA22 Post-lingual (1st) Mild-to-profound; progressive HL and hypertrophic cardiomyopathy 
DFNB37 Prelingual Severe-to-profound; progressive   
MYO7A 
DFNA11 
Post-lingual 
(1st/5th) 
Flat/gently downsloping; moderate; 
progressive. Mild vestibular symptoms in 
some patients. 
  
DFNB2 Prelingual/post-
lingual (1st/2nd) 
Downsloping; severe-to-profound. 
Vestibular symptoms in some patients. 
Usher syndrome 
OTOA DFNB22 Prelingual Moderate-to-profound; stable   
OTOG DFNB18B Prelingual Downsloping; mild-to-moderate; stable   
OTOGL DFNB84B Prelingual Downsloping; moderate; stable   
PCDH15 DFNB23 Prelingual Severe-to-profound; stable Usher syndrome 
POU3F4 DFNX2 Prelingual 
Sensorineural or mixed; progresses to 
profound. Female carriers have a later 
onset. Possible bony labirinth defects. 
  
POU4F3 DFNA15 Post-lingual 
(2nd/6th) 
Flat/downsloping; mild-to-severe; 
progressive 
  
SLC26A4 DFNB4 Prelingual Moderate-to-profound. EVA or 
Mondini dysplasia; vestibular symptoms.  
Pendred syndrome (HL and goiter) 
TECTA 
DFNA8/12 Prelingual/post-
lingual (1st/2nd) 
U-shaped; moderate-to-severe; 
stable/progressive 
  
DFNB21 Prelingual Flat/U-shaped; severe-to-profound; stable 
  TMC1 
DFNA36 Post-lingual 
(1st/3rd) 
Downsloping; severe-to-profound; 
progresses, involving all frequencies 
  
DFNB7/11 Prelingual Profound; stable   
TMIE DFNB6 Prelingual Severe-to-profound; stable  
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1.4.2. Syndromic hearing loss 
More than 400 syndromes that include hearing loss have been described. However, in some 
syndromes, HL is a minor component, whereas in others it is an important symptom for 
clinical diagnosis [Morton and Giersch, 2010]. Examples of syndromes in which HL is an 
important component include Pendred syndrome (PDS), Alport syndrome (AS) and 
Perrault syndrome (PRLTS) [Parker and Bitner-Glindzicz, 2015]. 
PDS, characterised by deafness, thyroid dysfunction and possible cochlear and vestibular 
malformations, is one of the most common form of autosomal recessive SHL [Koffler et 
al., 2015]. It is most frequently caused by biallelic pathogenic variants in SLC26A4, but 
cases of double heterozygosity for one mutation in SLC26A4 and one mutation in either 
KCNJ10 or FOXI1 genes have also been described [Yang et al., 2007; Yang et al., 2009]. 
While KCNJ10 potassium channels and pendrin (Paragraph 1.4.1) are essential for the 
generation and maintenance of the EP [Yang et al., 2009], FOXI1 is a transcription factor 
that regulates SLC26A4 expression [Yang et al., 2007]. In addition, pendrin is expressed in 
thyroid follicular cells, where it participates to the apical iodide secretion [Bizhanova and 
Kopp, 2009]. Mutations in these genes are also associated with NSHL (DFNB4, 
MIM#600791). However, since the association with syndromic features such as goitre 
could be delayed, a first diagnosis of NSHL could change in PDS over time [Parker and 
Bitner-Glindzicz, 2015]. 
AS is a progressive inherited renal disease characterised by sensorineural hearing loss and 
ocular anomalies. It is caused by mutations in the COL4A3, COL4A4, and COL4A5 genes, 
encoding the α3, α4, and α5 chains of collagen type IV. Indeed, the α3α4α5(IV) collagen 
triple helix is a major structural component of the glomerular basement membrane and of 
the basement membranes in the cochlea and eye. Mutations in these genes cause the 
formation of abnormal collagen chains which fail to be incorporated in the basement 
membranes and result in the persistence of the foetal collagen α1α1α2(IV) heterotrimer, 
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which is more susceptible to endoproteolysis. Therefore, the arrest of the developmental 
isoform switch undermines the integrity and mechanical stability of the basement 
membranes, consequently leading to the clinical phenotype observed in AS patients 
[Hudson et al., 2003; Kashtan, 2019]. While the most common form of AS is X-linked 
(MIM#301050, ~65% of cases) and it is caused by mutations in the COL4A5 gene, 
mutations in COL4A3 and COL4A4 genes are associated with both autosomal dominant 
(MIM#104200, ~20%) and autosomal recessive (MIM#203780, ~15%) AS. Renal disease 
usually progresses from microscopic hematuria to end-stage renal disease in all males with 
X-linked AS and in all males and females with autosomal recessive AS [Kashtan, 2019]. 
Some heterozygous mutations in COL4A3 and COL4A4 genes can cause benign familial 
hematuria (MIM#141200), a milder phenotype which is characterised by persistent 
microscopic hematuria, rarely combined with progressive proteinuria and end-stage renal 
disease [Stokman et al., 2016]. AS is characterised by a high allelic heterogeneity, which is 
paralleled by a high inter- and intra-familial phenotypic variability [Lemmink et al., 1997]. 
PRLTS (MIM #233400), is an autosomal recessive disorder that, to date, has been 
associated with mutation in 6 genes (CLPP, C10ORF2, ERAL1, HARS2, HSD17B4 and 
LARS2) [Newman et al., 2018]. It is characterised by sensorineural HL in both sexes and 
ovarian dysgenesis in females, so that it could be confused with NSHL in males from 
clinical diagnosis [Parker and Bitner-Glindzicz, 2015]. As the clinical diagnosis is mostly 
based on suggestive findings and family history, the genetic diagnosis can be very useful to 
confirm a suspect of PRLTS and to exclude other causes of HL and ovarian dysfunction. 
1.5. Next-generation sequencing and its application in studying the genetic bases of 
human hearing loss 
The high level of genetic and allelic heterogeneity of hearing loss and the lack of a precise 
phenotype-genotype correlation make its genetic diagnosis with traditional screening 
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methods (i.e. Sanger sequencing) extremely challenging. In fact, while mutations in the 
GJB2 gene are the most common cause of autosomal recessive NSHL in many 
populations, the vast majority of deafness-causing variants are private [Duman and Tekin, 
2012]. Moreover, Sanger sequencing is particularly expensive and time-consuming, as many 
HL genes have numerous and/or long exons. The development of next-generation 
sequencing (NGS) technologies, allowing the massively parallel analysis of millions of 
sequences in a single run, has dramatically reduced the cost and the time of DNA 
sequencing [Bamshad et al., 2011]. In addition, as 85% of disease-associated variants affects 
exonic or splice-site regions, exome represents a subset of the genome where to efficiently 
search for pathogenic variants. Indeed, whole-exome sequencing (WES) has provided a fast 
and cost-effective alternative screening method to search for alleles underlying Mendelian 
disorders [Bamshad et al., 2011]. 
Despite being characterised by different chemistry and protocols, the past and currently 
available NGS platforms share a similar workflow for WES. First, the genomic DNA is 
randomly fragmented, and the ends of the obtained fragments are ligated to platform-
specific adaptors. Then, the genomic regions of interest (e.g. the exome) are enriched, 
either by PCR amplification or by capturing by hybridization, and the resulting DNA 
molecules are clonally amplified. Each DNA molecule is amplified in an isolated space, 
generally by emulsion PCR (Roche 454 system, ThermoFisher Ion Torrent) or bridge PCR 
(Illumina platforms), and sequenced in a parallel fashion. The obtained sequences, called 
“reads”, are usually generated through sequencing-by-synthesis reactions, in which the 
nucleotides are detected as they are incorporated into a nascent DNA strand. For Ion 
Torrent, this is made possible by the detection of the changes in pH resulting from the 
incorporation of the different nucleotides. On the contrary, for Roche 454 and Illumina 
platforms, the sequence analysis is based on the use of optical detection, whether of light 
via pyrosequencing (Roche) or of the fluorescence emitted by specific reversible 
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terminators (Illumina) [Shendure and Ji, 2008; Levy and Myers, 2016]. Massive parallel 
sequencing allows to sequence at the same time many randomly overlapping DNA 
fragments, so that each nucleotide can be included in different fragments, which are 
analysed several times. This strategy allows to increase the depth of coverage and, 
consequently, the sequencing accuracy [Lin et al., 2012]. In addition, Illumina technology 
enables the “paired-end” sequencing, in which each DNA fragment is sequenced from 
both ends, improving the mapping of reads to the reference sequence [Levy and Myers, 
2016]. Even if Illumina is currently the predominantly used NGS technology, the so-called 
third-generation technologies are emerging, with the advantage of overcoming the 
requirement of DNA amplification and allowing the sequencing of longer reads. Indeed, 
platforms such as the Oxford Nanopore are valuable for the resolution of structural 
variations in the genome, which are hardly detected using short-read sequencing [Levy and 
Myers, 2016; Heather and Chain, 2016]. 
Concerning HL, NGS has allowed not only the creation of clinical panels to test known 
deafness genes [Brownstein et al., 2012], but also the discovery of novel HL genes. For 
instance, NGS has enabled the identification of the causative gene in “orphan” NSHL loci, 
which were mapped through linkage analyses in large families before the introduction of 
NGS technologies [Rehman et al., 2010; Santos-Cortez et al., 2014]. In addition, WES alone 
is particularly helpful for small pedigrees, which are not suitable for linkage analysis [Vona 
et al., 2015], and has been successfully applied to the discovery of novel NSHL and SHL 
genes and mutations [Chatzispyrou et al., 2017; Yousaf et al., 2018b]. Importantly, since the 
first publications describing the discovery of novel deafness genes using NGS in 2010 
[Rehman et al., 2010; Walsh et al., 2010] a total of 46 novel NSHL genes have been 
identified by targeted sequencing or WES – alone or coupled with linkage analyses [Vona et 
al., 2015; Hereditary Hearing Loss Homepage, https://hereditaryhearingloss.org/]. 
However, the pace of the discovery of novel deafness genes is not always followed by a 
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clear understanding of their role in the hearing function. For this purpose, animal models – 
primarily mice - can be particularly useful. 
1.6. The mouse as a model to study the genetics of hearing loss 
The study of the physiology of hearing and of the pathological mechanisms of hearing loss 
in humans is limited by the inaccessibility of the inner ear in living humans and demands 
the use of animal models. The laboratory mouse provides several advantages that are 
generally convenient for the study of the genetics bases of human disease, such as the 
relatively short gestation time (3 weeks), the short life span (enabling to follow the 
evolution of a disease in a contracted time period), the availability of inbred strains 
(isogenic mice, that ensures the study of a genetic feature in a homogenous genetic 
background), the high protein sequence conservation between mouse and human (~99% 
of genes in mice have a human orthologue), the mouse-human conserved synteny 
relationship (conservation of gene content and order on chromosomes) and the ease of 
genetic manipulation [Mouse Genome Sequencing Consortium et al., 2002; Kikkawa et al., 
2012]. In addition, the morphological and functional similarity of the hearing structures 
[Kikkawa et al., 2012] and the conservation of the principal inner ear development stages in 
mice and humans (Paragraph 1.2) make the mouse a model particularly suitable for hearing 
research.  
Mouse mutants have proven a highly effective research tool to investigate auditory 
function, as well as to characterise the molecular processes that are impaired once a 
mutation occurs in one of the critical genes for hearing. 
In many cases, the discovery of the ortholog mouse deafness gene has led to the 
subsequent identification of the human deafness gene. For example, a mutation in Myo6 
gene was first identified as the cause of deafness in the spontaneous mouse model Snell’s 
waltzer [Avraham et al., 1995]. Only some years later MYO6 was associated with autosomal 
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dominant (DFNA22) [Melchionda et al., 2001] and autosomal recessive (DFNB37) [Ahmed 
et al., 2003a] hearing loss in humans. 
In addition to the study of spontaneously occurring mutations, the investigation of 
chemically-induced mouse mutants has allowed the discovery of many genes involved in 
hearing and balance defect, thus helping to elucidate the physiological process of hearing 
and the pathological mechanism underlying deafness [Hardisty-Hughes et al., 2010]. 
Finally, knock-out and knock-in models, allowing the targeted mutation of specific genes, 
have enabled the understanding of the function of specific components of the hearing 
apparatus and the study of their interaction. For example, the targeted knock-out of Slc26a4 
gene provided insights into the function of pendrin, which had already been linked to 
DFNB4 and PDS [Everett et al., 2001]. Importantly, in 2006 the Sanger Institute’s Mouse 
Genetics Project (MGP) was established with the aim of producing mouse knock-outs of 
every gene and screening them for a large set of traits, including hearing defects [White et 
al., 2013]. This approach has already led to the identification of several novel genes 
associated with deafness and the data collected are made publicly available on the database 
of the International Mouse Phenotyping Consortium (IMPC, 
http://www.mousephenotype.org), of which the MGP is a founder member. 
Besides these international phenotyping efforts, the generation of mouse knock-outs and 
knock-ins is particularly useful to study the effect of human mutations identified in novel 
candidate deafness genes and, ultimately, to demonstrate the involvement of these genes in 
hearing loss. The process of generating specific mouse mutants harboring the 
corresponding mutations identified in human genes has been facilitated by the 
development of the CRISPR/Cas9 genome-editing technology, which enables the fast and 
efficient generation of these mouse models [Wang et al., 2013]. 
Despite the undeniable role of mouse models in the advancement of the knowledge in the 
auditory field, it is necessary to point out that there are also examples of mouse models that 
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don’t recapitulate the human phenotype. The lack of a suitable mouse model hampers the 
elucidation of the function of these genes, as well as of the pathophysiological mechanisms 
leading to deafness [Hosoya et al., 2016]. 
1.7. Thesis aims 
The overall goal of this project is to provide new insights into the genetic bases of deafness 
focussing on 11 families affected by hereditary hearing loss and applying whole-exome 
sequencing as a comprehensive screening for candidate causative variants.  
In the cases of identification of variants of unknown significance in known deafness genes, 
this work aims at functionally characterise the candidate mutations by specific in-silico and 
in-vitro studies. 
In the case of variants identified in novel candidate deafness genes, my project aims at 
demonstrating their involvement in the pathogenesis of hearing loss. In particular, 
DIAPH2 gene was identified as a novel candidate NSHL gene in one Italian family with a 
recessive inheritance pattern. DIAPH2 codes for a member of the Diaphanous-related 
formins, which are involved in the nucleation of linear unbranched actin filaments. 
Interestingly, other members of the gene family, namely DIAPH1 and DIAPH3, are 
associated with different types of hearing loss. This work aims at exploring the role of this 
gene in hearing function by studying the effect of the mutation by in-vitro studies and by 
using mouse models. The specific aims of this part of the work are: 
1. Evaluate the effect of the DIAPH2 candidate mutation 
2. Investigate whether DIAPH2 is mutated in other deaf individuals  
3. Analyse the expression of the mouse ortholog protein Diap2 in the cochlea 
4. Evaluate the hearing phenotype of Diaph2 knock-out and knock-in mouse models.
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2. Materials and Methods
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2.1. Patients 
A total of 11 HL families, including 8 families affected by dominant or recessive NSHL 
and 3 families diagnosed with Alport syndrome, were enrolled in the study described in the 
present thesis (Table 2.1).  
The study was approved by local Ethical Committees of the Fondazione IRCCS Cà Granda 
Ospedale Maggiore Policlinico of Milan and of ASST Grande Ospedale Metropolitano 
Niguarda and was performed according to the Declaration of Helsinki. Signed informed 
consent was obtained from all participants and from parents of subjects younger than 18 
years. Patients’ samples were anonymised and sensitive data were treated according to the 
Italian legislation and the European General Data Protection Regulation (GDPR).  
All available patients underwent ear, nose and throat examinations, and pure-tone 
audiometry, in accordance with International Standard Organization (ISO 8253-1-3) 
protocols. Nongenetic causes of deafness were excluded based on clinical history. Alport 
syndrome was primarily diagnosed by renal biopsy. 
All recruited probands were negative for mutations in the gap-junction proteins connexin 
26 and 30 (GJB2, GJB6), and the mitochondrial 12S rRNA (MTRNR1) genes. The 
enrolment of patients and the ascertainment of their family history and phenotype, the 
collection of biological samples and the screening of GJB2, GJB6 and MTRNR1 genes were 
performed by the Audiology Unit of the Policlinico Hospital of Milan and by the 
Laboratory of Medical Genetics of the Niguarda Hospital of Milan. 
For screening purposes, a cohort of 125 Italian audiologically-tested normal-hearing 
controls (mean age at withdrawal 32±9) and a cohort of ~650 deaf individuals were 
included in the study. 
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Table 2.1. HL families selected in the study. 
Family Inheritance Country HL phenotype Additional information 
NSHL3 AR/XR Italy 
Prelingual, downsloping 
audiogram 
 
NSHL7 AR Morocco 
Post-lingual, severe-to-
profound, progressive 
Consanguineous family 
NSHL16 AD Italy 
Post-lingual, high 
intrafamiliar variability 
 
NSHL17 AD Italy 
Post-lingual, late-onset, 
asymmetric 
 
NSHL18 AR Italy 
Early-onset, moderate-
to-severe 
Consanguineous family 
NSHL19 AD Italy 
Post-lingual, ski-slope 
audiogram 
 
NSHL20 AD Italy 
Post-lingual, late-onset, 
ski-slope audiogram 
 
NSHL22 AR/XR Italy 
Early-onset, severe; 
vertigo reported 
 
AS1 AD/XD Italy Post-lingual Alport syndrome 
AS2 AD/XD Italy Post-lingual Alport syndrome 
AS3 AR Italy Post-lingual Alport syndrome 
AR/AD: autosomal recessive/dominant, XR/D: X-linked recessive/dominant. 
2.2. Whole-exome sequencing (WES) 
Genomic DNA was extracted from peripheral blood according to standard protocols. 
For family NSHL7, WES was performed starting from 1 µg of genomic DNA and using 
the SeqCap EZ Human Exome Library v.2.0 (Roche NimbleGen) kit, following the 
manufacturer’s instructions. Paired-end 75-bp (base pairs) libraries were sequenced on an 
HiSeq 2000 (Illumina) at the service facility of the Yale Center for Genome Analysis. For 
all the other families I used the Nextera Rapid Capture Exome Enrichment kit (Illumina) 
to prepare 150-bp paired-end libraries, starting from 50 ng of genomic DNA and following 
the manufacturer’s instructions. Briefly, genomic DNA was fragmented and linked to 
adapter sequences and subsequently PCR-amplified. Then, the amplified DNA library was 
hybridised with capture probes to select the targeted region of interest (the exome). Up to 
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12 different libraries were pooled, subjected to a second round of hybridisation, to ensure 
high specificity of the captured regions, and PCR amplified. Finally, the obtained exome 
libraries were sequenced on a NextSeq500 platform (Illumina) at the Humanitas Genomic 
facility. Our WES data analysis pipeline included: 1) run quality control (with FastQC), 2) 
alignment to hg19 reference genome (using the BWA program), 3) PCR duplicates removal 
and realignment (Picard and GATK software), 4) variant calling and annotation (GATK 
and Annovar programs), and 5) variant prioritisation (in-house pipeline). In particular, 
common single nucleotide variants (SNVs) and insertion-deletions were excluded by 
filtering against 1000 Genome Project, National Heart, Lung, and Blood Institute Exome 
Sequencing Project (NHLBI-ESP; 6500 exomes, http://evs.gs.washington.edu/EVS/), and 
dbSNP135 (except variants flagged as clinically relevant) databases (see Paragraph 3.1). 
2.3. Linkage analysis 
Thirteen individuals (III7, III8, III10, III11, IV1 to IV8, IV10, Fig. 3.2A) from the NSHL7 
family were genotyped using the Infinium OmniExpressExome-8 v1.4 BeadChip array 
(Illumina), following the manufacturer’s instruction. This array comprises more than 
950,000 polymorphic markers, providing a comprehensive coverage of the genome for 
linkage analysis and association studies. In brief, genomic DNA was amplified by whole-
genome amplification, fragmented and subsequently hybridised onto an array containing 
millions of beads coated with copies of DNA oligonucleotide probes specific to a locus of 
interest. The hybridised DNA was used as template for an enzymatic single-base extension 
of each probe, in correspondence with a specific SNP. Then, the specific staining of the 
added nucleotide with fluorescence dyes ensured the discrimination between the different 
alleles for each bead type. Finally, the detection of fluorescence signal intensities on the 
array was performed with the iScan System (Illumina) and intensity files were converted 
into genotype calls by Genome Studio (Illumina). Data were analysed using the 
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EasyLinkage program, and the GeneHunter algorhitm [Lindner and Hoffmann, 2005]. 
Linkage analyses were performed by Dr. Michela Robusto. 
2.4. Mutational screening 
All candidate variants identified by WES were confirmed by Sanger sequencing. 
Briefly, the genomic regions carrying the variants were PCR amplified using sets of primers 
designed based on the known GenBank sequence (Table 2.2). PCRs were performed on 
10–20 ng of genomic DNA, following standard procedures. Direct sequencing of PCR 
amplicons was performed on both strands using the BigDye Terminator Cycle Sequencing 
Ready Reaction Kit v.1.1 and an automated ABI-3500DX DNA sequencer (Applied 
Biosystem). The Variant Reporter software (Applied Biosystems) was used for variant 
detection. 
Additionally, a High-Resolution Melting (HRM) assay to screen SLC22A4 exon 1 was 
performed on our in-house database of 125 audiologically-tested normal-hearing controls. 
A new specific primer pair (Table 2.2) was designed to PCR amplify a 265-bp genomic 
DNA fragment encompassing the SLC22A4 c.338G>A mutation, and PCR amplicons 
were screened for mutations by HRM on a LightCycler 480 using the HRM Master kit 
(Roche) and a touch-down protocol. Amplicons were analysed with the Gene Scanning 
Software (Roche). All SLC22A4 exons and adjacent splice junctions were also screened - at 
the Laboratory of Medical Genetics of the Niguarda Hospital of Milan - in 7 additional 
unrelated NSHL patients of North African origin (2 from Morocco, 4 from Egypt and 1 
from Tunisia). 
For family NSHL18, serial PCRs were performed to better define the extent of the deleted 
region encompassing the entire OTOA gene (Table 2.2). 
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Table 2.2. Primers used in mutational screening. 
Family RefSeq Accession 
No PCR assay Primer sequence (5’-3’) 
Size 
(bp) 
NSHL3 NM_006729.4 DIAPH2 AACCTCATTGTGGGGGTATG 
TCTGCTCAATCACTTTGAATCC 495 
NSHL7 NM_003059.2 
SLC22A4 CCAATGGCTTCAATGGTATGT 
CCGCTGCTGGAAGTATGAAC 440 
SLC22A4_HRM CTGGCGCAACAACAGTGTC 
ACGCAGAGGGAGGGTCAG 265 
NSHL16 
NM_005422.2 TECTA CTTCGACGGCCACTACTACA 
CGGGCTTCTTCTTGTTGATG 320 
NM_172163.2 KCNQ4 GAGCCATGCGTCTCTGAGC 
CAGCACGTTGTAGACCCAGT 356 
NM_001172411.1 VANGL1 GTTTCCCACCCTCGTGGTAT 
GAGGGTACTGGCATCAGGAG 216 
NM_000817.2 GAD1 GGATGGCAGTTTTTCCAAGA 
CCACATCAGCCAGAACTTGA 325 
NM_001369.2 DNAH5 CACCCAACTGACCACAACAG 
GAGGCAAGTGTGACCCAAAT 381 
NSHL17 NM_138691.2 TMC1 TATGCAGAACAATTTGCCTTTCAG 
AGACACCGATTGTATTCTCCTC 244 
NSHL18 
NM_170664.2 
5’_OTOA1 CCTTGAGTAGCGTGATGTTCC 
GGCTCCTACTGTTGCTTCCA 2732 
5’_OTOA2 CACGCCTATCACAGAAAGCA 
GAGTGCAACTGGATGGGACT 5184 
5’_OTOA3 ACGGTGAATTTGGTGGAGAG 
GTGGGCTCCAGTTGATGAAT 4991  
OTOA ATGAGGTGATGCCAGGACTC 
TCTCCCCATTTCTCTGGCTA 467 
3’_OTOA1 GGGGTAAAACTGTCCCTGGT 
TGTTTCCACCCTTTCTTTGG 3360 
 
3’_OTOA2 CGCCCAGTCAACAGATAGGT 
AGCAGGTGGGTGAAGCTCT 5158 
NM_021072.3 HCN1 TGATTTCTGATACACCCTAACAATG 
TGCATACTGAGGACAATAAATCTT 231 
NSHL20 NM_001135058.1 COCH TCTTACCACATGCCCAACTG 
ATGAGGCGGAAATTGCTATC 170 
AS1 NM_000495.4 COL4A5 CCTGTTTCCAATCCTTCCAT 
TGCAGTGACAGCCTCCATAC 359 
AS2 NM_000495.4 COL4A5 AGTCGGCCTCTATCGTTGTC 
GTAAGCCAGGTTCCCCCTTC 369 
AS3 NM_000091.4 COL4A3 GACCGAGCCCTACAAAACC 
GTGGAGGAGGGATGGAAGTG 282 
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2.5. Expression vector preparation 
For the functional characterisation of candidate splicing mutations, the genomic DNA 
regions containing the identified variants were PCR amplified from patients’ genomic 
DNA (with primers including NdeI restriction sites; Table 2.3) and cloned in the hybrid 
alpha-globin-fibronectin minigene plasmid (modified pBS-KS) [Baralle et al., 2003]. 
For the functional characterisation of the COL4A3 signal-peptide deletion, the genomic 
DNA region coding for the predicted signal peptide was PCR amplified from the patient's 
genomic DNA (with primers including XhoI and KpnI restriction sites; Table 2.3) and 
cloned in-frame upstream of the EGFP (Enhanced Green Fluorescent Protein) coding 
region in the pEGFP-N1 plasmid (Clontech). 
Finally, expression vectors containing human DIAPH2, SLC22A4 and HCN1 coding 
sequences were kindly provided, respectively, by the laboratory of Professor Marino Zerial 
(pCMV_HA-hDIA2B) [Gasman et al., 2003], of Professor Giovambattista Pani 
(pCDNA3.1_OCTN1) [Martini et al., 2012] and of Professor Christel Depienne 
(pCDNA3.1_hHCN1) [Nava et al., 2014]. Point variations were introduced by site-direct 
mutagenesis, using specific sets of primers (Table 2.3) and the QuickChange Site-Directed 
Mutagenesis Kit (Agilent Technologies). 
The plasmid encoding a constitutively active form of RhoA, used in DIAPH2 
immunolocalisation studies, was provided by the laboratory of Professor Taroh Iiri 
(pCDNA3.1_Myc-RhoA_G14V) [Oishi et al., 2012]. 
Recombinant plasmids were extracted with the PureYield Plasmid Midiprep System 
(Promega), and verified by sequencing. 
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Table 2.3. Plasmids used in transfection experiments. 
Family Experiment Plasmid Cloning/mutagenesis primer sequence (5’-3’)* 
NSHL3 
splicing 
pBS-KS-DIAPH2_ex8_wt 
pBS-KS-DIAPH2_ex8_mut 
ggaattccatatgCAAGGAGCAACAACTCCAAGA 
ggaattccatatgTCTGCTCAATCACTTTGAATCC 
immunolocalisation 
pCMV_HA-hDIA2B_wt Gasman et al., 2003 
pCMV_HA-hDIA2B_mut 
GTTGGAGAAGAGAACgTTCTAGATAAACTTT 
AAAGTTTATCTAGAAcGTTCTCTTCTCCAAC 
immunolocalisation pcDNA3.1_Myc-RhoA_G14V Oishi et al., 2012 
NSHL7 immunolocalisation 
pCDNA3.1_Myc_OCTN1_wt Martini et al., 2012 
pCDNA3.1_Myc_OCTN1_mut 
TGGAGCAGGAGAGCTaCCTGGATGGCTGGGA 
TCCCAGCCATCCAGGtAGCTCTCCTGCTCCA 
NSHL17 splicing 
pBS-KS-TMC1_ex19_wt 
pBS-KS-TMC1_ex19_mut 
ggaattcCATATGCAGAACAATTTGCCTTTCAG 
ggaattccatatgAGACACCGATTGTATTCTCCTC 
NSHL18 
immunolocalisation, 
patch-clamp 
pCDNA3.1_HCN1_wt Nava et al., 2014 
pCDNA3.1_HCN1_Y417C 
AGCAAGTGGAACAATgCATGTCATTCCATAAG 
TTATGGAATGACATGcATTGTTCCACTTGCTT 
patch-clamp pCDNA3.1_HCN1_Y417F 
AGCAAGTGGAACAATtCATGTCATTCCATAAG 
CTTATGGAATGACATGaATTGTTCCACTTGCT 
AS1 splicing 
pBS-KS-COL4A5_ex29_wt 
pBS-KS-COL4A5_ex29_mut 
ggaattccatatgACCCTGTTTCCAATCCTTCCA 
ggaattccatatgGCCGGGCCATGATTTTATT 
AS3 immunolocalisation 
COL4A3-SP-wt-hybEGFP 
COL4A3-SP-mut-hybEGFP 
ggcctcgaGGTGGCCTGAGAGCCTGA 
agaggtaccTGGAGGAGGGATGGAAGTG 
* Lowercase letters indicate nucleotides added to the primers to introduce the restriction sites (note 
that, for pBS-KS-TMC1_ex19 plasmids, the NdeI restriction site located in intron 18 was used). The 
red lowercase letter in mutagenesis primers indicate the variant nucleotide. 
2.6. Cell cultures and transfections  
HeLa and HEK293 cells were cultured in Dulbecco's modified Eagle medium 
supplemented with 2 mM L-glutamine, 10% fetal bovine serum (FBS) and antibiotics (100 
U/ml penicillin and 100 μg/ml streptomycin; Euroclone) and grown at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air, according to the standard procedures. 
UB/OC-2 cells, deriving from the organ of Corti of E13 temperature-sensitive 
Immortomouse [Rivolta and Holley, 2002], were cultured in Minimum Essential Medium 
(MEM; ThermoFisher Scientific) supplemented with GlutaMAX, 10% FBS and 50 U/ml γ-
IFN (gamma-interferon, PeproTech) and grown at 33°C in a humidified atmosphere of 5% 
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CO2. These conditions maintain cells in the proliferative state. To differentiate the cells, γ-
IFN was rinsed off and cells were cultured in MEM with only GlutaMAX and 10% FBS at 
33°C for 2 days and then moved to 39°C in a humidified atmosphere of 5% CO2. 
For splicing studies, an equal number of cells (2.5*105 HeLa or UB/OC-2 in proliferative 
state; 3*105 HEK293 or UB/OC-2 in differentiating conditions) were transiently 
transfected with 1 µg of either wild-type or mutant recombinant pBS-KS vector (Table 
2.3). 
For immunofluorescence assays, 2*105 HeLa or 2.5*105 HEK293 cells were seeded on 
22x22 mm glass coverslip and transfected with 500 ng of plasmid encoding either the wild-
type or the mutant protein under study. For immunolocalisation of DIAPH2 protein, an 
equimolar quantity of the pcDNA3.1_Myc_RhoA-G14V vector was also cotransfected. 
The Jet-PRIME reagent (Euroclone) was used for transfections in HeLa and HEK293 
cells, whereas Lipofectamine 2000 (Thermo Fisher scientific) was used as transfection 
reagent in the UB/OC-2 cell line. 
For electrophysiology analyses, 2.5*105 HEK293 cells were seeded on 20x20 mm glass 
coverslip and cotransfected with 1 µg of plasmid encoding either the wild-type or one of 
the mutant HCN1 channels (Table 2.3) and with 0.5 µg of pEGFP using the Lipofectamine 
2000 reagent (Thermo Fisher scientific) and following the manufacturer’s instructions. 
2.7. Splicing analyses 
Total RNA was isolated from cells 24 hours after transfection, using the EuroGold TriFast 
reagent (Euroclone). Random hexamers and the ImProm-II Reverse Transcriptase 
(Promega) were used to perform first-strand cDNA synthesis, starting from 500 ng of total 
RNA, according to the manufacturer's instructions. Of a total of 20 μL of the RT reaction, 
1 μL was used as template for amplifications, using primers annealing to the flanking α-
globin/FN1 exonic sequences (α2-3: 5’-CAACTTCAAGCTCCTAAGCCACTGC-3’ and 
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Bra2: 5’-CAATGGATGGGGGTGGAG-3’). RT-PCRs were performed under standard 
conditions using the GoTaq DNA Polymerase (Promega) on a Mastercycler EPgradient 
(Eppendorf). 
Competitive-fluorescent RT-PCRs were performed on RNA from transfected cells, using 
the same oligonucleotide pair adopted for splicing assays, with the reverse Bra2 primer 
labelled with 6-FAM (6-Carboxyfluorescein). Amplified fragments were separated on an 
ABI-3500DX sequencer and quantitated by the GeneMapper v4.0 software (Applied 
Biosystems). The sum of all fluorescence peak areas in a single run was set equal to 100%, 
and the relative quantity of each transcript expressed as a fraction of the total. 
2.8. Cell immunofluorescence experiments 
Cells seeded on coverslips were fixed 24 or 48 hours after transfection using 4% 
paraformaldehyde for 10 minutes at room temperature. The cells were washed twice for 15 
minutes in 100 mM glycine and permeabilised/blocked for 30 minutes in GDB (gelatin 
dilution buffer: 0.1% gelatin, 0.3% Triton X-100, 450 mM NaCl, 20 mM phosphate buffer 
pH 7.4). Coverslips were washed in HS (high salt: 500 mM NaCl, 20 mM phosphate buffer 
pH 7.4) buffer and incubated for 2 hours with primary antibodies diluted in GDB (Table 
2.4). The cells were then washed 3 times in HS buffer and incubated 1 hour with 
fluorophore-conjugated secondary antibodies (Table 2.4). After 3 washes in HS buffer, cell 
nuclei were counterstained with DAPI (4',6-Diamidino-2-Phenylindole) for 5 minutes and 
cells were washed once in HS and LS (low salt: 150 mM NaCl, 10 mM phosphate buffer 
pH 7.4) buffers and bidistilled water. Coverslips were mounted with FluorPreserve reagent 
(Merck Millipore). Alternatively, ProLong Diamond Antifade Mountant with DAPI 
(Molecular Probes) was used for mounting and nuclei counterstaining. For actin staining, 
cells were labelled with ActinGreen 488 ReadyProbes Reagent (Molecular Probes) before 
mounting, following the manufacturer’s instructions. Confocal images were acquired using 
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a 60x UPLSAPO oil-immersion objective (N.A. 1.35, Olympus) with an Olympus 
FluoView FV1000 confocal microscope or a 63x HC PL APO 63x oil-immersion objective 
(N.A. 1.40, Leica) with a Leica TCS SP8 confocal microscope at a resolution of 1 airy unit. 
Identical gain, offset, exposure, and laser-power settings were applied to wild-type and 
mutant conditions in every experiment. 
Images were analysed with Fiji (Fiji is just ImageJ) software [Schindelin et al., 2012]. 
Table 2.4. Antibodies used in cell immunofluorescence experiments. 
Host 
species Antibody (id, manufacturer) 
Working 
dilution Type 
mouse Anti-HA probe (sc-7392, Santa-Cruz Biotechnology) 1:75 primary 
rabbit Anti-Myc tag (ab9106, Abcam) 1:100 primary 
rabbit Anti-HCN1 (APC-056, Alomone Labs) 1:100 primary 
mouse Anti-calnexin (sc-23954, Santa-Cruz Biotechnology) 1:75 primary 
mouse Anti-TGN38 (sc-166594, Santa-Cruz Biotechnology) 1:75 primary 
goat Dylight 549 anti-mouse (115-505-174, Jackson 
ImmunoResearch) 1:200 secondary 
goat Alexa Fluor 488 anti-rabbit (ab150077, Abcam) 1:200 secondary 
goat Alexa Fluor 633 anti-rabbit (A21072, Molecular Probes) 1:200 secondary 
2.9. Patch-clamp analyses 
Whole-cell patch clamp recordings were performed on GFP-expressing cells 24 hours after 
transfection using an Axopatch 200B amplifier and a Digidata 1440 analog/digital interface 
(Molecular Devices) as described previously [Nava et al., 2014]. The extracellular solution 
contained 130 mM NaCl, 15 mM KCl, 0.5 mM MgCl2, 1.8 mM CaCl2, 10 mM glucose and 
5 mM HEPES, adjusted to pH 7.4 with NaOH. The pipette solution contained 120 mM 
potassium aspartate, 10 mM NaCl, 10 mM KCl, 1 mM CaCl2, 10 mM EGTA, 2 mM 
MgATP and 10 mM HEPES, adjusted to pH 7.2 with KOH. Microelectrodes were pulled 
55 
 
from borosilicate glass (uncoated, PG165T-10; Harvard Apparatus) and had a resistance of 
2–4 MΩ. Liquid junction potential was not corrected. Electrophysiological recordings were 
carried out at room temperature (21–23 °C). Whole-cell voltage-clamp mode was used to 
investigate the ion currents through the membrane of transfected cells. A series of test 
pulses, ranging from −140 to +40 mV in 10-mV increments from a holding potential of 
−20 mV, was applied to the cells for 1 second. Currents were measured in steady state at 
the end of the test pulses. Data were acquired and analysed with Clampfit 10.7 (Molecular 
Devices) software. Patch-clamp experiments were performed by Mr. Filippo Mirabella. 
2.10. Mouse studies 
Mouse studies were performed at the laboratory of Professor Karen Steel (King’s College 
London, London, UK) in accordance with the UK Home Office regulations and the UK 
Animals (Scientific Procedures) Act 1986 (ASPA) under UK Home Office licences, and the 
study was approved by the King’s College London Ethical Review Committee. 
Mice were culled using methods approved under these licences to minimise any possibility 
of suffering. 
2.11. Mutant mice 
The Slc26a4tm1(CreERT2_EGFP)Wtsi mice (PEND colony) were produced at the Wellcome Trust 
Sanger Institute and have a C57BL/6N genetic background. Slc26a4tm1(CreERT2_EGFP)Wtsi mice 
carry a CreERT2_EGFP knock-in allele that both interrupts Slc26a4 transcription and 
expresses EGFP and CreERT2 fusion protein under the control of Slc26a4 promoter. 
CreERT2 comprises the Cre recombinase from bacteriophage P1 fused with a variant of 
the human estrogen receptor harboring three mutations. These mutations abolish the 
binding of the physiologic ligand (17β-estradiol), but not of tamoxifen, which allows the 
translocation of Cre in the nucleus. When crossed with mice containing a loxP-flanked 
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(floxed) sequence, tamoxifen-induced Cre recombination results in the deletion of the 
floxed sequence only in the cells expressing Slc26a4 of the offspring. Therefore, this mouse 
model is useful for the creation of cell-type-specific tamoxifen-inducible conditional knock-
outs. 
To assess the function of the new candidate human deafness gene DIAPH2, found 
mutated in family NSHL3, the Diaph2em2Kcl knock-out mice (DIAH colony) and the 
Diaph2em3Kcl knock-in mice (DIA colony) were generated by the Genome Editing & 
Embryology Core (GEEC, King’s College London, London, UK) using the CRISPR-Cas9 
technology. Both mice have a C57BL/6J genetic background. Diaph2em2Kcl mice display a 
19-bp deletion (NM_172493.2:c.855_873del) resulting in a frameshift and hence creating a 
premature stop codon in exon 9. Diaph2em3Kcl mice display the missense point mutation 
NM_172493.2:c.877A>G; NP_766081.1:p.I293V in exon 8, corresponding to the 
NM_006729.4:c.868A>G; NP_006720.1:p.I290V variant identified in family NSHL3. Of 
note, three additional synonymous variants were introduced (NM_172493.2:c.852T>C, 
NM_172493.2:c.855T>A, NM_172493.2:c.867G>A) in order to destroy the gRNA 
binding and PAM site - thus preventing the re-cutting of Cas9 after successful integration 
of the oligo donor. 
2.12. Mouse genotyping 
Ear clip tissue was lysed overnight in lysis solution (200 mM NaCl, 100 mM Tris HCl pH 
8.0, 5 mM EDTA pH 8.0, 0.2% SDS) with 1 mg/mL proteinase K at 55ºC. Lysed samples 
were diluted 3 times in MilliQ water and, after centrifugation, the supernatant was diluted 
20 times. PCRs were performed on 2 µL of diluted supernatant using the DreamTaq Hot 
Start Green PCR Master Mix (Thermo Fisher Scientific) and specific sets of primers (Table 
2.5, Fig. 2.1). PCR products were separated by a 2% agarose gel electrophoresis. 
For mice of PEND colony, three PCR assays (Table 2.5) were used to identify the wild-
type (PEND wt) or mutant (PEND mut) allele and the presence of the cassette (by 
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detecting the Cre sequence). In the Slc26a4tm1(CreERT2_EGFP)Wtsi homozygous mice, the wild-
type-specific PCR assay fails due to the insertion of the cassette (Fig. 2.1A). 
For DIAH and DIA colonies, PCR products were digested overnight at 37°C, with MboII 
and NdeI restriction enzymes (New England BioLabs), respectively. In fact, the 19-bp 
deletion in the Diaph2em2Kcl allele abolishes a MboII restriction site present in the wild-type 
allele, whereas one of the synonymous variants introduced in the Diaph2em3Kcl allele creates 
a new NdeI restriction site (Fig. 2.1B). As a result, the restriction digestion reaction of the 
330 bp PCR amplicon yields two products (89 and 241 bp) for the wild-type allele in DIAH 
colony and two products (62 and 268 bp) for the Diaph2em3Kcl allele in DIA colony, thus 
allowing to recognise each genotype after gel electrophoresis. 
Table 2.5. Primers used in mouse genotyping. 
 * Diaph2em2Kcl allele displays a 19-bp deletion. 
 
 
Mouse colony PCR assay Primer sequence (5’-3’) Size (bp) 
WT MUT 
PEND 
PEND wt ACCAATGGCAGATAAGGAGGAC 
TCTGACCCAGCCAGAAAATG 597 / 
PEND mut ACCAATGGCAGATAAGGAGGAC 
TCGTGGTATCGTTATGCGCC / 326 
Cre CATTTGGGCCAGCTAAACAT 
TAAGCAATCCCCAGAAATGC / 233 
DIAH/DIA DIA2 AAGAGCAATTGACCCGAAAC 
TGATGGCTTTAGTGGGACAA 330/330 311*/330 
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Figure 2.1. Genotyping strategies for the PEND, DIAH and DIA mouse colonies. 
A. For Slc26a4tm1(CreERT2_EGFP)Wtsi mice, the three PCR assays used to verify the correct 
insertion of the cassette are shown (arrows indicate the primer pairs). PEND wt PCR fails 
in the mutant allele due to the presence of the cassette. FRT: flippase recognition target; 
loxP: locus of X(cross)-over in P1 (recognized by Cre recombinase). B. For DIAH and 
DIA colonies the same set of primers was used, and each genotype was assessed after a 
specific restriction digestion reaction. The sequence recognised by each restriction enzyme 
is underlined and the cutting sites are indicated by arrowheads. The dashes in Diaph2em2Kcl 
allele indicate the 19-bp deletion. The missense point mutation NM_172493.2:c.877A>G; 
NP_766081.1:p.I293V is indicated in red, while the synonymous variants are shown in 
orange. Note that Diaph2em2Kcl allele also carries the missense mutation and one of the 
synonymous variants. 
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2.13. Auditory brainstem response recordings 
Auditory brainstem responses (ABR) are synchronous neural responses to auditory stimuli. 
ABR measurements were performed to estimate the hearing sensitivity of wild-type and 
mutant mice to broadband click and frequency-specific stimuli. The evoked electrical 
potentials of the brainstem auditory neural activity are recorded from the scalp of 
anesthetised animals using electrodes. The protocol used for ABR, developed by Dr. Neil 
Ingham, is extensively described in his 2011 publication [Ingham et al., 2011]. 
Briefly, the mouse was weighed and tested for the presence of a Preyer reflex (a backwards 
movement of the pinnae elicited by the sound) using the “click-box”, which emits a ~20 
kHz sound at over 90 dB SPL (sound pressure level). Then, the mouse was anaesthetised 
by an intraperitoneal injection of ketamine/xylazine (respectively, 1 mg and 0.01 mg/g of 
mouse body weight) and placed in an empty cage on a heating pad until fully anaesthetised, 
as assessed by testing righting and pedal withdrawal reflexes. The animal was then placed in 
a sound-attenuating chamber on a heating blanked, in order to maintain the body 
temperature. The electrodes were placed subdermally at the vertex of the animal (between 
the ears, active electrode), in the patch of bare skin overlying the bulla behind the left ear 
(reference electrode), and right ear (ground electrode) (Fig. 2.2A). The mouse was laid in a 
natural position facing the loudspeaker, at a distance of 20 cm. 
To check the correct functioning of the system, at the beginning of ABR measurements a 
test ABR trace was recorded presenting a 70 dB SPL click to the mouse. The heart rate was 
also recorded to monitor the status of the mouse. First, a series of click stimuli was 
presented to the mouse at increasing SPLs from 0 to 95 dB SPL in 5-dB steps, to 
determine the ABR threshold to the click stimuli. Then, the responses to tone pips of 
several frequencies (3, 6, 12, 18, 24, 30, 36, 42 kHz) and SPL (0-95 dB SPL in 5-db steps) 
were recorded. The tone pips had 5 msec duration with 1 msec rise/fall time and were 
presented at 42.6/sec rate. Finally, the 70 dB SPL test ABR and heart rate recordings were 
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repeated, to ensure that no deterioration in the response and in the mouse condition had 
taken place during the measurements. 
The recovery was promoted with an intraperitoneal injection of atipamezole (0.001 mg/g 
body weight) and the mouse was placed back to its cage and monitored until fully 
conscious. 
The averaged ABR waveforms, resulting from the average of 256 sweep record for each 
stimulus, were visualized using TraceView custom software. For each mouse, the ABR 
threshold to the click stimuli and to tone stimuli of each frequency presented was visually 
determined as the lowest stimulus level where any characteristic peak or depression of the 
waveform could still be recognised (Fig. 2.2B). 
As the ABR thresholds for each stimulus were not normally distributed, they were analysed 
by the Mann-Whitney test (comparison between 2 genotype groups) or by the Kruskal-
Wallis test (comparison among >2 genotype groups). 
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Figure 2.2. ABR measurements. A. Positioning of the active electrode (AE) and of the 
reference (RE) and ground electrodes (GE). Adapted from Ingham et al., 2011. B. Example 
of visual determination of ABR threshold. The 5 characteristic peaks of the ABR waveform 
(P1-P5) are indicated by arrows. P1 is considered to represent the activities from the 
auditory nerve, while the other peaks are thought to be generated at higher level, within the 
central auditory system, even if the precise origins are not yet clear [Zhou et al., 2006]. The 
estimated threshold ABR (30 dB) is plotted as a heavy trace. 
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2.14. Immunohistochemistry on wax sections 
Immunohistochemical studies were performed to evaluate the expression of Diap2 protein 
in the mouse inner ear. For all experiments E14.5, E16.5 and P5 mice of the C57BL/6 
strain and E18.5 and P0 mice with a C3HeB/FeJ genetic background were used. For each 
age, a minimum of three mice was tested. 
Formalin-fixed paraffin-embedded wild-type mouse heads were sectioned sagittally at 8 μm 
thick using the Leica RM2255 microtome, mounted on Superfrost Plus slides (Thermo 
Fisher Scientific) and incubated at 42°C overnight.  The Ventana Discovery machine and 
reagents (all from Roche) were used for immunohistochemistry, following the 
manufacturer’s instructions. Briefly, the machine performed a deparaffinisation step using 
the EZ prep solution and antigen retrieval using the CC1 (cell conditioning 1) reagent in a 
heated step. The slides were incubated for 1 hour with the goat anti-Dia2 antibody (1:50, 
sc-10892, Santa Cruz Biotechnology) and subsequently incubated for 16 minutes with the 
Biotin-SP AffiniPure Donkey Anti-Goat IgG (H+L) secondary antibody (1:100, 705-065-
147, Jackson ImmunoResearch). Primary and secondary antibodies were diluted in a 
phosphate-buffered saline (PBS) solution containing 10% FBS, 2% bovine serum albumin, 
0.1% Triton-X100, and 10 mM sodium azide. After incubation with SA-HRP (streptavidin-
horseradish peroxidase) the immunohistochemistry reaction was revealed using DAB (3,3'-
Diaminobenzidine). Finally, slides were counterstained with haematoxylin. After staining, 
the slides were removed from Ventana machine and manually dehydrated using ascending 
ethanol concentrations (70%, 85%, 100%) and subsequently washed in acetone and xylene 
before mounting with Eukitt mounting medium (Sigma-Aldrich) and 24x50 mm coverslips. 
Brightfield images of the sections were acquired using a Zeiss Axioskop microscope 
connected with the Axiovision 3.0 software. 
 
 
63 
 
 
3. Results and discussion
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3.1. Whole-exome sequencing data analysis of HL families 
A total of 26 individuals from 11 families with HL and no molecular diagnosis were 
selected for WES, in collaboration with the Audiology Unit of the Policlinico Hospital of 
Milan and with the Laboratory of Medical Genetics of the Niguarda Hospital of Milan. 
Among them, 8 families were affected by dominant or recessive NSHL and were negative 
for mutations in the GJB2 and GJB6 genes. The other 3 families were diagnosed with 
Alport syndrome (AS) and had been subjected to extensive and repeated screenings of the 
three AS-causing genes (COL4A3, COL4A4, COL4A5) with no conclusive results. 
At least 2 affected individuals in each NSHL family were subjected to WES. In addition to 
the proband, we decided to sequence at least one sibling in recessive families. In dominant 
families, when available, we selected for WES the affected individuals most distantly related 
to the proband, in order to reduce the number of shared variants. Finally, in AS families, 
we sequenced only the proband.  
For NSHL7 family, WES was performed on two individuals through an external sequence 
provider (the Yale Center for Genome Analysis, YCGA, Yale University, USA) using a 
SeqCap EZ exome kit (44 Mb target region) and a HiSeq2000 platform (Illumina). For the 
other 10 families, I prepared WES libraries with the Nextera Rapid Capture kit (37 Mb 
target region) and sequenced them on a NextSeq500 platform (Illumina) at the Humanitas 
Genomic facility. Overall, we obtained an average of 8.4 Gb of high-quality sequence data 
per exome with a mean coverage of ~100X and ~99.6% coverage of the target. 
Reads were aligned to hg19 reference genome using the BWA (Burrows-Wheeler Aligner) 
program and variant calling and annotation were performed, respectively, with GATK 
(Genome Analysis Toolkit) and Annovar software. Detected variants were then prioritised 
using our in-house pipeline. In particular, to remove common variations, 
nonsynonymous/splice-site single nucleotide variants (SNVs) and insertion-deletions 
(indels) were filtered against 1000 Genome Project, National Heart, Lung, and Blood 
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Institute Exome Sequencing Project (NHLBI-ESP; 6500 exomes), and dbSNP135 (except 
variants flagged as clinically relevant) databases. The threshold for the maximum minor 
allele frequency (MAF) was set to 1% in case of recessive inheritance and to 0.1% for 
dominant NSHL [Bamshad et al., 2011]. Passing-filter variants were then prioritised 
depending on the inheritance pattern of the family. The availability of exome data from 
multiple members of the same family allowed to select only the variants shared between 
affected individuals and to filter out the variants also present in normal-hearing relatives. 
Furthermore, a homozygosity mapping analysis was performed on WES data from 
consanguineous families to identify runs of homozygosity (ROH) shared by affected 
relatives [Pippucci et al., 2011]. The frequency of the prioritised/candidate variants was 
further checked in the Genome Aggregation Database (gnomAD, http://gnomad-
beta.broadinstitute.org/) and in an in-house cohort of 3541 Italian control exomes, to 
identify population-specific variants. In addition, the pathogenicity of the variations was 
predicted using several in-silico programs (CADD, Condel, FATHMM, Mutation Assessor, 
MutationTaster, Polyphen 2 HumDiv, Polyphen 2 HumVar and SIFT for nonsynonymous 
changes; NNSPLICE, Human Splicing Finder and NetGene for splice-site variants). In 
parallel, the EXCAVATOR2 tool [D'Aurizio et al., 2016] was used to detect possible copy 
number variants (CNV) that escaped our standard SNV/indel analysis pipeline (Fig. 3.1). 
We confirmed all prioritised variants by Sanger sequencing and evaluated their segregation 
in the available family members.  
Finally, we selected the most promising pathogenic variants focussing first on already-
known deafness-causing genes and then considering novel candidates for further functional 
analyses. For the latter, we evaluated the expression of the encoded proteins in the cochlea 
and the connection with genes and pathways involved in deafness pathogenesis.   
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Figure 3.1. WES data analysis pipeline. The main steps of WES data analysis are shown 
in square shapes, with the program used in parentheses. The grey round shapes indicate the 
file produced and used in the subsequent steps of the analysis. The homozygosity mapping 
analysis was performed only in consanguineous families. 
68 
 
The above described approach was fundamental for the identification of pathogenic 
variants in known deafness genes (SLC22A4, OTOA, COCH, SLC26A4) in four NSHL 
families (NSHL7, NSHL18, NSHL20, and NSHL22, respectively) and highlighted the 
candidate NSHL-causing gene DIAPH2 in family NSHL3 (Table 3.1). 
Table 3.1. Top variants identified by WES data analyses in selected NSHL families. 
      Variants 
Family Inheritance Gene cDNA localisation Protein localisation Status 
NSHL3 AR/XR DIAPH2 NM_006729.4: 
c.868A>G 
NP_006720.1: 
p.I290V 
Novel candidate 
gene, novel variant 
NSHL7 AR SLC22A4 NM_003059.2: 
c.338G>A 
NP_003050.2: 
p.C113Y 
Known pathogenic 
variant in NSHL 
gene* 
NSHL18 AR OTOA NM_170664.2: 
~250-Kb deletion / 
Deletion spanning 
NSHL gene 
NSHL20 AD COCH NM_004086.2: 
c.1096G>A 
NP_001128530.1: 
p.V366M 
Novel variant in 
NSHL gene 
NSHL22 AR/XR SLC26A4 
NM_000441.1: 
c.1001G>T; 
c.1229C>T 
NP_000432.1: 
p.G334V; 
p.T410M 
Known pathogenic 
variants in NSHL 
gene 
AR: autosomal recessive, XR: X-linked recessive, AD: autosomal dominant. 
* At the time we started to study SLC22A4, the gene had not yet been associated with NSHL. 
3.2. NSHL7 family: the SLC22A4 gene 
Family NSHL7 is a large Moroccan consanguineous family affected by post-lingual bilateral 
severe-to-profound progressive NSHL, with a recessive pattern of inheritance. The 
proband (IV4) is a 12-year-old male with a 24-year-old deaf brother (IV2) and a normal-
hearing brother (IV1, 26 years old) and sister (IV3, 21 years old). The four deaf (three 
males, IV5-7, and one female, IV10) and three unaffected (two males, IV8-9, and one 
female, IV11) cousins of the proband, currently living in Morocco, were also available to 
the study (Fig. 3.2A-B). The exomes of IV2 and IV4 affected siblings were sequenced in 
2014 at the service facility of the Yale Center for Genome Analysis. We ruled out the 
presence of pathogenic variants in known deafness genes, with particular focus on the 58 
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recurrent mutations included in the North African Deafness (NADf) chip [Chakchouk et 
al., 2015]. Single nucleotide analyses of WES data prioritised 6 homozygous variants shared 
by IV2 and IV4 and affecting genes not associated with deafness. Considering the 
predicted pathogenicity of the variants and the function of the genes affected, we selected 
SLC22A4 as the most interesting candidate NSHL gene to further investigate. The 
NM_003059:c.338G>A (p.C113Y) variation within SLC22A4 exon 1 (Fig. 3.2C) is present 
in the homozygous state in all affected family members, but also in one normal hearing 
individual (IV1). Importantly, the variant is located in the only run of homozygosity shared 
by the two affected brothers, as assessed by the homozygosity mapping performed on 
WES data. To corroborate SLC22A4 candidacy as NSHL gene in the analysed family, a 
linkage study was performed - by Dr. Michela Robusto - in the 13 available NSHL7 family 
members using the Illumina Infinium OmniExpressExome-8 v1.4 BeadChip kit. 
Parametric multi-point SNPs genotyping data analysis with the GeneHunter v2.1 r5 
software evidenced a unique strong linkage signal peak (LOD>3.5) located in an interval of 
about 3.2 Mb on chromosome 5q23.3-q31.1 (chr5:128789554-131970885, hg19 Human 
reference genome coordinates), delimited by polymorphic markers rs11241999 and 
rs2237060 and encompassing SLC22A4 gene (Fig. 3.2A). Besides, the c.338G>A variant is 
absent in our in-house database, as well as in a cohort of 125 Italian audiologically-tested 
normal-hearing controls (mean age at withdrawal 32±9), tested with a specific high-
resolution melting assay. The substitution is also absent in the Greater Middle East 
Variome study cohort (GME, http://igm.ucsd.edu/gme/data-browser.php), which 
includes subjects from the North African population (85 from the Northwest Africa region 
and 423 from Northeast Africa) [Scott et al., 2016]. The exons and splice junctions of 
SLC22A4 gene were also screened in 7 additional unrelated NSHL patients of North 
African origin (2 from Morocco, 4 from Egypt and 1 from Tunisia; screening performed at 
the Laboratory of Medical Genetics of the Niguarda Hospital of Milan), but no putative 
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pathogenic variants were detected. Conversely, the variation is reported, in the 
heterozygous state, in 5 out of 114412 individuals in the gnomAD database, with an 
estimated allele frequency of 2.185e-5.  
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Figure 3.2. Identification of the c.338G>A variant in SLC22A4 gene within a linkage 
region in family NSHL7. A. Pedigree showing the co-segregation of NSHL with a 
haplotype spanning from polymorphic marker rs11241999 to rs2237060 (in red) within the 
chromosomal region 5q23.3-q31.1. The blue vertical bar indicates the disease-associated 
haplotype shared by all affected individuals. The genotype of available individuals is 
indicated below the corresponding symbols and the arrow points to the proband. W: wild-
type allele, M: mutant allele. na: not analysed by genetic linkage study. Linkage analyses 
were performed by Dr. Michela Robusto. B. Audiograms of the normal-hearing parents 
(III8, III10, on the left) and of the 4 siblings (IV1-4) (average hearing loss for the right and 
left ears is shown). IV3 is not compliant for further audiometric evaluations. Age at 
audiometric evaluation is shown. y.o.: years old. C. Schematic representation of SLC22A4 
gene, where exons are indicated by rectangles and introns by black lines. 
Electropherograms showing the sequence surrounding the mutated nucleotide in a normal-
hearing carrier (left) and in the proband (right). The position of the variant identified in 
family NSHL7 is indicated by an arrowhead. R: A or G. D. In-silico analyses of the p.C113Y 
missense variant identified in SLC22A4 gene. The amino acid sequence alignments of 
SLC22A4 orthologs in the region surrounding the mutant residue (p.C113) is shown on the 
top. Protein sequences were retrieved from UniProt, and alignments were generated with 
Clustal Omega. The amino acid residue affected by the mutation is shaded in red and 
indicated by a red arrow. Identical amino acids are marked by an asterisk, while partially 
conserved residues are indicated by a colon. At the bottom, pathogenicity prediction of the 
p.C113Y missense variant with 8 commonly-used software. FI, Functional Impact of a 
variant; CADD, Combined Annotation Dependent Depletion. FI is ranked as: high (H), 
medium (M) for predicted functional variants and low (L) for predicted non-functional 
variants. CADD Scaled C-score represents the PHRED-like [-10*log10(rank/total)] score, 
ranking a variant relative to all possible substitutions of the human genome (8.6x109). A 
scaled C-score of greater or equal to 10 indicates that these are predicted to be the 10% 
most deleterious substitutions that you can do to the human genome, a score of greater or 
equal to 20 indicates the 1% most deleterious and so on. 
SLC22A4 is located on chromosome 5q31.1, is composed of 10 exons and codes for 
OCTN1 (organic cation transporter 1). The organic cation/carnitine transporter OCTN1 is 
a 551-amino acid protein with 12 transmembrane domains [Burckhardt and Wolff, 2000] 
which is ubiquitously expressed in the body [Yabuuchi et al., 1999]. The SLC22A4 gene is 
also expressed in the cochlea, as reported in the SHIELD (Shared Harvard Inner-Ear 
Laboratory Database, https://shield.hms.harvard.edu) [Shen et al., 2015], and further 
supported by the result of a specific RT-PCR assay on a RNA sample of organ of Corti 
derived from a postnatal day 4 wild-type mouse (our data, not shown). More specifically, it 
was demonstrated to have a diffuse expression across the inner ear epithelia, including the 
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hair cells and the apical surface plasma membrane of the endothelial cells of the stria 
vascularis [Ben Said et al., 2016]. At the subcellular level, the encoded OCTN1 protein was 
described to localise in mitochondria, where it would participate in the maintenance of 
intracellular carnitine homeostasis [Lamhonwah and Tein, 2006]. In addition, in-vitro and in-
vivo studies identified ergothioneine, a potent antioxidant, as the key substrate of OCTN1. 
Indeed, a metabolome analysis of blood and several organs of Octn1-/- mice indicated 
complete deficiency of ergothioneine and greater susceptibility to intestinal inflammation 
[Gründemann et al., 2005; Kato et al., 2010]. These findings seem to provide support to 
genetic analyses in humans, where polymorphisms in the SLC22A4 gene have been 
previously linked to Crohn’s disease [Peltekova et al., 2004], colorectal cancer [Martini et al., 
2012; Li et al., 2017], and susceptibility to rheumatoid arthritis [Tokuhiro et al., 2003]. In the 
case of family NSHL7, however, no clinical symptoms or signs were reported from patients 
that could suggest the presence of inflammatory and/or intestinal diseases. Interestingly, 
the hearing phenotype of a different Slc22a4 knock-out mouse was recently made available 
by the International Mouse Phenotyping Consortium (Slc22a4tm1.1(KOMP)Vlcg allele; 
http://www.mousephenotype.org/data/genes/MGI:1353479): the evoked auditory 
brainstem responses are not significantly different between wild-type mice and 
homozygous mutants, indicating no apparent signs of hearing loss. 
The cysteine 113, affected by the mutation, is highly conserved across species (Fig. 3.2D) 
and it is one of the four highly-conserved cysteines that are present in all human organic 
cation transporter (OCTN1-2, OCT1-3), suggesting the importance of this residue for the 
protein structure [Burckhardt and Wolff, 2010]. Not surprisingly, the p.C113Y variation is 
predicted to be deleterious by all the software used (Fig. 3.2D). 
To evaluate the impact of the amino acid substitution on OCTN1 protein localisation, I 
performed immunolocalisation studies on HeLa and HEK293 cells overexpressing a Myc-
tagged isoform of the wild-type and mutant OCTN1 (pCDNA3.1_OCTN1-myc-wt, 
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pCDNA3.1_OCTN1-myc-mut) 48 hours after transfection. However, in contrast with the 
findings of Lamhonwah and Tein [Lamhonwah and Tein, 2006], who suggest a specific 
mitochondrial expression of the protein, my immunolocalisation studies do not show an 
exact co-localisation with the mitochondrial marker MitoTracker Orange, being the 
transporter seemingly confined in other intracellular compartments. In fact, the protein 
seems to localise along the secretory pathway, in perinuclear compartments as well as in an 
interconnected network that extend thorough the cytoplasm. It is thus plausible that, at 
later time points, the protein could be observed at the membrane, as postulated by other 
authors [Frigeni et al., 2016]. Nonetheless, our studies suggest that the p.C113Y variant 
does not alter OCTN1 localisation at the time point analysed (Fig. 3.3). 
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Figure 3.3. OCTN1 immunolocalisation studies. Co-localisation studies were 
performed on HeLa (upper panel) and HEK293 (lower panel) cells 48 hours after 
transfection with plasmids coding for Myc-tagged isoforms of OCTN1 wild-type or mutant 
proteins (OCTN1-myc WT, OCTN1-myc MUT). Images were acquired with Olympus 
FV1000 Inverted Confocal IX81 Microscope and are representative of 3 independent 
experiments. DAPI: 4',6-diamidino-2-phenylindole. Single confocal sections are shown. 
Scale bars: 10 μm. 
In 2016, SLC22A4 was identified as the DFNB60-associated gene responsible for NSHL 
in two unrelated consanguineous families of Tunisian ancestry [Ben Said et al., 2016]. 
Intriguingly, the same NM_003059.2:c.338G>A (p.C113Y) variation was detected in both 
Tunisian families, as in family NSHL7. The authors showed that the p.C113Y mutation 
alters the ergothioneine uptake activity, and consequently the fatty-acid-based metabolic 
energy production pathway. Starting from this finding and considering the protein’s 
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peculiar pattern of expression, the authors speculate that OCTN1 could be crucial for 
carnitine and ergothioneine transport into the inner ear. In addition, being the mutation 
located in the same haplotype in the two unrelated Tunisian families and found in an 
additional carrier among 122 Tunisian normal-hearing individuals, a founder effect of the 
p.C113Y mutation was hypothesised [Ben Said et al., 2016]. 
Importantly, the linkage region associated with the hearing impairment in the Moroccan 
family we analysed partially overlaps with the linkage regions of the previously-reported 
Tunisian families [Ben Said et al., 2016] (Fig. 3.4), thus further strengthening the hypothesis 
of a founder effect of the mutation.  
Figure 3.4. Schematic representation of the deafness-associated haplotype in the 
three unrelated North African families reported to carry the 
NM_003059.2:c.338G>A (p.C113Y) missense variation. A comparison between the 
linkage regions associated with the hearing impairment in the two previously-reported 
Tunisian families (FT13 and FT20) [Ben Said et al., 2016], and the Moroccan NSHL7 
family (in dark blue) on chromosome 5q23.2–q31.1 is reported, and the shared region 
containing SLC22A4 is shown (image adapted from the UCSC Genome Browser). 
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3.2.1. Discussion and conclusions on family NSHL7 
The frequency of the mutations associated with deafness can vary markedly in different 
ethnic groups. In the case of North Africans, the mutational landscape of NSHL is only 
partially overlapped with the one found in Caucasians. Indeed, NSHL-causing mutations 
identified in North African countries currently involve a relatively small set of genes, i.e. 
GJB2, MYO7A, MYO15A, SLC26A4, TMC1, TMPRSS3, DFNB31, ESRRB, ESPN, 
DFNB59, LRTOMT, LHFPL5, PNPT1, TPRN, and MT-RNR1 [Chakchouk et al., 2015]. 
Besides the bias due to the low number of genetically-analysed patients, this could also be 
related to the frequency of consanguineous marriages among North African populations, 
which inevitably leads to a clustering of rare recessive genetic defects [Rudman et al., 2017]. 
In addition, Northwest African samples from the GME study (comprising individuals from 
Morocco, Algeria, and Tunisia) were among the least admixed ones, and it is thus suggested 
that these three countries represent a unique founder population [Scott et al., 2016]. 
The association of the p.C113Y variant in SLC22A4 gene with recessive NSHL was 
published in 2016 [Ben Said et al., 2016], while I was also in the process of elucidating its 
role in the deafness of family NSHL7. The identification of the same mutation in family 
NSHL7 not only corroborates the involvement of the SLC22A4 gene in deafness, but also 
suggests that the p.C113Y substitution is possibly a founder NSHL mutation with a 
broader distribution than previously thought. This could have important implications for 
the genetic diagnosis of deafness at least in patients/families with known Northwest 
African origin. 
However, it should be noted that the p.C113Y variant was also found, in the homozygous 
state, in a normal-hearing NSHL7 family member, suggesting incomplete penetrance. 
Indeed, incomplete/reduced penetrance of the hearing phenotype in humans has been 
reported [Vona et al., 2015], and attempts were made to identify modifier genes that could 
explain this phenomenon. For example, the modifier gene METTL13 (DFNM1 locus) 
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have been identified as a dominant suppressor of recessive DFNB26/GAB1 deafness 
[Riazudin et al., 2000; Yousaf et al., 2018a]. By analogy with METTL13, it is tempting to 
hypothesise the involvement of a dominant modifier of SLC22A4, which could suppress 
the onset of deafness in the non-penetrant individual IV1 from family NSHL7. 
Unfortunately, the genetic mapping of such a modifier is currently unfeasible due to the 
limited number of subjects with non-penetrant phenotype associated with the SLC22A4 
p.C113Y variant. 
Another point that deserve further consideration is the discrepancy of the knock-out 
mouse phenotype. In fact, the ABR screening performed as part of the IMPC phenotyping 
pipeline did not show any sign of hearing impairment in the Slc22a4 knock-out mouse 
model. Although the number of analysed animals was very limited (8 homozygous mutants 
only), and the panel of experiments to test the hearing function could be certainly 
broadened, these results do not help in shedding light on the role of SLC22A4 in the 
normal hearing function. However, given 1) the absence of mutations in other NSHL-
associated genes (including the 58 pathogenic variants of the NADf chip [Chakchouk et al., 
2015]); 2) the geographical origins of the NSHL7 family; 3) the identification of a unique 
significant linkage signal peak in family NSHL7, encompassing SLC22A4 gene, and 4) the 
absence of more plausible pathogenic variants within the linkage region, it can be assumed 
that the p.C113Y substitution in SLC22A4 is the likely cause of deafness in family NSHL7 
and that it is recurrently associated with NSHL in Northwest African population. Further 
analysis in other NSHL families from the same geographical area would help in deciphering 
if this variation could be considered a solid marker of the disease, whose systematic 
screening could favorably influence deafness diagnosis. Also, it would be interesting to 
evaluate the impact of different genetic backgrounds on the expressivity of SLC22A4-
dependent hearing phenotype studying wider patient populations with different ethnic 
backgrounds. 
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3.3. NSHL18 family: the HCN1 and OTOA genes 
Family NSHL18 is a consanguineous family, segregating early-onset moderate-to-severe 
HL with a likely autosomal recessive inheritance pattern. The proband (IV3) is a 23-year-
old male with a 28-year-old deaf sister (IV1) and a 24-year-old normal-hearing brother 
(IV2). The proband’s parents (III1, III2) are first cousins and have normal hearing. 
Individuals III5 and III12, cousins of III1 and III2, also show HL. Unfortunately, the II6 
branch of the family was not available to the study. We subjected to WES the two affected 
siblings (IV2 and IV4) (Fig. 3.5A-B). I first performed a homozygosity mapping analysis to 
identify ROH shared by the affected siblings (Table 3.2). However, no likely pathogenic 
variants were identified in the two shared ROH. After ruling out the presence of mutations 
in known deafness genes, single nucleotide variant analyses of exome data prioritised 11 
possibly pathogenic variants present in the homozygous state in the two affected siblings. 
Then, pathogenicity predictions together with segregation studies selected the 
NM_021072:c.1250A>G (p.Y417C) variant within exon 5 of the HCN1 gene as the most 
promising candidate (Fig. 3.5C). Of note, HCN1 gene is the last gene on the short arm of 
chromosome 5 before the centromere. Therefore, we hypothesised that the gap of flanking 
SNV at the 3’ end of the gene could have prevented the detection of ROH in this genomic 
region. The c.1250A>G variation is present in the homozygous state in both affected 
siblings and in the heterozygous state in normal hearing relatives (III1 to 3, IV2) (Fig. 
3.5A). In addition, it is absent in the gnomAD database, as well as in our in-house database. 
Table 3.2. Runs of homozygosity shared between affected siblings. 
The localisation of ROHs, their length (Mb), the number of SNPs (NSNP) and the proportion of 
homozygous calls within the run (PHOM) are indicated. 
ID chr start end Mb NSNP PHOM 
IV1 16 55862901 58757683 2.89 85 0.988 
IV2 16 55862901 58757683 2.89 86 0.988 
IV1 20 60293919 62737318 2.44 114 0.991 
IV2 20  60293919 62714783 2.42 84 0.988 
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Figure 3.5. WES identifies one novel missense variant in the HCN1 gene. A. The 
pedigree of NSHL18 family members is shown. The genotypes of all available individuals 
are indicated below the corresponding symbols and the arrow points to the proband. W: 
wild-type allele, M: mutant allele.  B. Audiograms showing the threshold average for the 
right and left ear and the age at audiometric evaluation for each individual. C. Schematic 
representation of HCN1 gene, where exons are indicated by rectangles and introns by black 
lines. Electropherograms showing the sequence surrounding the mutated nucleotide in one 
carrier (left) and one homozygous (right) family member. The position of the variant 
identified in family NSHL18 is indicated by an arrowhead. R: A or G. 
HCN1 is located on chromosome 5p12, comprises 8 exons and codes for HCN1, one of 
the four members of the potassium/sodium hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels, which have a pivotal role in cellular excitability. HCNs belong to 
the 6TM (six transmembrane domains) ion channel superfamily and assemble in 
homo/hetero-tetrameric complexes. Each HCN subunit is thus composed of six 
transmembrane domains (S1-S6) with intracellular amino and carboxyl termini. The S4 
domain, containing positively charged amino acids, is the channel voltage sensor, while the 
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region spanning from S5 to S6 (including the reentrant pore loop) forms the pore region. 
The S6 domain is connected to the C-terminal cyclic nucleotide binding domain (CNBD) 
by the C-linker, which is composed of six α-helices (A’-F’) separated by short loops 
[Craven and Zagotta, 2006; Lee and MacKinnon, 2017] (Fig. 3.6A-B). HCNs are principally 
activated by hyperpolarization and modulated by binding of cyclic AMP (cAMP). In 
particular, cAMP enhances the channel activity binding to the CNBD and promoting its 
conformational change. This conformational change is transmitted to the C-linker and 
results in the release of the tonic inhibitions exerted by the CNBD on the channel pore. As 
a consequence of cAMP binding, the channel activation voltage shifts to more positive 
potentials [Wainger et al., 2001; Lolicato et al., 2011]. The opening probability is also 
enhanced by a Src-mediated tyrosine phosphorylation [Zong et al., 2005]. 
Tyrosine 417 is located in the A’-helix of the C-linker trait and it is highly conserved not 
only among HCNs, but also among the CNG (cyclic nucleotide-gated) channel subfamily 
(Fig. 3.6A-B), which are also regulated by cyclic nucleotide binding and share the same 
structural organization of HCNs [Craven and Zagotta, 2006]. In addition, the substitution 
with a cysteine is likely to disrupt the local α-helix structure, as calculated by the GOR IV 
secondary-structure prediction software (https://npsa-prabi.ibcp.fr/cgi-
bin/npsa_automat.pl?page=/NPSA/npsa_gor4.html, Fig. 3.8B), and is classified as 
deleterious by all of the 8 prediction software used (Fig. 3.6C).  
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Figure 3.6. In-silico analyses of the novel HCN1 p.Y417C missense variant 
identified in family NSHL18. A. Schematic representation of HCN1 protein showing the 
six transmembrane helices (S1-S6), the C-linker and the cyclic nucleotide-binding domain 
(CNBD). The tyrosine affected by the mutation is located in the A’ helix of C-linker 
domain and it is highly conserved among HCN channels as well as in the CNG channel 
family (lower panel). The amino acid residue affected by the mutation is shaded in red. 
Identical amino acids are marked by an asterisk, while partially conserved residues are 
indicated by a colon. Clustal Omega alignment of amino acid sequences retrieved from 
UniProt is shown. B. Ribbon representation of the mouse C-linker/CNBD Hcn1 subunit 
(PDB entry: 3UOZ). The mutated tyrosine is indicated by a black arrow. A’-F’: C-linker α-
helices. C. Pathogenicity prediction of the p.Y417C missense variant with 8 commonly-
used software. FI, Functional Impact of a variant; CADD, Combined Annotation 
Dependent Depletion. FI is ranked as: high (H), medium (M) for predicted functional 
variants and low (L) for predicted non-functional variants. CADD Scaled C-score 
represents the PHRED-like [-10*log10(rank/total)] score, ranking a variant relative to all 
possible substitutions of the human genome (8.6x109). 
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The HCN1 gene has been previously associated with epileptic encephalopathy, early 
infantile, 24 (EIEE24, MIM #615871), where five heterozygous de-novo mutations with a 
gain-of-function or a dominant-negative effect have been described [Nava et al., 2014]. 
However, I deemed HCN1 a good candidate for NSHL, since it is expressed in the 
mammalian cochlear hair cells and specifically interacts with stereociliary tip-link 
protocadherin 15 [Ramakrishnan et al., 2012]. Furthermore, HCN1 is the most expressed 
subunit in spiral ganglion neurons and functionally contribute to their signal transmission, 
so that Hcn1 deficient mice show longer latencies in auditory brainstem responses and 
have deficits in spatial acuity [Kim and Holt, 2013; Ison et al., 2017]. In addition, Ison and 
colleagues found that Hcn1-/- mice had higher ABR thresholds as compared to wild-types 
only at high frequencies [Ison et al., 2017]. Interestingly, the hearing impairment in the two 
affected siblings of family NSHL18 is less severe in the low frequencies (Fig. 3.5B). 
With this background, the p.Y417C variant was considered worth to be further 
investigated. First, to identify another patient carrying a mutation in the same region of 
HCN1 C-linker, I screened HCN1 exon 5 in 656 individuals from our cohort of deaf 
patients, but no variants were found. Second, in-vitro functional studies were performed - in 
collaboration with the laboratory of Professor Michela Matteoli (Humanitas Clinical and 
Research Center) - to evaluate the impact of the identified missense variant on HCN1 
channel function. In particular, over-expression experiments, using pCDNA3.1_hHCN1-
WT or pCDNA3.1_hHCN1-p.Y417C constructs,  were conducted in HEK293 cells first to 
assess the localisation of the wild-type and the p.Y417C mutant channels, and then to carry 
out whole-cell patch-clamp analyses. Immunofluorescence experiment showed that the 
missense variant does not impair HCN1 membrane localisation (data from Mr. Filippo 
Mirabella, not shown). Conversely, whole-cell patch-clamp recordings showed a strikingly 
decreased current of the p.Y417C mutant channel compared to the wild-type (Fig. 3.7A). 
Indeed, the current density for cells overexpressing p.Y417C protein was significantly 
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reduced as compared to cells overexpressing the wild-type channel (one-way ANOVA, p-
value < 0.01), while it did not differ significantly from endogenous current density (control 
cells, transfected with GFP) (Fig. 3.7B). Taken together, these data suggested a loss of 
function effect of the amino acid substitution. 
Figure 3.7. Electrophysiological analyses on HEK293 cells overexpressing wild-type 
or mutant HCN1 protein. A. Representative traces of whole-cell currents recorded in 
HEK293 cells transfected with vector expressing the wild-type (WT) or p.Y417C HCN1 
protein. B. Plot of mean current density as a function of test voltage for cells 
overexpressing WT or p.Y417C HCN1; cells transfected with GFP were used as control. 
Data are presented as mean ± SEM (standard error of the mean) with the numbers of 
experiments indicated in parentheses. Electrophysiological analyses were performed by Mr. 
Filippo Mirabella. 
To further characterise the mechanism by which the p.Y417C mutation causes the loss of 
channel function, I introduced a conservative mutation in HCN1 generating the mutant 
construct p.Y417F, in which the tyrosine 417 is substituted with a phenylalanine. Indeed, 
while the substitution of a tyrosine with a cysteine is predicted to disrupt HCN1 A’ α-helix 
structure by the GOR IV software, the amino acid phenylalanine differs from tyrosine just 
for the absence of the hydroxyl group in the para position of the benzene ring and it is not 
expected to alter HCN1 secondary structure (Fig. 3.8A-B). As opposed to cells 
overexpressing the p.Y417C HCN1 mutant, currents were recorded in HEK293 cells 
overexpressing the p.Y417F mutant protein (Fig. 3.8C); this observation suggested that the 
substitution with a cysteine could indeed disrupt the C-linker structure, possibly altering the 
normal regulation of the channel gating. 
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Figure 3.8. Evaluation of HCN1 p.Y417F mutant channel. A. Amino acid structures 
showing that phenylalanine differs from tyrosine for the absence of the hydroxyl group in 
the para position of the benzene ring. B. GOR IV software secondary structure prediction 
for WT, p.Y417C and p.Y417F proteins. The region corresponding to A’ α-helix is squared 
and the position of the substitution is indicated by a black arrow. Only the p.Y417C 
mutation is predicted to disrupt A’ α-helix and has also an effect on B’ α-helix. Random 
coil (c), α-helix (h), extended strand (e). C. Representative trace of whole-cell currents 
recorded in HEK293 cells overexpressing the p.Y417F HCN1 protein. 
Electrophysiological analyses were performed by Mr. Filippo Mirabella. 
Despite these encouraging data, the implementation of WES data analysis with the 
detection of structural variants (using the EXCAVATOR2 tool) led to the identification of 
a putative homozygous deletion encompassing the OTOA gene in the proband and his 
affected sister. 
OTOA gene is composed by 28 exons and is located on chromosome 16p12.2 within a 68 
Kb segmental duplication with a high sequence identity [Shahin et al., 2010]. It encodes the 
otoancorin, a noncollogeneous glycoprotein specifically expressed in the inner ear and 
necessary for the attachment of the tectorial membrane to the spiral limbus and, 
consequently, for the stimulation of inner hair cells [Zwaenepoel et al., 2002; Lukashkin et 
al., 2012]. ABR recordings of Otoa knock-out mice reported by the IMPC (Otoatm1.1(KOMP)Vlcg 
allele; http://www.mousephenotype.org/data/genes/MGI:2149209) show a severe HL at 
all frequencies, which is more accentuated at high frequencies. Furthermore, loss of 
function mutations in OTOA have been associated with autosomal recessive deafness 
DFNB22 (MIM #607039). Interestingly, two different large homozygous deletions 
including the OTOA gene were previously identified. The first one, spanning 320-550 Kb, 
was reported in a consanguineous Palestinian family and its carrier frequency in that 
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population was 1% [Shahin et al., 2010]. A smaller deletion, shorter than 190 Kb, was 
identified in a consanguineous Turkish family with mild-to-moderate sensorineural HL 
[Bademci et al., 2014]. In addition, a heterozygous 228.5 Kb-deletion in OTOA, together 
with a missense mutation on the other allele, was recently identified in an Italian family 
with prelingual severe HL [Fontana et al., 2017]. 
Serial PCR analyses, performed on genomic DNA from affected siblings and their parents, 
confirmed the presence of a 230-275 Kb homozygous deletion encompassing OTOA and 
the upstream and downstream nearest neighboring genes METTL9 and RRN3P1 in 
individuals IV1 and IV3 (Fig. 3.9). The presence of OTOA deletion was also independently 
confirmed by MLPA (Multiplex Ligation Probe Amplification) analysis at the Laboratory of 
Medical Genetics of the Niguarda Hospital of Milan (data not shown). Therefore, the loss 
of OTOA function was considered the most likely cause of deafness in the family.  
Figure 3.9. WES data analysis with EXCAVATOR2 identifies a homozygous 
deletion in OTOA gene. EXCAVATOR2 tool detected a ~433 Kb deletion 
encompassing the OTOA gene. Serial PCR analyses narrowed the deleted region to ~230-
275 Kb. The position of the PCR amplicons is shown. Plus and minus symbols indicate 
whether the PCR amplification yielded a product of the expected size or not (image 
adapted from the UCSC Genome Browser). 
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3.3.1. Discussion and conclusions on NSHL18 family 
The alignment of short reads on the reference genome is extremely challenging for highly 
similar sequences, since these reads cannot be mapped to a single region. Low mapping 
quality for exon 20-28 of OTOA gene is a well-known problem of the NGS approach 
[Mandelker et al., 2014], and is due to the peculiar location of these exons within a 68 Kb 
segmental duplication with more than 99% sequence identity [Shahin et al., 2010]. For the 
same reason, this region represents a hot spot for CNVs, occurring as a result of non-allelic 
homologous recombination [Shearer et al., 2014]. Several CNVs involving OTOA have 
been identified [Shahin et al., 2010; Shearer et al., 2014; Bademci et al., 2014], making this 
gene the second HL gene in which CNVs are most commonly detected [Shearer et al., 
2014]. Even if exome data are most suited to detect SNVs and short indels, specific tools 
have been designed to extract information on larger structural variants. Those programs are 
mostly based on a read count approach and are affected by the nonuniform efficiency of 
exome capture [D’aurizio et al., 2016]. For sequences with low mapping quality it is even 
more difficult to rely on the output of these tools, which perform poorly in case of 
repetitive regions [Pirooznia et al., 2015]. Nonetheless, in this case the use of the 
EXCAVATOR2 algorithm was fundamental to detect the large deletion including the 
OTOA gene, which escaped our first analyses. Given the important contribution of CNVs 
to NSHL [Shearer et al., 2014], it is thus essential to include a bioinformatic pipeline for 
their detection exploiting whole-exome data and, ideally, a specific genetic testing of CNV 
using other available technologies (e.g. arrayCGH) to integrate WES data [Moteki et al., 
2016]. 
Concerning the p.Y417C HCN1 variant, even though our in-vitro studies indicate a 
functional impact on the channel activity, it is difficult to establish its contribution to the 
phenotype of the NSHL18 family, whose deafness - at the current state of knowledge - can 
be entirely attributed to the homozygous deletion of the OTOA gene. 
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However, we speculated that the loss of HCN1 function in the two deaf siblings could 
cause an unreported phenotype, distinct to deafness. Based on the association of HCN1 
with neurological anomalies, further clinical investigations were proposed to family 
NSHL18. The proband had an electroencephalography (EEG) and an intelligence quotient 
(IQ) test. While no waveform abnormalities were found in the EEG, the IQ test diagnosed 
a mild mental retardation in the proband. Interestingly, learning and memory disabilities 
were reported in the corresponding Hcn1 knock-out mouse model [Nolan et al., 2003]. 
Based on all these evidences, it is indeed plausible that the p.Y417C variant in HCN1 might 
be the cause of the mild intellectual disability diagnosed in the proband. However, it has 
also been suggested that hearing impairment in children - especially if not promptly 
diagnosed – could contribute to cognitive deficits [Quittner et al., 2004]. Therefore, it 
would be important to evaluate the segregation of the p.Y417C variant with mild cognitive 
impairment in all NSHL18 family member, as well as to identify other unrelated individuals 
with a similar phenotype, carrying loss of function mutations in HCN1. 
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3.4. NSHL20 family: identification of a novel pathogenic variant in the COCH gene 
Family NSHL20 segregates late-onset hearing loss with an autosomal dominant inheritance 
pattern. The proband (IV2) is a 38-year-old man affected by bilateral deafness. The hearing 
in the family is characterised by a ski-slope loss, with a mild impairment in the low 
frequencies and a moderate-to-severe deafness in the middle and high frequencies. In 
individual II2, audiometrically tested at 82 years, the degree of hearing loss is more 
pronounced with a severe deafness in the low frequencies and a profound deafness at 
higher frequencies (Fig. 3.10A-B). The analysis of WES data from individuals III3, IV1 and 
IV2 pointed out 108 heterozygous variants shared only between deaf individuals. Among 
these, the NM_004086:c.1096 G>A transition (p.V366M) in the COCH gene was the only 
variant identified in a known NSHL gene and was thus considered the most likely cause of 
deafness in the family (Fig. 3.10C). 
Figure 3.10. WES identifies a novel mutation in the COCH gene. A. The pedigree of 
NSHL20 family is shown. The genotypes of all available individuals are indicated below the 
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corresponding symbols. The arrow points to the proband. W: wild-type allele, M: mutant 
allele. B. Audiograms showing the threshold average for the right and left ear and the age 
at audiometric evaluation for each individual. C. Schematic representation of the COCH 
gene, where exons are indicated by rectangles and introns by black lines. 
Electropherograms showing the sequence surrounding the mutated nucleotide in one wild-
type (left) and one heterozygous (right) family member. The position of the missense 
variant identified in family NSHL20 is indicated by an arrowhead. R: A or G. 
The COCH gene is located on chromosome 14q12 and is responsible for autosomal 
dominant deafness DFNA9 (MIM #601369), which is characterised by an adult onset (in 
the 2nd to 3rd decade, starting from high frequencies) and a progressive decline of hearing to 
anacusis (by the 6th or 7th decade) and could be accompanied by vestibular impairment 
[Robertson et al., 1998; JanssensdeVarebeke et al., 2018]. Although the real worldwide 
incidence of mutation in COCH is not known [Bae et al., 2014], DFNA9 has been reported 
to be the third most common type of autosomal dominant NSHL [Hildebrand et al., 2010].  
COCH comprises 12 exons and encodes cochlin, an extracellular matrix protein highly 
expressed in the inner ear. Cochlin is composed of a signal peptide (SP), a LCCL (Limulus 
factor C, cochlin, and late gestation lung protein Lgl1) domain, two intervening domains 
(ivd) and two von Willebrand factor A (vWFA)-like domains [Robertson et al., 2001; Bae et 
al., 2014] (Fig. 3.11). 
To date, 25 mutations in the COCH gene have been associated with ADNSHL [Bae et al., 
2014; Tsukada et al., 2015; Jung et al., 2015; Gu et al., 2016], mainly affecting LCCL or 
vWFA domains (Fig. 3.11). Interestingly, it has been reported that mutations in the LCCL 
domain cause HL with the presence of vestibular symptoms, whereas pathogenic variants 
in the vWFA domains are mostly associated with hearing defects only [Bae et al., 2014]. All 
the variants are thought to have a dominant negative or gain-of-function effect, presumably 
causing impaired protein secretion and the concomitant aggregation and accumulation of 
cochlin intracellularly. Recently, a homozygous nonsense COCH variant (c.292C>T; 
p.R98X) was reported in a consanguineous family of Moroccan origin segregating 
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ARNSHL. In contrast to the 25 heterozygous variants causing DFNA9, the homozygous 
variant is expected to have a loss of function effect and seems to be associated with an 
earlier age of onset (Fig. 3.11) [JanssensdeVarebeke et al., 2018]. 
Figure 3.11. Schematic representation of cochlin domains. SP: signal peptide, LCC: 
Limulus factor C, cochlin, and Lgl1, vWFA1/2: von Willebrand factor A-like 1/2, ivd 1/2: 
intervening domain 1/2. The positions of the previously reported mutations are indicated 
in black (autosomal dominant up, autosomal recessive down), whereas the missense 
mutation identified in NSHL20 family is shown in red. Modified from Bae et al., 2014. 
The p.V366M variant is located in the vWFA2 domain of cochlin protein and, in 
agreement with the aforementioned correlation, the affected individuals of the NSHL20 
family are reported solely with hearing impairment. In addition, although a follow-up of 
patients’ hearing thresholds is not available, a correlation between the severity of HL and 
age among the affected individuals in the family can be observed, with younger subjects 
showing a milder impairment (Fig. 3.10B). 
The missense mutation affects a highly conserved residue, which is invariant across 
vertebrates, and it is predicted to significantly impact on protein function by 7 out of 8 
commonly used programs to predict the deleteriousness of a given amino-acid substitution 
(Fig. 3.12). Furthermore, this variation is extremely rare both worldwide and in Italy, being 
absent in the gnomAD database and in our in-house collection of more than 3500 Italian 
exomes. Interestingly, a different substitution in the same nucleotide (c.1096 G>T, 
p.V366L) is reported, at the heterozygous state, in just 1 out of 15490 individuals from the 
gnomAD (allelic frequency 3.228e-5). 
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In conclusion, based on the genotype-phenotype correlation and on the in-silico predictions, 
we propose that the p.V366M mutation is responsible for NSHL in family 20.  
Figure 3.12. In-silico analyses of the novel COCH p.V366M missense variant 
identified in family NSHL20. A. Amino acid sequence alignments of COCH orthologs 
in the region surrounding the mutant residue (p.V366). Protein sequences were retrieved 
from UniProt, and alignments were generated with Clustal Omega. The amino acid residue 
affected by the mutation is shaded in red and indicated by a red arrow. Identical amino 
acids are marked by an asterisk, while partially conserved residues are indicated by a colon. 
B. Pathogenicity prediction of the p.V366M missense variant generated with 8 commonly-
used software. FI, Functional Impact of a variant; CADD, Combined Annotation 
Dependent Depletion. FI is ranked as: high (H), medium (M) for predicted functional 
variants and low (L) for predicted non-functional variants. CADD Scaled C-score 
represents the PHRED-like [-10*log10(rank/total)] score, ranking a variant relative to all 
possible substitutions of the human genome (8.6x109).  
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3.5. NSHL22 family: identification of two known pathogenic variants in SLC26A4 gene 
The NSHL22 pedigree is compatible with a recessive (autosomal or X-linked) inheritance 
(Fig. 3.13A). The two siblings (II2 and II3) were diagnosed with early-onset severe bilateral 
HL. II2 is a 39-year-old man who reports vertigo, which worsened in 2008 after cochlear 
implantation. II3 is 37 years old and was diagnosed with NSHL at 3 years of age (Fig. 
3.13A-B). We subjected both siblings to WES, and analysed the data following the pipeline 
described in paragraph 3.1. We identified possibly pathogenic variants in the homozygous 
or compound heterozygous state affecting 9 genes. Among these putative mutations, we 
found two known pathogenic variants in the SLC26A4 gene: NM_000441:c.1001G>T 
(p.G334V; rs146281367; ClinVar: 189039) [Walsh et al., 2006; Kahrizi et al., 2009] and 
NM_00441:c.1129C>T (p.T410M; rs111033220; ClinVar: 43498) [López-Bigas et al., 2001; 
Arellano et al., 2005] (Fig. 3.13C). 
Figure 3.13. Identification of two known pathogenic variants in the SLC26A4 gene. 
A. Family NSHL22 pedigree. The genotypes are indicated below the corresponding symbol 
and the arrow points to the proband. W: wild-type allele, M: mutant alleles. The two 
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mutations are indicated with different colors. The segregation analysis was performed at 
the Laboratory of Medical Genetics of the Niguarda Hospital of Milan. B. Pure-tone air-
conduction thresholds of NSHL22 family members. For each individual the threshold 
average for the right and left ear and the age at audiometric evaluation is shown. C. 
Schematic representation of SLC26A4 gene, where exons are indicated by rectangles and 
introns by black lines. Electropherograms showing the sequence surrounding the mutated 
nucleotides in the proband. The position of the variants identified in family NSHL22 is 
indicated by arrowheads. K: G or T; Y: C or T. Exonic nucleotides are indicated with 
uppercase, while intronic nucleotides are indicated with lowercase letters. 
The SLC26A4 gene, comprising 21 exons, is located on chromosome 7q22.3. It codes for 
the 780-amino-acids Cl-/HCO3
- exchanger pendrin, which is expressed in different tissues 
including the inner ear and the thyroid [Dror et al., 2011]. In the cochlea, pendrin is 
expressed in non-sensory epithelial cells of the outer sulcus and spiral prominence [Royaux 
et al., 2003], and it mediates the secretion of HCO3
- in the endolymph, thus contributing to 
the maintenance of the fluid pH [Wangemann et al., 2007]. Pendrin also participates to the 
apical iodide secretion in thyroid follicular cells [Bizhanova and Kopp, 2009]. Not 
surprisingly, mutations in the gene have been associated with both autosomal recessive 
NSHL with EVA - enlarged vestibular aqueduct - (DFNB4, MIM#600791) and Pendred 
syndrome (PDS, MIM #274600), which is characterised by congenital deafness and 
impaired iodide organification, possibly leading to goitre. However, PDS is often under-
recognised, as goitre usually manifest in adulthood [Hilgert et al., 2009].  Moreover, EVA 
can occur alone or together with Mondini dysplasia, a malformation of the cochlear turns. 
Despite the variety of clinical manifestation associated with SLC26A4 mutations, a detailed 
genotype-phenotype correlation has not been defined, since some of the mutations have 
been associated with different phenotypes [Dror et al., 2011]. 
Both variants are predicted to be deleterious by 8 out of 8 software used and affect amino 
acids highly conserved across vertebrates (Fig. 3.14). 
The c.1001G>T variant is reported, in the heterozygous state, in 2 out of 122538 
individuals in the gnomAD database and it was firstly described in the homozygous state in 
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a consanguineous Palestinian family segregating severe-to-profound HL with EVA. In 
particular, the mutation affects the last nucleotide of exon 8, and causes both an amino acid 
substitution (NP_000432.1:p.G334V) and a splicing defect. Indeed, it was shown to cause 
the retention of the first 41 nucleotides of intron 8, leading to a premature stop codon 
immediately after glycine 334 [Walsh et al., 2006]. The homozygous c.1001G>T mutation 
was also associated with a PDS phenotype in an Iranian consanguineous family [Kahrizi et 
al., 2009] and it was shown to dramatically impair pendrin transport activity [Dossena et al., 
2011]. 
Similarly, the p.T410M variant (present in the heterozygous state in 51/138276 from the 
gnomAD database and in 3/3541 Italian control exomes) was described in the 
homozygous state both in individuals with deafness and normal thyroid function [López-
Bigas et al., 2001] and in PDS patients; this phenotypic variability has also been reported 
within the same family [Arellano et al., 2005]. Taylor and colleagues demonstrated that the 
mutant protein fails to reach the plasma membrane, being retained in the endoplasmic 
reticulum [Taylor et al., 2002]. 
The analysis of the segregation of the two variants within family NSHL22 confirmed that 
each variant was inherited from one of the normal-hearing parents (performed at the 
Laboratory of Medical Genetics of the Niguarda Hospital of Milan). Following molecular 
diagnosis, one of the affected sibling self-reported “thyroid problems”. Considering that 
the variants were also described in PDS patients, II2 and II3 were referred to a thyroid 
endocrinologist and subjected to further clinical evaluation and management. In this family, 
WES not only was fundamental to provide a genetic diagnosis, but also allowed to address 
the patients to the more suitable monitoring and treatment.   
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Figure 3.14. In-silico analyses of the two SLC26A4 missense variants (p.G334V and 
p.T410M) identified in family NSHL22 in the compound heterozygous state. A. 
Amino acid sequence alignments of SLC26A4 orthologs in the region surrounding the two 
mutant residues (p.G334 and p.T410). Protein sequences were retrieved from UniProt, and 
alignments were generated with Clustal Omega. The amino acid residues affected by the 
mutations are shaded in red and indicated by an orange and a blue arrow respectively. 
Identical amino acids are marked by an asterisk, while partially conserved residues are 
indicated by a colon. B. Pathogenicity prediction of the p.G334V and p.T410M missense 
variants with 8 commonly-used software and presence in databases. FI, Functional Impact 
of a variant; CADD, Combined Annotation Dependent Depletion. FI is ranked as: high 
(H), medium (M) for predicted functional variants and low (L) for predicted non-functional 
variants. CADD Scaled C-score represents the PHRED-like [-10*log10(rank/total)] score, 
ranking a variant relative to all possible substitutions of the human genome (8.6x109).  
3.5.1. Mouse models of DFNB4 
The study of Slc26a4 knock-out and knock-in mouse models have facilitated the 
understanding of pendrin function and its role in DFNB4 and PDS hearing loss. The lack 
of pendrin in mice prevent the development of hearing function and causes the 
enlargement of the vestibular aqueduct, mimicking the early-onset deafness and EVA 
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observed in humans [Wangemann, 2013]. In contrast to PDS patients, however, Slc26a4-/- 
mice show no signs of thyroid abnormalities [Everett et al., 2001], thus not recapitulating 
the complete PDS phenotype. 
The Slc26a4tm1(CreERT2_EGFP)Wtsi mouse analysed in this work carries a CreERT2_EGFP 
cassette in Slc26a4 intron 2 which interrupts the gene transcription and ensures the 
expression of EGFP and CreERT2 under the control of Slc26a4 promoter (see Paragraph 
2.11 and Fig. 2.1A). Therefore, Slc26a4 expression is abolished in Slc26a4tm1(CreERT2_EGFP)Wtsi 
homozygous mice and CreERT2 is expressed - only in cells expressing Slc26a4 – both in 
homozygous and heterozygous mice. Therefore, the Slc26a4tm1(CreERT2_EGFP)Wtsi mice can be 
used to create conditional knock-outs (i.e. heterozygous for Slc26a4tm1(CreERT2_EGFP)Wtsi allele 
and homozygous for a floxed sequence in a gene of interest) that don’t express a specific 
gene of interest only in the cells where pendrin is expressed, and in a tamoxifen-inducible 
manner. 
3.5.1.1. Auditory phenotype of Slc26a4tm1(CreERT2_EGFP)Wtsi  mice 
The auditory function of Slc26a4tm1(CreERT2_EGFP)Wtsi heterozygous and homozygous mice and 
of wild-type littermates was evaluated using ABR recordings at different ages. In particular, 
mice of each genotype were tested at 3, 4 and 8 weeks of age.  
As expected, Slc26a4tm1(CreERT2_EGFP)Wtsi homozygous mice are profoundly deaf already at 3 
weeks of age, showing no responses at the maximum sound level presented (95 dB SPL) at 
all frequencies tested (3-42 kHz) (Fig. 3.15). Mutant mice did not show any evident sign of 
vestibular impairment (e.g. circling, head tilting) at the ages tested for ABRs. The early-
onset of deafness in the homozygous mutant mice is consistent with the prelingual HL 
reported in the NSHL22 family. However, the severity of hearing impairment in the deaf 
siblings varies at different frequencies, being moderate in the low frequencies and severe-
to-profound in the middle and high frequencies. This difference in the severity of the 
phenotype in mice and humans have already been reported [Choi et al., 2011] and might be 
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in part explained by the different pathogenic mechanisms associated with the different 
mutations in the gene. 
Of note, no statistically significant difference was observed in ABR thresholds from 
Slc26a4tm1(CreERT2_EGFP)Wtsi heterozygous and wild-type groups at all frequencies and at any of 
the age tested. As heterozygous mice have normal hearing, this mouse model can be 
“safely” used to generate cell-type specific tamoxifen-inducible conditional knock-outs, to 
study the function of a gene of interest in hearing, in a region-specific and temporally-
restricted fashion. 
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Figure 3.15. ABR recordings of Slc26a4tm1(CreERT2_EGFP)Wtsi mutant mice at 3, 4 and 8 
weeks. Mean ABR thresholds (± SD, standard deviation) for clicks and tone pips are 
plotted for wild-type (+/+, in green), heterozygous (+/-, in blue) and homozygous (-/-, in 
red) mice aged 3, 4 and 8 weeks. For each stimulus, data were analysed by the Kruskal-
Wallis test followed by the Dunn’s post-hoc analysis. Asterisks indicate p-values (*: p<0.05; 
**: p<0.01; ***: p<0.001; ****: p<0.0001). Statistical analyses were performed with 
GraphPad Prism 8.0.  I performed all the ABR measurements at 3 weeks and in 9 and 12 
mice at 4 and 8 weeks, respectively. The remaining ABR recordings and threshold calls (at 
4 and 8 weeks) had already been performed by Dr. Jing Chen and Ms. Elysia James. ABR 
measurements for each individual mouse I personally tested are shown in Appendix 6.2. 
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3.6. NSHL3 family: the DIAPH2 gene 
Family NSHL3 pedigree is compatible with recessive (autosomal or X-linked) inheritance 
(Fig. 3.16A). The proband (III5) is a 15-year-old male with a 23-year-old deaf brother (III3) 
and a 20-year-old normal-hearing brother (III4). Both affected siblings have pre-lingual 
bilateral hearing loss which is more severe in the middle and high frequencies. HL in III5 is 
moderate in the low frequencies and severe-to-profound in middle-high frequencies, 
whereas in III3 is severe in low frequencies and profound in middle-high frequencies (Fig. 
3.16B). The three siblings (III3, III4 and III5) were subjected to WES, and data analysis 
(Table 3.3), following the pipeline described in paragraph 3.1, lead to the identification of 
the NM_006729.4:c.868A>G (p.I290V) variant within exon 8 of the DIAPH2 gene on 
chromosome X (Fig. 3.16C). The putative mutation co-segregates with the phenotype in 
the family, being present in the heterozygous state in female carriers and in the hemizygous 
state in the affected brothers. In addition, it is absent in the normal hearing brother and in 
one normal hearing male cousin, who is the son of a carrier individual (Fig. 3.16A). 
DIAPH2 has not yet been associated with NSHL, but the identified variation is absent 
both in our in-house database of about 3500 Italian exomes, and in a cohort of 125 Italian 
audiologically-tested normal-hearing controls (data from Dr. Michela Robusto). In 
addition, it is reported in the gnomAD database in the heterozygous state only in 3 
European non-Finnish females (allele frequency: 1.816e-5).  
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 Figure 3.16. Identification of a variant in the novel candidate NSHL gene DIAPH2. 
A. Pedigree of family NSHL3, showing the segregation of the variant within the family. 
The genotypes of available individuals are indicated below the corresponding symbol and 
the proband is indicated by a black arrow. W: wild-type allele, M: mutant allele. ○: obligate 
carrier, ●: carrier of the mutation confirmed by Sanger sequencing. B. Pure-tone air-
conduction thresholds of NSHL3 family members. For each subject the threshold average 
for the right and left ear and the age at audiometric evaluation is shown. C. Schematic 
representation of DIAPH2 gene, where exons are indicated by rectangles and introns by 
black lines. Electropherograms showing the sequence surrounding the mutated nucleotide 
in the proband (right) and his mother (heterozygous carrier, left). The position of the 
variant identified in family NSHL3 is indicated by an arrowhead. R: A or G. Exonic 
nucleotides are indicated with uppercase, while intronic nucleotides are indicated with 
lowercase letters. 
Table 3.3. Prioritisation of variants identified with WES in family NSHL3. 
Filter type Nr of  variants 
  III3 III4 III5 
Tot 42647 42532 43528 
NS/SS/I 13963 13801 14239 
Not in 1000Genomes 3412 3412 3539 
Not in NHLBI-ESP 3256 3267 3384 
Not in dbSNP135 1137 1154 1164 
Hom/Hemi/compound Het 142 143 140 
Shared by the affected siblings 4* 
Within known ARNSHL genes / 
NS: non-synonymous variant, SS: splice-site variant, I: indel. * The remaining 3 variants were 
excluded for the high frequency in later releases of dbSNP, for the presence of hemizygous 
individuals in the gnomAD database, or for lack of segregation with phenotype. 
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DIAPH2, comprising 27 exons, is located on chromosome Xq21.33 and codes for a 
member of the Diaphanous-related formins (DRFs), which are involved in the nucleation of 
linear unbranched actin filaments [Campellone and Welch, 2010] and in the alignment and 
stabilisation of microtubules [Yasuda et al., 2004]. As the two other DRFs, DIAPH1 and 
DIAPH3, the DIAPH2 protein can be functionally divided into two halves. The C-terminal 
half is required for actin assembly and includes three structural and functional domains: i) 
the profiling-binding FH1 (formin homology 1) domain; ii) the actin-binding FH2 (formin 
homology 2) domain; and iii) the DAD (diaphanous autoregulatory domain), which can 
interact with the N-terminal portion. The N-terminal half is the regulatory region of DRFs 
and it is divided in the GTPase binding domain (GBD) and the diaphanous inhibitory 
domain (DID) [Goode and Eck, 2007]. Furthermore, a dimerisation domain (DD) and a 
coiled coil (CC) domain are present to mediate the dimerisation of the N-terminal of DRFs 
which are active as dimers [Campellone and Welch, 2010]. The interaction between the N-
terminal DID and the C-terminal DAD determinates the transition of the DRF to its 
inactive conformation. In addition, the first portion of DID domain is also involved in the 
interaction with Rho family GTPases [Otomo et al., 2005; Rose et al., 2005]. As a result of 
the partial overlap of DAD and Rho binding sites, the binding of Rho GTPases induces 
the release of the DAD autoinhibitory domain and stimulate actin nucleation functions 
[Young and Copeland, 2010] (Fig. 3.17). DIAPH1, DIAPH2 and DIAPH3 genes are the 
orthologs of the Drosphila melanogaster diaphanous (dia) gene, which has important roles in 
fertility and hearing in the fly. Indeed, mutant dia alleles have been associated both to 
sterility and impaired response to sound [Castrillon and Wasserman, 1994; Schoen et al., 
2010]. In humans, DIAPH1 and DIAPH3, have been associated with different types of 
HL. In particular, heterozygous mutations in DIAPH1 are responsible for autosomal 
dominant NSHL with or without thrombocytopenia (locus DFNA1, MIM #124900) 
[Lynch et al., 1997; Stritt et al., 2016], whereas overexpression of DIAPH3 – resulting from 
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a mutation in the 5’ UTR of the gene - causes auditory neuropathy, autosomal dominant, 1 
(AUNA1, MIM #609129) [Schoen et al., 2010]. Interestingly, homozygous truncating 
mutations of DIAPH1 have been associated with seizures, cortical blindness, microcephaly 
syndrome (SCBMS, MIM #616632) [Ercan-Sencicek et al., 2015]. Concerning DIAPH2, 
until now it has only been linked to premature ovarian failure 2 (POF2A, MIM #300511). 
Indeed, in a mother and daughter affected by POF, a balanced translocation 
t(X;12)(q21;p13) was found to disrupt the DIAPH2 gene [Bione et al., 1998]. Nonetheless, 
given its membership to DRFs and the important function of actin nucleation in hair-cell 
stereocilia (see Paragraph 1.1 and 1.4.1), we hypothesised a possible role of DIAPH2 as an 
actin regulator in sensory hair cells, thus considering DIAPH2 a promising candidate 
NSHL gene to further characterise. 
Figure 3.17. Schematic representation of diaphanous-related formin domains. The 
structural/functional domains of the DRFs are shown. The arrow indicates the binding site 
of Rho GTPases. GBD: GTPase-binding domain; DID: diaphanous inhibitory domain; DD: 
dimerisation domain; FH1: formin homology 1, FH2: formin homology 2; DAD: 
diaphanous autoregulatory domain; N: N-terminus; C: C-terminus. 
3.6.1. Effect of the c.868A>G variant on DIAPH2 splicing 
Besides being a missense variant, the c.868A>G variant in DIAPH2 affects a nucleotide in 
exon 8 located only two base pairs upstream of the donor splice site and was thus also 
annotated as a candidate splicing mutation. For this reason, the possible effect of the 
variant on DIAPH2 splicing had been previously investigated in whole blood from all 
available family members. However, the RT-PCR results suggested that the variant does 
not alter exon 8 splicing at least in the analysed tissue. Minigene transfection experiments – 
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using the pBS-KS_modified hybrid minigene vector containing either wild-type or mutant 
exon 8 with the surrounding intronic sequences (Fig. 3.18A) – had also been performed in 
several human cell-lines (HeLa, HEK293, HepG2). Interestingly, in the very first 
experiment performed, the RT-PCR showed that the variant could induce exon 8 skipping. 
In addition, it was observed a different degree of exon 8 skipping in the three cell lines 
analysed, suggesting a tissue specificity of this splicing event. However, any attempt to 
replicate these results in the same cell lines failed, as no alternative splicing was observed in 
the cells transfected with the mutant construct in subsequent experiments (independent 
transfections, RNA extractions, and RT-PCR assays; data from Dr. Michela Robusto, not 
shown). Given the lack of reproducibility of the results, I decided to perform the same 
minigene transfection experiments using a cell line more suitable for inner ear studies, i.e. 
the UB/OC-2 cell line, derived from the prosensory epithelium of the H-2Kb-tsA58 
transgenic mouse [Jat et al., 1991; Holley and Lawlor, 1997]. Nevertheless, the RT-PCR 
analyses did not show any difference in the splicing pattern of UB/OC-2 cells transfected 
with the mutant minigene vector compared with those transfected with the wild-type, both 
in proliferative and differentiating conditions (Fig. 3.18B, n=3 for both conditions). The 
results were also confirmed by a competitive fluorescent RT-PCR assay, which showed a 
unique peak corresponding to the amplification of the transcript including the DIAPH2 
exon 8 (data not shown). In conclusion, we could not find any evidence that the 
NM_006729.4:c.868A>G variant alters DIAPH2 exon 8 splicing. 
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Figure 3.18. In-vitro analysis of the impact of c.868A>G variant on DIAPH2 pre-
mRNA splicing in UB/OC-2 cells. A. Schematic representation of the hybrid pBS-KS-
DIAPH2_ex8 minigene where α-globin exons are represented by light blue boxes, 
fibronectin (FN1) exons by grey boxes, whereas introns are shown as black lines (not to 
scale). Exon 8 of DIAPH2 is represented by a blue box. The c.868A>G variant in exon 8 
is indicated by a black star. Black arrows represent the primers used in RT-PCR assays. B. 
On the left, agarose gel electrophoresis of RT-PCR products obtained from RNA of 
UB/OC-2 cells under proliferative or differentiating conditions, transfected with the wild-
type (wt), mutant (mut), or empty (mock) minigene vector. M: molecular weight marker 
(pUC9/HaeIII). On the right, schematic representation of the splicing products, as verified 
by Sanger sequencing. The length of each fragment is shown. 
3.6.2. Effect of the p.I290V variant on the DIAPH2 protein 
Despite being a conservative amino-acid substitution – isoleucine to valine - the p.I290V 
variant is predicted to be deleterious by 7 out of 8 different software used (Fig. 3.19C). In 
addition, the isoleucine 290 is highly conserved across vertebrates and it localises in a 
region of the inhibitory domain possibly involved both in the auto-inhibition of the protein 
and in the interaction with Rho GTPases (Fig. 3.19A-B). To evaluate whether the variation 
could affect DIAPH2 localisation, I performed immunofluorescence localisation assays on 
HeLa and HEK293 cells 48 hours after transfection with wild-type or mutant plasmids 
expressing an HA-tagged DIAPH2 isoform (pCMV-HA-hDIA2B_wt, pCMV-HA-
hDIA2B_mut). These studies suggested that the variant does not alter DIAPH2 
cytoplasmic localisation, at least in basal conditions (Fig. 3.20). Therefore, I studied the 
localisation of wild-type and mutant DIAPH2 protein under activating stimuli, by 
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performing immunolocalisation assays on HeLa and HEK293 cells co-expressing wild-type 
or mutant DIAPH2 together with a constitutively active form of the activator RhoA 
(pCDNA3.1-Myc-RhoA-G14V). The activation of DIAPH2 by RhoA changes the 
localisation of DIAPH2 from the cytoplasm to the plasma membrane, where the protein 
co-localises with actin filaments. Co-localisation with actin can be observed both for the 
wild-type and the mutant DIAPH2; however, the overlap of red and green signals seems to 
be higher in cells expressing the wild-type protein (Fig. 3.21). In addition, the presence of 
RhoA promotes a morphological change of the cells, with the formation of stress fibers in 
HeLa cells and actin-rich membrane protrusions in HEK293 cells (Fig. 3.22). Considering 
base sections of the cells (at the level of their adhesion to the glass), DIAPH2 protein can 
be observed as red dots which, most clearly in HEK293 cells, are localised at the end of the 
actin bundles. Similar morphological changes are induced in cells expressing either the 
wild-type or the mutant DIAPH2 together with RhoA. Nevertheless, there is a statistically 
significant difference in the average length (measured with Fiji software) of the membrane 
protrusions in HEK293, being ~20% shorter in cells expressing mutant DIAPH2 
(unpaired t test, p<0.01) (Fig. 3.23). 
 
106 
 
Figure 3.19. In-silico analyses of the DIAPH2 p.I290V missense variant identified in 
family NSHL3. A. Schematic representation of DIAPH2 protein. The position of the 
p.I290V is indicated by a black star. B. Amino acid sequence alignments of DIAPH2 
orthologs in the region surrounding the mutant residue (p.I290). Protein sequences were 
retrieved from UniProt, and alignments were generated with Clustal Omega. The amino 
acid residue affected by the mutation is shaded in red and indicated by a red arrow. 
Identical amino acids are marked by an asterisk, while partially conserved residues are 
indicated by a colon. C. Pathogenicity prediction of the p.I290V missense variant with 8 
commonly-used software. FI, Functional Impact of a variant; CADD, Combined 
Annotation Dependent Depletion. FI is ranked as: high (H), medium (M) for predicted 
functional variants and low (L) for predicted non-functional variants. CADD Scaled C-
score represents the PHRED-like [-10*log10(rank/total)] score, ranking a variant relative to 
all possible substitutions of the human genome (8.6x109). 
107 
 
Figure 3.20. DIAPH2 immunolocalisation studies in basal conditions. DIAPH2 
localisation was studied in HeLa (upper panel) and HEK293 (lower panel) cells 48 hours 
after transfection with plasmids coding for HA-tagged isoforms of wild-type or mutant 
DIAPH2 proteins (DIAPH2-HA-WT, DIAPH2-HA-MUT). Images were acquired with 
Leica True Confocal Scanner (TCS) SP8 and are representative of 3 experiments. Single 
confocal sections are shown. DAPI: 4',6-diamidino-2-phenylindole. Scale bars: 10 μm. 
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Figure 3.21. Co-localisation of DIAPH2 and actin under activating stimuli. DIAPH2 
localisation was studied in HeLa (upper panel) and HEK293 (lower panel) cells 48 hours 
after transfection with plasmids coding for HA-tagged isoforms of wild-type or mutant 
DIAPH2 (DIAPH2-HA WT, DIAPH2-HA MUT), together with a Myc-tagged active 
form of RhoA (Myc-RhoA). On the right, merged image of the blue, red and green 
channels showing the partial co-localisation of DIAPH2 with actin. Images were acquired 
with Leica True Confocal Scanner (TCS) SP8 and are representative of 3 experiments. 
Single middle confocal sections are show. Scale bars: 10 μm. 
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Figure 3.22. Evaluation of cell morphology and DIAPH2 localisation under 
activating stimuli. DIAPH2 localisation was studied in HeLa (upper panel) and HEK293 
(lower panel) cells 48 hours after transfection with plasmids coding for HA-tagged 
isoforms of wild-type or mutant DIAPH2 (DIAPH2-HA WT, DIAPH2-HA MUT), 
together with a Myc-tagged active form of RhoA (Myc-RhoA). On the right, merged image 
of the blue, red and green channels. Images were acquired with Leica True Confocal 
Scanner (TCS) SP8 and are representative of 3 experiments. Single confocal sections cells 
at the level of their adhesion to the glass are shown. Scale bars: 10 μm. 
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Figure 3.23. Evaluation of the length of membrane protrusions in HEK293 cells 
under activating stimuli. The length of membrane protrusions was measured using Fiji in 
HEK293 cells 48 hours after transfection with plasmids coding for HA-tagged isoforms of 
wild-type (wt) or mutant (mut) DIAPH2, together with a Myc-tagged active form of RhoA. 
The histograms represent the mean length of protrusions measured in 20 wt and 20 mut 
HEK293 cells, with error bars showing the standard deviations. Significance level of 
unpaired t-test (performed with GraphPad Prism 8.0) is shown (**: p<0.01). 
3.6.3. Search for other HL patients with variants in DIAPH2 gene 
In order to validate DIAPH2 as a novel NSHL gene, we aimed at identifying other HL 
patients carrying variants in the gene. 
Since no variants were previously identified in 16 NSHL patients compatible with a X-
linked pattern of inheritance from our cohort (data from Dr. Michela Robusto), DIAPH2 
gene was posted on GeneMatcher (http://www.genematcher.org), a web-based tool 
designed to help the identification of additional patients with variants in the same gene of 
interest [Sobreira et al., 2015]. A total of 7 patients with hemizygous variants in the 
DIAPH2 gene were identified through GeneMatcher. However, none of the patients 
matched with the HL phenotype (Table 3.4). Of note, the same p.R1075W variant was 
identified by two different groups in two patients with a different phenotype, whereas the 
p.R1091H variant is also present at the hemizygous state in one individual from the 
gnomAD database. At present, all these variations should be considered variant of 
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unknown significance (VUS), as no experimental evidence in support of their 
pathogenicity, nor of their actual involvement in producing the associated phenotype has 
been provided. Therefore, we still lack additional genetic data in support of DIAPH2 role 
in HL, as well as in other human diseases apart from POF. 
Table 3.4. GeneMatcher matches for DIAPH2. 
  Variant       
Match NM_006729.4: NP_006720.1: Phenotype gnomAD 
frequency 
CADD 
score 1 exon6:c.662+1G>A 
splicing variant 
  
  / Intellectual disability   / 34 
2 exon26:c.3223C>T p.R1075W Nephrotic syndrome 1.112e-5 24.4 
3 exon26:c.3223C>T p.R1075W Cerebral palsy and 
epilepsy 
1.112e-5 24.4 
4* exon27:c.3272G>A p.R1091H Congenital heart 
disease 
1.169e-5 25.4 
5** na na 
Spasticity, motor 
delay  and intellectual 
disability 
na na 
6 na na 
Developmental delay, 
macrocephaly and 
epilepsy 
na na 
* The variant is present at the hemizygous state in a male European non-Finnish individual from 
the gnomAD database. 
**A de novo variant was identified in the hemizygous state in 2 male individuals. na: variant 
position not available. 
3.6.4. Expression of the mouse ortholog protein Diap2 in the mouse inner ear 
To better understand the physiologic function of DIAPH2 in the inner ear, I performed 
immunohistochemical studies to evaluate the expression of the mouse ortholog protein 
Diap2 in the mouse cochlea at different ages. Immunohistochemical studies showed a low 
Diap2 expression in the developing cochlear duct in E14.5 and E16.5 mice foetuses with a 
similar localisation of the protein in cells lining the cochlear duct. In fact, Diap2 seems to 
be principally expressed in the dorsal wall of cochlear duct, which will develop into the 
organ of Corti (Fig. 3.24 and 3.25, n=3 for each stage). 
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In E18.5 and P0 wild-type mice, Diap2 is highly expressed in the outer hair cells (OHCs), 
principally in the stereocilia. In addition, it is expressed in the Kölliker's organ and in the 
stria vascularis. Interestingly, the expression varies along the developing cochlea in these 
stages. In fact, the epithelial cells of the cochlear duct start to differentiate from the base to 
the apex and Diap2 is expressed in OHCs in the basal turn, while its expression towards 
the apex is localised in the luminal cells of the dorsal wall of the cochlear duct, similarly to 
the expression at earlier stages (Fig. 3.26 and 3.27, n=5 for each stage). 
In P5 wild-type mice, Diap2 is expressed at low levels in the sensory epithelium, and it is 
mainly expressed in the stria vascularis, in the root cells and in the epithelial layer of the 
Reissner membrane (Fig. 3.28, n=5). 
Immunohistochemical studies were also carried out in three older wild-type mice of the 
C57BL/6 strain (one P7 and two P14 mice), in which Diap2 was detected at very low levels 
in the stria vascularis only (data not shown). 
Figure 3.24. Diap2 expression in E14.5 wild-type mouse cochlea. A. Cross section of 
the cochlea of a E14.5 wild-type mouse embryo. At this stage, the scala vestibuli and scala 
tympani have not yet developed, and only one chamber – the developing scala media – is 
present. Also, the different cells composing the organ of Corti have not differentiated yet. 
Dorsal to the bottom. Scale bar: 100 µm. B-D. Higher magnification of the turns of the 
developing cochlear duct. Diap2 expression is indicated by arrowheads. Scale bars: 10 µm. 
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 Figure 3.25. Diap2 expression in E16.5 wild-type mouse cochlea. A. Cross section of 
the cochlea of a E16.5 wild-type mouse foetus. At this stage, the scala vestibuli and scala 
tympani begin to open starting from the base of the cochlea. Dorsal to the bottom. Scale 
bar: 100 µm. B-E. Higher magnification of the apical (B), middle (C, E) and basal (D) turns 
of the developing cochlear duct. Arrowheads point to Diap2 expression. Scale bars: 10 µm. 
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Figure 3.26. Diap2 expression in E18.5 wild-type mouse cochlea. A. Cross section of 
the cochlea of a E18.5 wild-type mouse foetus. At this stage, a different degree of cell 
differentiation can be observed from the base to the apex. Dorsal to the bottom. Scale bar: 
100 µm. B-E. Higher magnification of the apical (C), middle (B, E) and basal (D) turns of 
the developing cochlear duct. The square brackets indicate OHCs. Diap2 expression is 
indicated by arrowheads. The arrow in C indicates the boundary between GER and LER. 
Scale bars: 10 µm. 
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Figure 3.27. Diap2 expression in P0 wild-type mouse cochlea. A-D. Cross section of 
the cochlear turns (B: apical, A, D: mid, C: basal turn) of a P0 wild-type mouse. At this 
stage, a different degree of cell differentiation can be observed from the base to the apex. 
The square brackets indicate OHCs (outer hair cells). KO: Kölliker’s organ, RM: Reissner 
membrane, SV: stria vascularis. Dorsal to the bottom.  E. Higher magnification of the stria 
vascularis in C. F-G. Higher magnification of the OHC shown, respectively, in C and D. 
Diap2 expression is indicated by arrowheads. Scale bars: 10 µm.  
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Figure 3.28. Diap2 expression in P5 wild-type mouse cochlea. A. Scala media of the 
middle turn of cochlea. Scale bar: 100 µm. A’-A’’. Higher magnification of the stria 
vascularis and of the outer sulcus shown in A. Scale bars: 10 µm. B. Scala media of the 
basal turn of cochlea. Scale bar: 100 µm. B’-B’’. Higher magnification of the stria vascularis 
and of the organ of Corti shown in B. Scale bars: 10 µm. Arrowheads point to Diap2 
expression. OC: organ of Corti; RC: root cells; RM: Reissner membrane; SV: stria 
vascularis. 
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3.6.5. Auditory phenotype of the Diaph2em2Kcl knock-out mouse 
I evaluated the auditory function of the Diaph2em2Kcl knock-out mice using ABR recordings 
at 4 and 8 weeks of age. In details, I tested 7 wild-type (4 males and 3 females), 2 
heterozygous female and 6 hemizygous male mice at 4 weeks of age. Two wild-type males 
and 4 hemizygous males were also tested at 8 weeks of age. The remaining mice were not 
yet 8 weeks old at the end of my research period at Professor Steel’s laboratory. 
As no difference was observed in wild-type males and females, all wild-type mice were 
plotted together and compared to the heterozygous and hemizygous groups. A statistically 
significant difference in hearing thresholds between wild-type and hemizygous mice groups 
was only observed at 36 kHz (Fig. 3.29A); however, this small difference is probably not 
biologically relevant. In addition, no difference between genotypes was observed in the 
mice tested at 8 weeks (Fig. 3.29B). These first results on a limited number of animals 
suggest that lack of Diaph2 does not impair the development of normal hearing function in 
mice. Nonetheless, a later onset of HL cannot be excluded, and older mice need to be 
tested. 
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Figure 3.29. ABR recordings of Diaph2em2Kcl knock-out mice at 4 and 8 weeks. Mean 
ABR thresholds (± SD) for clicks and tone pips are plotted for wild-type (wt, in green), 
heterozygous females (het, in blue) and hemizygous (hemi, in lilac) mice aged 4 (A) and 8 
(B) weeks. A. Data were not normally distributed and were thus analysed by the Kruskal-
Wallis test followed by the Dunn’s post-hoc analysis to compare the three genotype groups. 
A statistically significant difference in hearing thresholds was only observed at 36 kHz. 
Asterisks indicate p-values (*: p<0.05). B. Mann-Whitney test was performed to compare 
ABR threshold of 8-week-old wild-type and hemizygous mice at each frequency. Only 6 (2 
wild-types and 4 hemizygotes) of the 15 mice tested at 4 weeks were also tested at 8 weeks. 
No difference between genotypes was observed at 8 weeks. All statistical analyses were 
performed with GraphPad Prism 8.0. ABR measurements for each individual mouse are 
shown in Appendix 6.3. 
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3.6.6. Auditory phenotype of the Diaph2em3Kcl knock-in mouse 
In order to evaluate the effect of the specific variant identified in family NSHL3, ABR 
measurements were also performed in Diaph2em3Kcl knock-in mice. A total of 5 wild-type (3 
females and 2 males) and 5 hemizygous mice were tested at 4 weeks. Three wild-types (2 
females and 1 male) and 3 hemizygotes were tested at 8 weeks of age. Wild-type mice of 
both sexes were plotted together, since no difference was observed among them. At 4 
weeks, a statistically significant difference in hearing thresholds between wild-type and 
hemizygous groups was observed for thresholds at 30 kHz (Fig. 3.30A). This small 
difference was considered of no biological meaning, especially as it was not observed in 8-
week-old mice (Fig. 3.30B). Even if the number of animal tested is very limited, these first 
recordings did not show any relevant impairment of hearing function at least at the ages 
tested, indicating that the point mutation in Diaph2 gene (NM_172493.2:c.877A>G; 
NP_766081.1:p.I293V) does not affect the development of normal hearing in mice. 
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Figure 3.30. ABR recordings of Diaph2em3Kcl knock-in mice at 4 and 8 weeks. Mean 
ABR thresholds (± SD) for clicks and tone pips are plotted for wild-type (wt, in green) and 
hemizygous (hemi, in lilac) mice aged 4 (A) and 8 (B) weeks. Mann-Whitney test was 
performed to compare ABR threshold of 4- (A) and 8- (B) week-old wild-type and 
hemizygous mice at each frequency. Only 6 (3 wild-types and 3 hemizygotes) of the 10 
mice tested at 4 weeks were also tested at 8 weeks. A statistically significant difference in 
hearing thresholds was observed at 30 kHz at 4 weeks (A), but no difference was observed 
in 8-week-old mice (B). All statistical analyses were performed with GraphPad Prism 8.0. 
ABR measurements for each individual mouse are shown in Appendix 6.4. 
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3.6.7. Discussion and conclusions on NSHL3 family 
Although the possibility to screen hundreds of genes by WES is a powerful tool for 
detecting potentially pathogenic variants underlying NSHL, the actual demonstration of the 
causal role of mutations - especially when found in novel candidate genes - still represents a 
critical and limiting step. In family NSHL3, WES variant prioritisation and segregation 
analyses pointed out the NM_006729.4:c.868A>G (p.I290V) variant in DIAPH2 gene as 
the most likely candidate mutation for the prelingual HL of II3 and II5 individuals. Despite 
the progress made in this work in elucidating the function of DIAPH2 gene, the actual 
pathogenic effect of the variant and the role of the gene in hearing function remain elusive. 
For instance, despite the predicted effect of the variant on splicing and the observation of 
exon 8 skipping in one single in-vitro assay, the irreproducibility of our results led us to 
exclude the c.868A>G variant as a splicing mutation. 
Furthermore, the immunofluorescence studies of DIAPH2 wild-type and mutant protein 
did not demonstrate a major effect of the p.I290V missense variant on DIAPH2 protein 
localisation. Although a statistically significant reduction in the average length of the RhoA-
induced membrane protrusions in HEK293 cells expressing mutant DIAPH2 was 
observed, it could be argued that a modest length difference might not be biologically 
relevant. It is important to consider that, in the cochlea, the actin filaments are essential 
components of the sensory hair-cell stereocilia, whose length is precisely regulated. Indeed, 
actin dynamics play a critical role in this regulation. As the precise architecture of the hair 
bundle is required for the synchronous gating of mechanotransduction channels 
[Narayanan et al., 2015], it is likely that even a modest disruption of this finely regulated 
structures could have an effect on the signal transmission. In addition, it should be noted 
that, in HEK293 cells, RhoA activation of endogenous DIAPH2 - and possibly of other 
formins - might have partially compensated for the effect of the mutant protein. 
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Concerning the physiologic role of DIAPH2 in hearing, immunohistochemistry studies in 
wild-type mice gave some insights into the expression pattern of the mouse ortholog 
protein Diap2 in the cochlea. Indeed, Diap2 showed a low expression in the developing 
cochlear duct at E14.5 and E16.5 and a specific strong expression in outer hair-cell 
stereocilia at later stages (E18.5 and P0). Finally, in P5 mice, Diap2 was mainly restricted to 
structures important for the cochlear fluid homeostasis (root cells, stria vascularis). These 
data suggested a possible function of Diap2 in the development of stereocilia of OHCs 
supporting our hypothesis of a role of DIAPH2 as an actin regulator in the cochlear 
sensory cells. Also, the early expression in the cochlea could explain the prelingual onset of 
NSHL in family NSHL3. On the other hand, the expression of Diap2 – postnatally - in 
structures required for fluid homeostasis and endocochlear potential maintenance, suggest 
other possible roles of the protein in hearing function. 
As mouse mutants have proven a highly effective research tool to investigate the molecular 
processes affected as a consequence of mutations in genes critical for hearing, we aimed at 
characterising the auditory phenotype of Diaph2 knock-out and knock-in mice carrying the 
corresponding variant identified in NSHL3 family. However, the first ABR recordings, 
performed in 4- and 8-week-old mice, did not indicate a clear hearing phenotype in mutant 
mice, as compared to wild-type littermates. Of note, the phenotype of a knock-out model 
of Diaph2 was recently reported by the IMPC (Diaph2tm1b(EUCOMM)Hmgu allele; 
http://www.mousephenotype.org/data/genes/MGI:1858500). Although no significant 
sign of hearing impairment was reported in the 14-week-old mice tested, homozygous 
knock-out females showed slightly higher threshold at high frequencies (30 kHz). 
Therefore, before ruling out DIAPH2 as a deafness gene, it is essential to extend ABR 
measurements to more mice of all genotypes and to repeat the experiments in older mice. 
However, given a possible functional redundancy in the Diaph gene family, it is conceivable 
that the absence of a hearing phenotype may be due to a compensation of Diaph2 loss of 
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function by the other Diaph genes. In support of this hypothesis, it was reported that the 
Diaph1 knock-out mice don’t recapitulate the microcephaly phenotype described in humans 
with homozygous truncating mutation in DIAPH1. However, Diaph1/Diaph2 double 
knock-outs showed several abnormalities in neural development [Toyoda et al., 2013]. 
Indeed, while both Diaph1 and Diaph2 are required for the assembly of the apical actin belt 
in neuroepithelial cells, the loss of only Diaph1 does not affect this structure [Ercan-
Sencicek et al., 2015]. A similar redundancy of Diaph genes might thus also exist in the 
cochlea. 
Although we have not collected enough evidence to support DIAPH2 causality in the 
pathogenesis of deafness, the c.868A>G variant is still the best candidate resulting from 
exome data. Therefore, it would be very important to verify the presence of pathogenic 
variants in the gene by gaining access to genomic data from larger cohorts of hearing-
impaired individuals. Nevertheless, it is also possible to speculate that variants in other 
genes could have a synergic role together with DIAPH2 variant and account for family 
NSHL3 phenotype. Finally, the possibility cannot be excluded of intronic/intergenic 
variants or other complex rearrangements not detectable using WES. 
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3.7. Genetically undiagnosed NSHL families: NSHL16, NSHL17, NSHL19 
In three families (NSHL16, NSHL17, NSHL19), all compatible with an autosomal 
dominant inheritance (Fig. 3.31), the search for NSHL-causing variant is still ongoing. 
Figure 3.31. Pedigree and audiograms of genetically undiagnosed NSHL families. 
The pedigree and audiograms of family NSHL16 (A), NSHL17 (B) and NSHL19 (C) are 
shown. The arrows point to the probands, whereas asterisks indicate individuals selected 
for WES. The threshold average for the right and left ear (in black) or the distinct 
threshold for each ear (right in red, left in blue) and the age at audiometric evaluation for 
each individual are shown.  
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In family NSHL16, individual II4 is a 52-year-old man who developed a bilateral high-
frequency HL at the age of 8 years old. He has a normal-hearing daughter (III2, 22 years 
old) and two deaf sons (III1, 26 years old and III3, 19 years old), who developed NSHL at 
10 and 3 years old, respectively. Interestingly, the hearing impairment is different between 
the two siblings, being bilateral and more severe in the low frequencies in III1 and 
unilateral and severe in all frequencies in III3 and thus differing also from the father’s 
phenotype (Fig. 3.31A). WES data of the three affected individuals were first analysed 
considering a dominant inheritance. Given the high number (> 200) of heterozygous 
variants shared between the affected family members, a further selection was performed. 
First, variants identified in genes repeatedly mutated in the exomes sequenced in our 
laboratory, and representing false positive of the technology, were filtered out. Then, the 
remaining variants were further prioritised considering their frequency in the gnomAD 
database and the possible role of the gene affected in hearing function (Fig. 3.32). 
However, the variants identified in known NSHL gene were not confirmed by Sanger 
sequencing, being WES false positives. Also, none of the variants in novel putative NSHL 
genes were segregating with the phenotype in the family, being present also in the normal 
hearing sister (III2). 
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Figure 3.32. Variants shared between affected individuals screened by Sanger 
sequencing. Pathogenicity prediction of the variants selected for segregation analyses with 
8 commonly-used software and presence in databases is shown. The variants with CADD 
Scaled C-score > 20 were further selected based on the possible function in hearing. FI, 
Functional Impact of a variant; CADD, Combined Annotation Dependent Depletion. FI is 
ranked as: high (H), medium (M) for predicted functional variants and low (L) for 
predicted non-functional variants. CADD Scaled C-score represents the PHRED-like [-
10*log10(rank/total)] score, ranking a variant relative to all possible substitutions of the 
human genome (8.6x109). 
Since no signs of hearing impairment were reported in the parents of the proband II4 (I1 
and I2), I also explored the less likely possibility of a recessive segregation. Under this 
hypothesis, individual II4 would carry two mutant alleles (one inherited from the mother 
and one inherited from the father) and would have transmitted one of them to his sons. 
Therefore, III1 and III3 might have inherited the same or a different allele from the father 
and would at least share the mutant allele of the gene inherited from the mother. 
Consequently, WES data were re-analysed under a recessive transmission model, focussing 
on genes with two prioritised variants, of which at least one shared between affected 
siblings and one shared with their father. Of note, each individual carried two variants that 
passed the filters of our prioritisation pipeline in at least one autosomal recessive NSHL 
gene, but that were not annotated as pathogenic in public databases. However, I couldn’t 
identify any shared prioritised variant fitting the hypothesised recessive mode of 
inheritance. 
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Family NSHL17 shows autosomal dominant HL with late-onset (Fig. 3.31B). Both the 
proband II2 (91 years old) and her daughter III3 (71 years old) developed bilateral HL - 
more severe in the left ear - at ~40 years; the other daughter (III4, 65 years old) shows 
normal hearing. WES data analysis performed on II2, III3 and III4 yielded ~400 variants 
passing quality and prioritisation filters in each individual. After filtering out likely false 
positive of WES, less than 60 variants were shared among affected family members and 
were not present in the normal-hearing sibling. Among these, I identified an intronic 
heterozygous deletion in the NSHL gene TMC1 (NM_138691:c.1696-14_1696-13delTG, 
13 bp upstream of the acceptor splice site of exon 19), which was confirmed by Sanger 
sequencing. The identified variant is reported in the gnomAD database in the heterozygous 
state in 34 out of 125640 individuals (allele frequency: 1.353e-4). On the other hand, the 
variant was predicted to have a possible effect on TMC1 exon 19 acceptor site recognition 
by 3 out of 3 prediction software used (NNSPLICE, Human Splicing Finder and 
NetGene). Therefore, I further investigated the potential pathogenicity of the 2-bp deletion 
using an in-vitro assay. In details, exon 19 of the TMC1 gene with the surrounding intronic 
sequences, either wild-type or carrying the identified variant, was cloned into the pBS-
KS_modified hybrid minigene vector (Fig. 3.33A). The obtained constructs (pBS-KS-
TMC1_ex19_wt and pBS-KS-TMC1_ex19_mut) were transiently transfected into HeLa, 
HEK293 or UB/OC-2 cells and TMC1 splicing products were analysed by RT-PCR assays. 
No alternative splicing isoforms were observed in any cell line transfected with the mutant 
construct (Fig. 3.33B, n=2), as also confirmed by a competitive fluorescent RT-PCR assay 
(not shown). These results seem to exclude the pathogenicity of the NM_138691:c.1696-
14_1696-13delTG variant. None of the other variants affecting known deafness genes were 
shared between the affected individuals only, and no promising novel candidate gene was 
identified, thus leaving NSHL17 family without a genetic diagnosis. 
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Figure 3.33. In-vitro analysis of the impact of c.1696-14_1696-13delTG variant on 
TMC1 pre-mRNA splicing. A. Schematic representation of the hybrid pBS-KS-
TMC1_ex19 minigene where α-globin exons are represented by light blue boxes, 
fibronectin (FN1) exons by grey boxes, whereas introns are shown as black lines (not to 
scale). Exon 19 of TMC1 is represented by a blue box. The c.1696-14_1696-13delTG 
variant in intron 18 is indicated by a black star. Black arrows represent the primers used in 
RT-PCR assays. B. Agarose gel electrophoresis of RT-PCR products obtained from RNA 
of HeLa, HEK293 and UB/OC-2 cells under proliferative conditions, transfected with the 
wild-type (wt), mutant (mut), or empty (mock) minigene vector. M: molecular weight 
marker (pUC9/HaeIII). 
In family NSHL19, the 25-year-old proband V1 developed moderate sensorineural HL at 
the high frequencies at the age of 17 years. The mother IV2 (53 years old) and her siblings 
IV3 (52 years old) and IV4 (43 years old) also show a similar impairment, more severe at 
the high frequencies. The cousins of IV2-4 (IV6, 46 years old and IV7, 45 years old) were 
also available to the study and show a mild hearing impairment at the high frequencies (Fig. 
3.31C). Despite having analysed WES data from 5 individuals (IV3, IV4, IV6, IV7 and V1), 
we could not identify any candidate pathogenic variant shared between all affected family 
members. More than 250 variants were shared between the 5 individuals, but only 21 genes 
were involved. Most of these genes were excluded, as variants in these genes are known to 
be false positives of WES. None of the shared prioritised variants affected a deafness-
associated gene, however affected individuals carried from 4 to 18 different passing-filters 
variants in known NSHL genes. Interestingly, individuals IV6 and IV7, showing a milder 
hearing impairment, carried respectively 4 and 6 variants only. It would be thus interesting 
to evaluate if these variants of unknown significance might contribute to the phenotype. 
129 
 
3.7.1. Discussion on genetically undiagnosed families 
Despite the unquestionable progress promoted by NGS technologies in the detection of 
potentially pathogenic variants underlying heterogeneous diseases, the diagnostic yield of 
WES for NSHL is still under 50% [Neveling et al., 2013; Likar et al., 2018; Sheppard et al., 
2018]. In this work, the difficulties we encountered in identifying the genetic cause of 
deafness in three of the analysed families could originate from the WES analysis pipeline 
applied or from the intrinsic limitations of the technology. 
For instance, synonymous variations located outside canonical splicing sites were 
considered non-pathogenic and filtered out. However, there is increasing evidence that 
synonymous variants can have a deleterious effect on the protein, for example disrupting 
splicing enhancer or silencer elements, affecting mRNA stability or altering the translation 
kinetics [Sauna and Kimchi-Sarfaty, 2011]. Therefore, the disease-causing variants might 
have been missed in the first step of the prioritisation pipeline. In addition, setting the 
MAF threshold at 0.1% for variant filtering in dominant families, generated a list of 
thousands of variants for each individual. The selection of the variants only shared between 
affected individuals considerably reduced the number of possible pathogenic variants; 
however, the selected variants were still too numerous, making experimental validation 
unfeasible without a further selection. In absence of mutations in known deafness genes, 
variants were further prioritised based on their predicted pathogenicity (taking CADD 
score into account) and the possible role of the gene affected in hearing function. This 
approach might have excluded the real causative variants from further validation analyses. 
In the case of family NSHL16, an additional point to raise is the intrafamilial variability of 
the phenotype, that I attempted to explain considering a recessive inheritance pattern with 
affected individuals carrying different variants in the same deafness gene. Even if this 
hypothesis was not confirmed, it cannot be excluded that other genetic or environmental 
factors could play a role in this variability. In fact, the variability between ears of individual 
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III3 might suggest the presence of genetic modifiers, as well as the presence of stochastic 
effects contributing to the development of hearing loss. Therefore, it should also be 
considered that potential causes of acquired HL might have not been reported in the 
patient’s medical history and that it might be necessary to modify data analyses accordingly. 
Another limitation of WES data analysis is the detection of CNVs. Although a CNV 
analysis from WES data was attempted, the interpretation of the output is particularly 
challenging when searching for heterozygous variants. In fact, the read count approach of 
the tools used for CNV detection is affected by the nonuniform efficiency of exome 
capture [D’aurizio et al., 2016]. Therefore, it could be worth integrating the analysis of the 
undiagnosed families using specific technologies for the detection of CNVs and 
chromosomal changes, such as arrayCGH.  
It is important to note that some of the limitations in the detection of pathogenic variants 
are intrinsic to WES technology. For instance, WES is affected by a reduction of coverage 
in the GC-rich regions, as a result of the PCR stage [Veal et al., 2012]. Also, the detection of 
variants is particularly challenging in duplicated regions (e.g. genes with pseudogenes or 
paralogues) due to reads misalignment. Indeed, many of the rare heterozygous variants 
identified in the three undiagnosed families were in genes (e.g. belonging to mucin and 
ankyrin gene families), which are frequently found mutated and that are considered false 
positive of WES [Fuentes Fajardo et al., 2012]. Besides false positives, the difficulties in 
calling variants in duplicated regions might also negatively affect the identification of 
mutations in deafness genes with pseudogenes (i.e. STRC) or located within segmental 
duplications (such as OTOA) [Shahin et al., 2010; Mandelker et al., 2014]. 
Finally, although being highly enriched in possible pathogenic variants, the exome 
represents only the 1-2% of the genome and variants located in deep-intronic or intergenic 
regions are obviously missed using WES. 
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3.8. SHL families: Alport syndrome 
We selected 3 AS families (AS1 and AS2 with a likely autosomal dominant or X-linked 
inheritance and AS3 compatible with a recessive pattern of inheritance) who had been 
previously subjected to several genetic screenings (including targeted resequencing of the 3 
AS genes COL4A3, COL4A4, and COL4A5 by Roche 454) without obtaining a molecular 
diagnosis. We subjected to WES the proband of each AS family and first focused data 
analysis on known Alport genes only. We verified that all exons of COL4A3, COL4A4, 
and COL4A5 were adequately covered by WES, with COL4A3 exon 1 being the least well-
covered exon (mean coverage of 31X, 16X, and 42X in AS1, AS2, and AS3, respectively). 
We identified a candidate pathogenic variant within one AS gene in each patient (Table 
3.5). 
Table 3.5. Variants identified by WES data analyses in AS families. 
      Variants 
Family Inheritance Gene cDNA localisation Protein localisation Classification 
AS1 AD/XD COL4A5 NM_000495.4:c.2245-
40A>G / splicing 
AS2 AD/XD COL4A5 NM_000495.4:c.2822G>A NP_000486.1:p.G941D missense 
AS3 AR COL4A3 NM_000091.4:c.40_63del NP_000082.2:p.L14_L21del in-frame 
deletion 
3.8.1. Family AS1: identification of a novel intronic variant in COL4A5 gene 
Proband III3 of family AS1 is a 49-year-old woman with history of hematuria and slight 
proteinuria; she was diagnosed with AS after kidney biopsy. The mother of the proband 
(II2, 71 years old) only shows microhematuria, while the proband’s daughter (IV1), 
currently 23 years old, has hematuria, proteinuria and developed sensorineural HL in the 
first decade of age. We detected a novel heterozygous A-to-G transition 
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(NM_000495.4:c.2245-40A>G) within COL4A5 intron 28, 40 nucleotide upstream of exon 
29. The variant is absent in the proband’s unaffected siblings (III1, III2) and is present in 
her mother and daughter (Fig. 3.34). The intronic variant is absent in the gnomAD 
database as well as in our in-house collection of Italian exomes. The particular location of 
this nucleotide substitution suggested it might affect the branch point sequence, a 
conserved splicing signal located 20-50 bases upstream of the 3’ end of the intron, and, 
consequently, alter COL4A5 mRNA splicing. 
Figure 3.34. Identification of the COL4A5 c.2245-40A>G variant in family AS1. 
Pedigree of family AS1 showing the segregation of the identified variant with AS. The 
proband, analysed by WES, is pointed by an arrow. The genotypes of all available 
individuals are indicated below the corresponding symbol. On the right, electropherograms 
show the sequence surrounding the mutated nucleotide in a wild-type relative and in the 
proband, carrying the variant. W: wild-type allele, M: mutant allele. R: A or G. CKD: 
chronic kidney disease. 
The in-silico predictions performed with Human Splicing Finder indicate that the wild-type 
nucleotide resides in the best-scoring branch-point sequence, although it does not reach the 
software significance threshold of 67. The A-to-G substitution decreases the score of the 
putative branch site, suggesting that the variant could impact on exon 29 recognition (Fig. 
3.35).  
Given the unavailability of a suitable tissue from the patient to extract RNA, we used an in-
vitro model to verify the effect of c.2545-40A>G variant on splicing. In details, exon 29 of 
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the COL4A5 gene with the surrounding intronic sequences, either wild-type or carrying the 
identified variant, was cloned into the pBS-KS_modified hybrid minigene vector (Fig. 
3.36A). The obtained constructs (pBS-KS-COL4A5_ex29_wt and pBS-KS-
COL4A5_ex29_mut) were transiently transfected into HEK293 cells and COL4A5 splicing 
products were analysed by an RT-PCR assay using primers that map in the exon upstream 
and downstream of the cloning site (Fig. 3.36A). All amplified products were sequenced to 
characterise splicing isoforms generated by either the wild-type or the mutant construct. 
Furthermore, relative quantitation of all splicing products was performed by competitive 
fluorescent RT-PCRs. Transfection with the pBS-KS-COL4A5_ex29_mut vector 
originated two aberrant products: the most abundant (~93.9%) and shorter amplicon 
derived from the skipping of the entire exon 29, whereas the other one (~6.1%) derived 
from the activation of a cryptic 3' acceptor splice site located downstream of the wild-type 
one, thus resulting in the retention of a shortened exon 29. In addition, competitive 
fluorescent RT-PCR of splicing isoforms also helped in confirming the absence of residual 
amounts of the wild-type transcript in the mutant (Fig. 3.36B, n=3). Both the skipping of 
the entire exon 29 and the inclusion of a shorter exon 29 are predicted to cause frameshifts 
leading to the introduction of a premature stop codon after 767 and 776 amino acids, 
respectively. Exon 29 skipping was also detected in about the 28% of splicing products 
derived from the pBS-KS-COL4A5_ex29_wt construct, suggesting that low amount of this 
aberrant transcript can be produced in physiologic conditions, probably due to “leaky” 
natural splice site recognition (Fig. 3.36B). 
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Figure 3.35. Human Splice Finder branch point sequence analysis. A. Schematic 
representation of COL4A5 gene, where exons are indicated by rectangles and introns by 
black lines. The position of the variant in intron 28 is indicated by an arrowhead. B. Wild-
type COL4A5 intron 28: the score of branch point sequences (heptamers) are indicated 
under the first base of the heptamer. The c.2545-40 adenine (indicated by the black arrow) 
is included in the best-scoring branch point heptamer (whose first base is indicated by the 
black asterisk). The dark yellow box includes the strongest branch-point site candidates. C. 
The c.2545-40A>G substitution decreases the score of the best-scoring branch-point site 
(black asterisk) from 59.27 (green dot) to 29.64 (red dot). 
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Figure 3.36. In-vitro analysis of the impact of c.2245-40A>G variant on COL4A5 
pre-mRNA splicing. A. Schematic representation of the hybrid pBS-KS-COL4A5_ex29 
minigene where α-globin exons are represented by light blue boxes, fibronectin (FN1) 
exons by grey boxes, whereas introns are shown as black lines (not to scale). Exon 29 of 
COL4A5 is represented by a blue box. The c.2245-40A>G mutation in intron 28 is 
indicated by a star. Primers used in RT-PCR assays are also indicated. B. On the left, 
agarose gel electrophoresis of RT-PCR products obtained from RNA of HEK293 cells 
transfected with the wild-type (wt) or mutant (mut) minigene vector. L: DNA ladder 
pUC9-HaeIII molecular weight marker). In the middle, GeneMapper windows show 
fluorescence peaks corresponding to the molecular species amplified by RT-PCR. Blue 
peaks correspond to the RT-PCR-labeled products, whose relative quantitation is reported 
on the right of the panel (%). Red peaks represent the size standard (ROX-500 HD). The x 
axis indicates fluorescence units. On the right, schematic representation of the splicing 
products, as verified by Sanger sequencing. The length of each fragment is shown. 
Since the three heterozygous female carriers (II2, III3, IV1) of the NM_000495.4:c.2245-
40A>G variant showed a different severity of phenotypic manifestations (Fig. 3.34), we 
investigated the possibility that these differences might be due to skewed inactivation of X 
chromosome, and consequent preferential expression of one of the two alleles (either the 
wild-type or the mutant one). Hence, we evaluated the methylation status of the two alleles, 
using a methylation-sensitive restriction-enzyme assay on DNA extracted from patients' 
blood. Subsequently, we discriminated the wild-type from the mutant allele using a 
polymorphic marker co-segregating with COL4A5, for which the tested females were 
heterozygous. The results showed a skewed inactivation (91%) of wild-type COL4A5 allele 
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in IV1, a balanced inactivation of both alleles in III3 (45 vs 55%), and a greater inactivation 
(89%) of the mutant COL4A5 allele in II2 (Fig. 3.37), nicely correlating with the 
progressively milder phenotypic manifestations.   
Figure 3.37. X-inactivation analysis of AS1 family. GeneMapper windows with peaks 
showing the X-inactivation patterns in the female carriers of the COL4A5 c.2245-40A>G 
mutation. Methylation assays were performed on the AR CAG polymorphic region. No 
digestion: undigested genomic DNA; Xa digestion: DNA pre-digested with the methylation 
sensitive enzyme HpaII, which only cuts restriction sites on the unmethylated, active X 
(Xa). The size (bp) of the amplification products for the CAG-repeat region on the two 
alleles is indicated below the corresponding peak. GeneScan 500 ROX Size Standard is 
shown in red. Wt: wild-type allele; Mut: mutant allele. 
3.8.2. Family AS2: identification of a novel missense variant in COL4A5 gene 
Proband IV3 is a 22-year-old man diagnosed with AS after renal biopsy. At the age of 3 he 
started to show microhaematuria and episodes of macrohaematuria with proteinuria. He 
has chronic kidney disease and developed sensorineural HL at the age of 10. The probands 
mother (III4) showed microhaematuria and proteinuria with normal renal function, while 
the grandmother (II3) only presented with microhaematuria (Fig. 3.38).  
137 
 
Figure 3.38. Identification of the COL4A5 c.2822G>A variant in family AS2. Pedigree 
of family AS2 showing the segregation of the identified variant with AS. The proband is 
pointed by an arrow and the genotypes of all available individuals are indicated below the 
corresponding symbols. On the right, electropherograms show the sequence surrounding 
the mutated nucleotide in a heterozygous female carrier and in the proband, who is 
hemizygous for the mutant allele. W: wild-type allele, M: mutant allele. R: A or G. CKD: 
chronic kidney disease. 
We identified a novel missense variant in COL4A5 exon 33 (NM_000495.4:c.2822G>A), 
causing the p.G941D amino acid substitution. The variant is present in the hemizygous 
state in the proband and in his affected male cousin (IV1), and in the heterozygous state in 
all affected female relatives (II2, III2, III4), while it is absent in all available unaffected 
individuals (II1, III1, III5) (Fig. 3.38). In addition, the variant is absent both in publicly 
available and our in-house databases, it affects an evolutionary-conserved amino acid and is 
predicted to be deleterious by all the software used (Fig. 3.39). Indeed, glycine substitutions 
within the repetitive triplet sequence (Gly)-X-Y of the collagenous domain represent one of 
the most common type of missense pathogenic variant found in COL4A5, as they are 
suspected to introduce kinks in the molecule, thus interfering with the proper folding of 
the collagen triple helix [Kashtan, 2019]. Importantly, a different nucleotide substitution in 
the same amino acid (c.2821G>T, p.G941D) was previously reported in AS patients 
[Martin et al., 1998; Hertz et al., 2001]. Of note, exon 33 was not properly covered by the 
previously performed Roche 454 targeted resequencing, explaining why the variant could 
have been missed. 
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Based on the segregation analyses, in-silico predictions, and on the previously reported 
pathogenetic substitution of glycine 941, we propose that the p.G941D mutation is the 
cause of AS in family AS2.  
Figure 3.39. In-silico analyses of the novel COL4A5 p.G941D missense variant 
identified in family AS2. A. Amino acid sequence alignments of COL4A5 orthologs in 
the region surrounding the mutant residue (p.G941). Protein sequences were retrieved 
from UniProt, and alignments were generated with Clustal Omega. The amino acid residue 
affected by the mutation is shaded in red and indicated by a red arrow. Identical amino 
acids are marked by an asterisk, while partially conserved residues are indicated by a colon. 
B. Pathogenicity prediction of the p.G941D missense variant with 8 commonly-used 
software. FI, Functional Impact of a variant; CADD, Combined Annotation Dependent 
Depletion. FI is ranked as: high (H), medium (M) for predicted functional variants and low 
(L) for predicted non-functional variants. CADD Scaled C-score represents the PHRED-
like [-10*log10(rank/total)] score, ranking a variant relative to all possible substitutions of 
the human genome (8.6x109).  
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3.8.3. Family AS3: identification of a 24-bp in-frame deletion in COL4A3 exon 1 
Proband III4, a 27-year-old woman with a family history of microhematuria, developed 
microhematuria, proteinuria and sensorineural HL within the first decade of age and was 
diagnosed with AS after renal biopsy. A slight maculopathy was evidenced at the age of 21. 
WES data analysis identified an in-frame 24-bp deletion in COL4A3 exon 1 
(NM_000091.4:c.30_53del:p.V11_L18del or NM_000091.4:c.40_63del24:p.L14_L21del). 
The deletion is present in the homozygous state in the proband and in the heterozygous 
state in the mother (II5), who suffers from microhaematuria (Fig. 3.40A).  
The variant is reported in the gnomAD database with a minor allele frequency of 
0.0001404, being present at the heterozygous state in 17 individuals, most of whom have 
an Ashkenazi Jewish heritage. Moreover, given the repetitive nature of the surrounding 
sequence, the variant is ambiguously annotated in dbSNP147 as rs774798108 (lacking 
clinical annotation) or rs876657397 (OMIM:120070.0011; ClinVar: 192299) (Fig. 3.40B). 
We deem possible that the first annotation was produced by automated short-read 
alignment of NGS data, while the second could derive from operator-dependent 
observation of Sanger sequencing electropherograms, conforming to HGVS (Human 
Genome Variation Society) recommendation for variant nomenclature and annotation. 
Nomenclature aside, the deletion in exon 1 eliminates 8 amino acids from the signal 
peptide and is thus expected to alter COL4A3 protein secretion. Indeed, in-silico analyses, 
using 3 different programs to predict the presence and location of signal peptides (SignalP 
4.1: http://www.cbs.dtu.dk/services/SignalP/, PrediSi: http://www.predisi.de/ and 
Signal-3L 2.0: http://www.csbio.sjtu.edu.cn/bioinf/Signal-3L/), indicate the disruption of 
the physiologic signal peptide (amino acids 1 to 28) in the mutant protein (Table 3.6). In 
addition, both PrediSi and WoLF PSORT (https://wolfpsort.hgc.jp/) programs suggest 
that the mutant protein would not be secreted. 
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The identified deletion has already been reported in AS patients of different ethnic origins 
[Longo et al., 2002; Tazón Vega et al., 2003; Webb et al., 2014; Zhang et al., 2012], although 
it was not functionally characterised. 
Figure 3.40. Identification of the COL4A3 c.40_63del variant in family AS3. A. 
Pedigree of family AS3 showing the segregation of the identified variant with AS. The 
proband, analysed by WES, is pointed by an arrow. The genotypes of all available 
individuals are indicated below the corresponding symbols. AS phenotype is indicated by a 
black symbol, while grey symbols indicate isolated microhaematuria. W: wild-type allele, M: 
mutant allele. B. Given the presence of repetitions (in red), sequence carrying the 24-bp 
deletion can be aligned to the reference genome in two different ways, resulting in different 
annotations: 1) rs774798108, corresponding to deletion of bases from 228029472 to 
228029495 (GGTGCTCCTGCTGCCGCTCCTGCT), and 2) rs876657397 (OMIM: 
120070.0011; ClinVar: 192299), corresponding to the 228029482-228029505 deletion 
(CTGCCGCTCCTGCTGGTGCTCCTG). Coordinates refer to the hg19 reference 
genome. Electropherograms of individuals II5 and III4 (the repetitive sequence is 
highlighted in red) are shown. S: G or C. Y: C or T. 
Table 3.6. Signal peptide in-silico predictions. 
 
SignalP 4.1 PrediSi Signal-3L 
COL4A3 Score Cleavage 
position 
Signal 
Peptide Score 
Cleavage 
position 
Signal 
Peptide 
Cleavage 
position 
Signal 
Peptide 
Wild-type 0.79 28 Yes 1.00 28 Yes 28 Yes 
p.L14_L21del 0.21 n.c. No 0.45 22 No n.c. No 
n.c.: not calculated 
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To demonstrate that the NM_000091.4:c.40_63del variant alters the physiologic COL4A3 
signal peptide, potentially affecting collagen secretion, we performed localisation assays in 
HEK293 cells using an hybrid fluorescent reporter protein (hybEGFP, Enhanced Green 
Fluorescent Protein) containing at the N-terminus either the complete COL4A3 signal 
peptide (amino acid 1 to 29: SP-wt-hybEGFP) or the partially deleted localisation signal 
(p.L14_L21del: SP-del-hybEGFP). Our results show that, while the wild-type signal 
peptide seems to drive hybEGFP expression along the secretory pathway, the mutant 
peptide - lacking 8 amino acids - retains hybEGFP within the cell (Fig. 3.41). Indeed, 
hybEGFP fused with a deleted COL4A3 signal peptide show a diffuse and uniform 
localisation in the cytoplasm and in the nucleus, similarly to the soluble wild-type EGFP 
(pEGFP-N1; Fig. 3.41). Co-localisation studies using either a marker of the endoplasmic 
reticulum (the calnexin protein), or a marker of the Golgi apparatus (Trans-Golgi Network 
protein 38, TGN38) further support the hypothesis that the SP-del-hybEGFP is not 
included in the secretory pathway (Fig. 3.42). 
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Figure 3.41. Functional characterisation of the signal peptide deletion in COL4A3. 
Single confocal sections of HEK293 cells expressing EGFP N-terminus fused either with 
the entire COL4A3 signal peptide (SP-wt-hybEGFP, top panels) or the 8-amino-acid 
deleted signal peptide (SP-del-hybEGFP, middle panels). Positive control cells, expressing 
a soluble EGFP (pEGFP-N1) are also shown (bottom panels). Cells were fixed 24 hours 
after transfection. Images were acquired with Olympus FV1000 Inverted Confocal IX81 
Microscope and are representative of 3 independent experiments.  DAPI: 4',6-diamidino-2-
phenylindole; EGFP, Enhanced Green Fluorescent Protein. Scale bars: 10 μm. 
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Figure 3.42. Co-localisation studies of hybEGFP with markers of the secretory 
pathway. Single confocal sections of HEK293 cells expressing COL4A3-SP-wt-hybEGFP 
or COL4A3-SP-del-hybEGFP and stained for calnexin (endoplasmic reticulum 
transmembrane protein, top panel) or TGN38 (trans-Golgi network protein, bottom 
panels). SP-del-hybEGFP does not show any co-localisation with either secretory pathway 
markers. Cells were fixed 24 hours after transfection. Images were acquired with Olympus 
FV1000 Inverted Confocal IX81 Microscope and are representative of 2 independent 
experiments. Scale bars: 10 μm. 
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3.8.4. Conclusion on AS families 
Our approach, combining WES and functional studies, was fundamental to identify the 
pathogenic variants causing AS in 3 families with no genetic diagnosis, thus allowing us to 
solve elusive cases. 
In family AS1, the COL4A5 branch-point variant was probably missed in previous 
screenings because of its location. Indeed, only consensus splice sites and surrounding 
nucleotides are usually analysed, whereas branch-point site – which are more difficult to 
predict on the basis of nucleotide sequence alone [Houdayer et al., 2012] – are not usually 
detected. AS1 is the first AS family in which a branch-point site mutation has been 
identified. 
In family AS3, we identified the in-frame deletion c.40_63del, which escaped previous 
genetic screenings. COL4A3 exon 1 has been reported to be difficult to sequence by NGS 
due to its high GC content (~77%) [Morinière et al., 2014]. Indeed, it was not amplified in 
the previous NGS targeted re-sequencing on the proband and it was also the least covered 
exon among the three type IV collagen genes in our WES data. Despite being ambiguously 
annotated in databases, the c.40_63del variant has been repeatedly reported in AS patients. 
It was first described in the heterozygous state in an Italian patient with microhaematuria 
and mild proteinuria [Longo et al., 2002]. Subsequently, it was detected in one Spanish 
patient [Tazón Vega et al., 2003] and four Chinese patients [Zhang et al., 2012] with 
autosomal recessive AS: in four of them, the mutation was present in compound 
heterozygosity with other pathogenic variants [Tazón Vega et al., 2003; Zhang et al., 2012], 
whereas in the fifth patient it was present in the homozygous state [Zhang et al., 2012]. 
Finally, the same in-frame deletion was found as a founder mutation in Ashkenazi Jews, 
with an estimated carrier frequency of 1:183 [Webb et al., 2014]. Indeed, in the gnomAD 
database the minor allele frequency of the variant in the Ashkenazi population is 0.001282 
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(carrier frequency ~1:390), being thus ~21 times the MAF of the variant considering all the 
other populations in gnomAD together. 
In the heterozygous state, the c.40_63del is not associated with significant renal 
dysfunctions, while in the homozygous state or in compound heterozygosity with another 
loss-of-function variant, it causes severe AS with HL and, as in the Spanish patient [Tazón 
Vega et al., 2003] and in the proband of family AS3, ocular abnormalities. Due to the 
recurrence of the variant in different populations, it would be important to specifically 
screen COL4A3 exon 1 in case of diagnosis of autosomal recessive HL and/or family 
history of isolated microhaematuria. 
The results of this work have been recently published in the Plos One journal [Chiereghin 
et al., 2017]. 
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4. Concluding remarks
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The research reported in this thesis has provided new insights into the mutational 
landscape of hearing loss, showing the advantages of the use of whole-exome sequencing 
for the study of the molecular bases of this genetically heterogeneous disease. 
In this work, WES has proven a powerful tool for the identification of possible pathogenic 
variants also in small families – such as NSHL22 - unsuitable for linkage analysis. However, 
this work has also highlighted the limitations of an approach uniquely based on exome 
sequencing for the definition of the genetic cause of HL. In fact, while the attribution of a 
genetic diagnosis is a simple task in case of known pathogenic variants in deafness genes, 
when a novel variation is identified its co-segregation with the phenotype within a family is 
not always sufficient to validate the variant as pathogenic, especially when few individuals 
are available for screening. Therefore, it is important to integrate WES analyses with 
functional studies designed to examine the specific effect of the candidate mutations 
identified. An approach aimed at discriminating false leads from genetic variants with clear 
functional effects supporting their role in deafness is critical, as many predicted pathogenic 
variants in HL genes are also identified in the general population [Lewis et al., 2018]. 
An even more cautious and critical approach is needed in case of identification of likely 
pathogenic variants in novel candidate deafness genes. In fact, even genes whose 
association to deafness was supported by the identification of likely pathogenic variants in 
several unrelated individuals are now being called into question [Vona et al., 2015]. In 
particular, MYO1A gene, which was considered for over 10 years the gene underlying 
autosomal dominant DFNA48 [Donaudy et al., 2003], has been disqualified as a NSHL 
gene. Indeed, putative pathogenic variants (including nonsense mutations) were identified 
both in patients and in unaffected relatives [Eisenberger et al., 2014].  In the case of 
DIAPH2, the c.868A>G variant described here has not been reported in the hemizygous 
state in healthy individuals; however, different variants have been identified in individuals 
affected by diverse diseases (Paragraph 3.6.3). Nonetheless, a few deafness genes have also 
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been associated with quite dissimilar diseases, such as the case of TBC1D24 gene, 
associated with DFNA65 and DFNB86, but also with early-infantile epileptic 
encephalopathy 16 and other complex diseases with epileptic features [Mucha et al., 2017]. 
Therefore, further studies – primarily in the available Diaph2 mouse models – are needed to 
confirm or disqualify DIAPH2 variants as a cause of deafness and, eventually, of the other 
diseases in which hemizygous variants were identified. 
Although the introduction of NGS technologies has considerably improved the genetic 
diagnosis of deafness, previously relying mostly on the screening of the single GJB2 gene, 
the diagnostic yield of WES is still below 50% and varies based on several factors, 
including inheritance mode of selected patients and prescreening prior to comprehensive 
testing. For example, the diagnostic rate was reported to be lower in autosomal recessive or 
sporadic cases and in case of prescreened patients [Shearer and Smith, 2015]. Of note, 
families were not selected on the basis of the inheritance pathway (both recessive and 
dominant families without potential nongenetic causes of HL were included), and all 
recruited probands had been previously screened for mutations in the GJB2 and GJB6 
genes. In this study we detected the genetic cause of the disease in at least 7 out of 11 
families analysed (>60%). Although, the combination of a diligent exome-sequencing data 
analysis, together with an accurate functional validation, allowed us to increase the expected 
diagnostic outcome, some improvements might be implemented. For example, it would be 
very important to have an unrelated normal-hearing control cohort for screening purposes. 
In fact, despite the availability of 125 Italian audiologically-tested normal-hearing controls, 
many of these individuals were relatives of deaf patients (not included in this study). Also, 
the access to sequence data from large cohorts of hearing-impaired patients might help in 
confirming the association of prioritised variants with the disease. Finally, other approaches 
could be applied to further enhance our results. For instance, RNA sequencing might be a 
suitable approach to comprehensively detect splicing mutations in HL genes that are also 
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expressed in accessible tissues (e.g. blood), although the splicing pattern in the tissue 
analysed might not accurately represent that of the inner ear. In addition, using linkage 
analysis in large families to narrow the region in which to search for pathogenic variants, 
and including specific molecular techniques to evaluate genomic imbalances might be 
useful to decipher the genetic cause of HL in the undiagnosed families. Certainly, it would 
not be feasible - especially in terms of time - to translate the approach applied in this thesis 
to a high-throughput clinical service. However, functional studies aimed at discriminating 
between neutral polymorphisms and HL-causing variants might be collated in a publicly-
available expert-curated database (e.g. the Deafness Variation Database, 
http://deafnessvariationdatabase.org/) to help variant interpretation. The construction of a 
comprehensive database would undoubtedly help clinical decision making and enhance the 
diagnostic yield also in a clinical setting. 
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6.1. NSHL genes and their clinical manifestations. 
Gene Locus Onset NSHL phenotype Additional features (SHL) 
ACTG1 DFNA20/26 Post-lingual 
(1st/2nd) 
Downsloping; audiogram moderate-
to-profound; progressive 
  
ADCY1 DFNB44 Prelingual Mild-to-moderate/profound; 
sensorineural or mixed; stable 
 
BDP1 DFNB112 Post-lingual (1st) 
Downsloping; mild-to-severe; 
progresses, also involving low 
frequencies 
 
BSND DFNB73 Prelingual Severe-to-profound; stable Some variants cause Bartter syndrome 
(deafness and nephropathy) 
CABP2 DFNB93 Prelingual U-shaped audiogram; moderate-to-
severe; stable 
 
CCDC50 DFNA440 Post-lingual (1st) 
Low-mid frequency; moderate-to-
profound; progresses, involving all 
frequencies 
  
CD164 DFNA66 Prelingual/post-
lingual (1st/2nd) 
Flat or U-shaped audiogram; 
stable/progressive 
  
CDC14A DFNB32/105 Prelingual Moderate-to-profound; progressive Some variants cause Deafness-Infertility 
Syndrome in males 
CDH23 DFNB12 Prelingual 
Downsloping; moderate-to-
profound; progressive 
Also associated with Usher syndrome 
Type ID (profound congenital HL, 
retinitis pigmentosa, constant vestibular 
dysfunction) 
CEACAM16 
DFNB113 Post-lingual (2nd) Mild-to-moderate; progressive  
DFNA4B 
Post-lingual 
(1st/2nd) 
Severe to profound; progressive. 
High-frequency tinnitus at onset in 
some patients. 
  
CIB2 DFNB48 Prelingual Severe-to-profound  
CLDN14 DFNB29 Prelingual Severe-to-profound; stable  
CLIC5 DFNB103 Prelingual 
High-mid frequency; severe-to-
profound; progresses, also involving 
low frequencies. Vestibular areflexia 
in the second decade of life. 
 
COCH 
DFNB110 Prelingual Downsloping; moderate-to-severe  
DFNA9 
Post-lingual 
(2nd/3rd) 
Downsloping; moderate-to-
profound; progresses to anacusis. 
Variants in LCCL domain are 
associated with HL and vestibular 
symptoms. 
  
COL11A1 DFNA37 Post-lingual (1st) 
Mild-to-moderate; slowly 
progressive 
Also associated with Stickler syndrome 
type II and Marshall syndrome (ocular, 
auditory, skeletal, and orofacial 
abnormalities) 
COL11A2 
DFNB53 Prelingual Severe-to-profound; stable  
DFNA13 
Post-lingual 
(2nd/4th) 
Moderate-to-severe; progressive 
Some variants cause 
otospondylomegaepiphyseal dysplasia 
(sensorineural deafness and short 
extremities with large epiphyses) 
CRYM DFNA40 Prelingual Moderate-to-severe   
DCDC2 DFNB66 Prelingual Severe-to-profound  
DIABLO DFNA64 
Post-lingual 
(2nd/3rd) 
Mild-to-severe; progressive. 
Frequent high-frequency tinnitus at 
onset. 
  
DIAPH1 DFNA1 Post-lingual (1st) 
Low-frequency; progresses to 
profound HL involving all 
frequencies 
Some variants cause high-frequency 
progressive HL with thrombocytopenia 
DIAPH3 AUNA1 Post-lingual (2nd) Profound; auditory neuropathy   
DMXL2 DFNA71 Post-lingual (2nd) Mild-to-profound; progressive   
ELMOD3 DFNB88 Prelingual Severe-to-profound; mixed  
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Gene Locus Onset NSHL phenotype Additional features (SHL) 
EPS8 DFNB102 Prelingual Severe-to-profound  
EPS8L2 DFNB106 Post-lingual (1st) Downsloping; moderate-to-
profound; progressive 
 
ESPN DFNB36 Prelingual Profound with or without vestibular 
areflexia 
 
ESRP1 DFNB109 Prelingual Severe-to-profound. Vestibular 
dysplasia without balance problems. 
 
ESRRB DFNB35 Prelingual Severe-to-profound; stable  
EYA4 DFNA10 Post-lingual 
(2nd/5th) 
Severe-to-profound; progressive   
GAB1 DFNB26 Prelingual 
Severe-to-profound. Incomplete 
penetrance: a variant in METTL13 
gene prevents GAB1-associated 
deafness. 
 
GIPC3 DFNB15/72/95 Prelingual Moderate-to-severe/profound; 
stable 
 
GJB2 
DFNB1A Prelingual 
Mild-to-profound (variable); 
progressive in ~50% of cases. ~50% 
of cases report vestibular symptoms. 
 
DFNA3A Prelingual/post-
lingual (1st/2nd) 
Downsloping; mild-to-profound 
(variable); progressive 
Associated with different syndromic 
forms causing HL and skin problems 
GJB3 DFNA2B Post-lingual (4th) Downsloping; progressive   
GJB6 
DFNB1B Prelingual Severe; stable. Vestibular symptoms 
in some patients. 
 
DFNA3B Prelingual Downsloping; mild-to-profound 
(variable); progressive 
  
GRHL2 DFNA28 
Post-lingual 
(variable, from 
1st) 
Mild-to-moderate; progresses to 
severe in high frequencies by 5th 
decade 
  
GRXCR1 DFNB25 Prelingual 
Moderate-to-profound; progressive. 
Vestibular symptoms in some 
patients. 
 
GRXCR2 DFNB101 Prelingual Moderate-to-profound; progressive  
GSDME DFNA5 Post-lingual (1st) Downsloping; progresses, involving 
all frequencies 
  
HGF DFNB39 Prelingual Downsloping; severe-to-profound  
HOMER2 DFNA68 Post-lingual (1st) Downsloping; progresses, involving 
all frequencies 
  
IFNLR1 DFNA2C Post-lingual (2nd) 
Downsloping; progresses, involving 
all frequencies. Generally 
accompanied by high-frequency 
tinnitus. 
  
ILDR1 DFNB42 Prelingual Moderate-to-profound; stable  
KARS DFNB89 Prelingual Moderate-to-severe; stable  
KCNQ4 DFNA2A Post-lingual 
(1st/2nd) 
Downsloping; progresses, involving 
all frequencies 
  
KITLG DFNA69 Prelingual 
Unilateral or bilateral asymmetric; 
stable. Subclinical vestibular 
dysfunction in some patients. 
  
LHFPL5 DFNB66/67 Prelingual Severe-to-profound; stable  
LMX1A DFNA7 
Prelingual/post-
lingual (1st/3rd) 
Variable severity and progression 
rate. Vestibular symptoms in some 
patients. 
  
LOXHD1 DFNB77 Post-lingual (1st) 
Downsloping; moderate-to-
profound; progressive, flattening of 
the audiogram over time 
 
LRTOMT DFNB63 Prelingual Severe-to-profound; stable  
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Gene Locus Onset NSHL phenotype Additional features (SHL) 
MARVELD2 DFNB49 Prelingual Moderate-to-profound; stable  
MCM2 DFNA70 Post-lingual 
(from 1st) 
Flat/downsloping; mild-to-
profound; progressive 
 
MET DFNB97 Prelingual Severe-to-profound  
MIR96 DFNA50 Post-lingual (1st) Flat; mild-to-profound; progressive   
MPZL2 DFNB111 Prelingual/post-
lingual (1st) 
Moderate-to-severe; slowly 
progressive 
 
MSRB3 DFNB74 Prelingual Profound  
MYH14 DFNA4A 
Post-lingual 
(1st/2nd) 
Severe-to-profound; progressive 
One variant has been associated with 
peripheral neuropathy, myopathy, 
hoarseness, and hearing loss in one 
family 
MYH9 DFNA17 
Post-lingual 
(1st/3rd) 
Downsloping; progressive 
Also associated with 
macrothrombocytopenia and granulocyte 
inclusions with or without nephritis or 
sensorineural hearing loss 
MYO15A DFNB3 Prelingual Severe-to-profound; stable  
MYO3A 
DFNB30 Prelingual Downsloping; moderate-to-
profound; progressive 
 
- Post-lingual (1st) Moderate-to-profound; progressive   
MYO6 
DFNB37 Prelingual Severe-to-profound; progressive  
DFNA22 Post-lingual (1st) Mild-to-profound; progressive 
One variant has been associated with 
deafness and hypertrophic 
cardiomyopathy 
MYO7A 
DFNB2 
Prelingual/post-
lingual (1st/2nd) 
Downsloping; severe-to-profound. 
Vestibular symptoms in some 
patients.  
Also associated with Usher syndrome 
Type IB (profound congenital HL, 
retinitis pigmentosa, constant vestibular 
dysfunction) 
DFNA11 
Post-lingual 
(1st/5th) 
Flat/gently downsloping; moderate; 
progressive. Mild vestibular 
symptoms in some patients. 
  
NARS2 DFNB94 Prelingual Profound; stable  
NLRP3 DFNA34 
Post-lingual 
(1st/4th) 
Variable severity; slowly progressive. 
Some patients have pure NSHL, while 
others have features of an 
autoinflammatory disorder with systemic 
manifestations, including periodic fevers, 
arthralgias, and episodic urticaria. 
NLRP3 gene is also associated with 
Muckle-Wells syndrome (episodic skin 
rash, arthralgias, and fever associated 
with late-onset sensorineural deafness 
and renal amyloidosis). 
OSBPL2 DFNA67 
Post-lingual 
(1st/3rd) 
Downsloping; mild-to-profound; 
progresses to all frequencies. 
Generally accompanied by high-
frequency tinnitus. 
  
OTOA DFNB22 Prelingual Moderate-to-profound; stable   
OTOF DFNB9 Prelingual Severe-to-profound; stable   
OTOG DFNB18B Prelingual Downsloping; mild -to-moderate; 
stable 
  
OTOGL DFNB84B Prelingual Downsloping; moderate; stable   
P2RX2 DFNA41 Post-lingual (2nd) 
Downsloping in males, upsloping 
audiogram in females; patterns tend 
to converge with HL progression. 
Moderate-to-severe; progressive. 
Generally accompanied by high-
frequency tinnitus. 
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Gene Locus Onset NSHL phenotype Additional features (SHL) 
PCDH15 DFNB23 Prelingual Severe-to-profound; stable 
Also associated with Usher syndrome 
Type IF (profound congenital HL, 
retinitis pigmentosa, constant vestibular 
dysfunction) 
PDE1C DFNA74 Post-lingual 
(1st/3rd) 
Downsloping; mild-to-profound; 
progressive 
  
PDZD7 DFNB57 Prelingual 
Downsloping; mild-to-profound; 
mildly progressive 
Also associated with Usher syndrome 
Type IIC (moderate-to-severe congenital 
HL, retinitis pigmentosa) 
PJVK DFNB59 Prelingual Severe-to-profound   
PNPT1 DFNB70 Prelingual Severe 
Also associated with combined oxidative 
phosphorylation deficiency-13 
(multisystem disorder characterised by 
severe neurologic impairment, including 
HL) 
POU4F3 DFNA15 Post-lingual 
(2nd/6th) 
Flat/downsloping; mild-to-severe; 
progressive 
  
PPIP5K2 DFNB100 Prelingual Severe-to-profound   
PTPRQ 
DFNB84A Prelingual Moderate-to-profound; progressive. 
Vestibular dysfunction. 
  
DFNA73 Post-lingual 
(1st/3rd) 
Mild-to-severe   
RDX DFNB24 Prelingual Severe-to-profound; stable   
REST DFNA27 Post-lingual 
(1st/3rd) 
Moderate-to-profound; progressive   
RIPOR2 DFNB104 Prelingual Severe-to-profound   
ROR1 DFNB108 Prelingual 
Profound. Fusion of the cochlea and 
vestibule into a common cavity; no 
vestibular dysfunction. 
  
S1PR2 DFNB68 Prelingual Profound   
SERPINB6 DFNB91 Post-lingual (2nd) Moderate-to-severe; progressive   
SIX1 DFNA23 Prelingual 
Downsloping; mild-to-profond; 
sensorineural or mixed 
Also associated with Branchiootic 
syndrome 3 (HL, branchial arch defects, 
lacrimal duct stenosis) 
SLC17A8 DFNA25 Post-lingual 
(2nd/6th) 
Downsloping; slowly progressive   
SLC22A4 DFNB60 Prelingual Severe-to-profound   
SLC26A4 DFNB4 Prelingual 
Moderate-to-profound. Associated 
with cochlear abnormalities (EVA or 
Mondini dysplasia) and vestibular 
symptoms in some patients.  
Also associated with Pendred syndrome 
(HL and goiter) 
SLC26A5 DFNB61 Prelingual Moderate-to-profound; stable   
STRC DFNB16 Prelingual 
Downsloping; mild-to-profound; 
stable 
Deletion of STRC in conjunction with 
CATSPER2 gene causes Deafness-
Infertility syndrome  
SYNE4 DFNB76 Prelingual Downsloping; moderate-to-severe; 
progressive 
  
TBC1D24 
DFNB86 Prelingual Flat audiogram; profound   
DFNA65 
Post-lingual 
(2nd/3rd) 
Downsloping; severe-to-profound; 
progresses, also involving low 
frequencies 
  
TECTA 
DFNB21 Prelingual Flat/U-shaped audiogram; severe-to-
profound; stable 
  
DFNA8/12 Prelingual/post-
lingual (1st/2nd) 
U-shaped audiogram; moderate-to-
severe; stable/progressive 
  
TJP2 DFNA51 Post-lingual (4th) Downsloping; severe-to-profound; 
progresses, involving all frequencies 
  
179 
 
Adapted and updated from Shearer et al., 2017 and Hereditary Hearing Loss Homepage, 
https://hereditaryhearingloss.org/. 
Gene Locus Onset NSHL phenotype Additional features (SHL) 
TMC1 
DFNB7/11 Prelingual Profound; stable   
DFNA36 Post-lingual 
(1st/3rd) 
Downsloping; severe-to-profound; 
progresses, involving all frequencies 
  
TMEM132E DFNB99 Prelingual Severe-to-profound   
TMIE DFNB6 Prelingual Severe-to-profound; stable   
TMPRSS3 DFNB8/10 Prelingual/post-
lingual (1st) 
Moderate-to-profound   
TNC DFNA56 Post-lingual 
(1st/3rd) 
Low-frequency; mild-to-severe; 
progresses, involving all frequencies 
  
TPRN DFNB79 Prelingual Severe-profound; progressive   
TRIOBP DFNB28 Prelingual Severe-to-profound; stable   
TSPEAR DFNB98 Prelingual Flat audiogram; profound   
USH1C DFNB18A Prelingual Severe-to-profound; stable 
Also associated with Usher syndrome 
Type IC (profound congenital HL, 
progressive retinitis pigmentosa, 
vestibular hypofunction) 
WBP2 DFNB107 Prelingual Downsloping; severe-to-profound   
WFS1 DFNA6/14/38 Prelingual Low-frequency; progressive 
Also associated with Wolfram syndrome 
1 (diabetes insipidus and mellitus with 
optic atrophy and HL)  
WHRN DFNB31 Prelingual Profound 
Also associated with Usher syndrome 
Type IID (moderate congenital HL, 
retinitis pigmentosa) 
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6.2. ABR recordings of individual Slc26a4tm1(CreERT2_EGFP)Wtsi mice 
The auditory function of Slc26a4tm1(CreERT2_EGFP)Wtsi mice was evaluated using ABR recordings 
at 3, 4 and 8 weeks of age. The individual ABR recordings of each mouse I personally 
tested are reported. The personal ID of each mouse is indicated on the right.  
6.2.1. ABR recordings of individual 3-week-old Slc26a4tm1(CreERT2_EGFP)Wtsi mice  
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6.2.2. ABR recordings of individual 4-week-old Slc26a4tm1(CreERT2_EGFP)Wtsi mice 
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6.2.3. ABR recordings of individual 8-week-old Slc26a4tm1(CreERT2_EGFP)Wtsi mice 
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6.3. ABR recordings of individual Diaph2em2Kcl knock-out mice 
The auditory function of Diaph2em2Kcl mice was evaluated using ABR recordings at 4 and 8 
weeks of age. The individual ABR recordings of each mouse I personally tested are 
reported. The personal ID of each mouse is indicated on the right. 
6.3.1. ABR recordings of individual 4-week-old Diaph2em2Kcl knock-out mice 
 
 
 
 
 
 
 
 
 
185 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
186 
 
 
6.3.2. ABR recordings of individual 8-week-old Diaph2em2Kcl knock-out mice 
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6.4. ABR recordings of individual Diaph2em3Kcl knock-in mice 
The auditory function of Diaph2em3Kcl mice was evaluated using ABR recordings at 4 and 8 
weeks of age. The individual ABR recordings of each mouse I personally tested are 
reported. The personal ID of each mouse is indicated on the right. 
6.4.1. ABR recordings of individual 4-week-old Diaph2em3Kcl knock-in mice 
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6.4.2. ABR recordings of individual 8-week-old Diaph2em3Kcl knock-in mice 
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